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c-myb Alternative Splicing: A Novel Biomarker in
Leukemia
By
Ye E. Zhou
M.S Pharmacokinetics
Ph.D Biomedical Science

Abstract
c-myb encodes a transcription factor that is essential for hematopoiesis and
for normal development of other tissues. There is ample evidence showing the
activated alleles of c-myb gene can induce leukemias in several animal species.
However, there was no clear evidence showing that c-myb could be oncogenic in
human cancers until recent studies revealed that the human c-myb locus is
subjected to chromosomal rearrangement in some pediatric T-ALL and adenoid
cystic carcinoma (ACC) patient samples. The c-myb gene contains 15 constant
exons and 6 alternative exons and can undergo extensive alternative splicing.
These alternatively spliced variants encode variant Myb proteins sharing the
same DNA binding domain but distinct C-terminal domains. Evidence suggests
that despite their identical DNA binding domains, these c-Myb variant proteins
have unique transcriptional activities: the differences in the proteins allow the
proteins to regulate different sets of target genes. Most importantly, some of the
variants have C-terminal deletions that resemble the deletions in v-Myb, the
oncogenic variant of c-Myb that can induce acute leukemias in chickens and
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mice. Previous studies showed that c-myb alternative splicing is tightly regulated
during hematopoiesis. The profiles of c-myb alternative splicing in some
leukemias are different from the profiles in normal bone marrow samples. We
hypothesized that c-myb is a unique oncogene that is activated by alternative
splicing in leukemias, resulting in the production of variant forms of c-Myb protein
that contribute to hematopoietic cell transformation and the development of
leukemia. To evaluate the clinical significance of c-myb alternative splicing and
find out its correlation with leukemia, profiling of c-myb alternative splicing in a
cohort of leukemia patient samples is needed. We developed a single-molecule
exontyping method to characterize the alternative splicing of c-myb RNAs in a
small cohort of pediatric pre-B-ALL samples and correlated the level or the
pattern of c-myb splice variants with survival time of these patients. We detected
that c-myb alternative splicing is more complex and more prevalent in leukemia
patients than in normal cells. Furthermore, some splice variants encoding Myb
proteins with truncations in the C-terminal domain are correlated with poor
survival. We further explored the possibility of adapting high-throughput low-cost
Next-Generation Sequencing methods to analyze c-myb alternative splicing at a
large scale. We conclude that de-regulated c-myb alternative splicing could be an
important contributor to the development of leukemia and that the analysis of cmyb splicing could provide a unique and novel approach of classifying leukemias,
which is distinct from analyses performed with other technologies, such as
microarray assays of gene expression.
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Chapter 1: Myb proteins: angels and demons in normal and
transformed cells

Abstract
A key regulator of proliferation, differentiation and cell fate, the c-Myb
transcription factor regulates the expression of hundreds of genes and is in turn
regulated by numerous pathways and protein interactions. However, the most
unique feature of c-Myb is that it can be converted into an oncogenic
transforming protein through a few mutations that completely change its activity
and specificity. The c-Myb protein is a myriad of interactions and activities rolled
up in a protein that controls proliferation and differentiation in many different cell
types. Here we discuss the background and recent progress that have led to a
better understanding of this complex protein, and outline the questions that have
yet to be answered.

Introduction
Significance of c-Myb in human disease
Features that make c-Myb unique
Several things make c-myb a unique type of oncogene and an unusual
transcription factor. Unlike some oncogenes whose normal functions are closely
linked to the regulation of the cell cycle or to the mitogenic response (e.g. SRC,
1

MYC, FOS), the normal role of c-myb is most closely associated with the
regulation of differentiation, especially in immature hematopoietic cells 21,22.
Transformation by the v-myb oncogenes is associated with a block in
differentiation 23,24 and disrupting the function of v-myb in transformed cells
causes them to stop proliferating and to differentiate 25. This raises the question
of whether c-Myb regulates both differentiation and proliferation, or whether
changes in proliferation occur as a consequence of Myb-regulated changes in
differentiation. For example, the more immature transformed cells may respond
more vigorously to cytokines or growth factors, resulting in increased
proliferation. Alternatively, c-Myb could be involved in the regulation of both
proliferation and differentiation. Another unique feature of c-Myb, which may be
the key to understanding how it functions as an oncogene, is that its activity is
malleable: it regulates different genes in different situations and its activity can be
dramatically altered by relatively minor mutations, even single amino acid
changes 26,27. Thus, c-Myb appears to have many different functions and many
different roles in various tissue types and situations, and mutations or
mechanisms that disrupt these context-specific effects may increase oncogenic
activity.
One of the most unique features of c-myb is the extremely complex nature
of its regulation. The expression of the c-myb gene is regulated at several levels,
including a sophisticated control of transcriptional elongation that occurs in the
first exon and that may be regulated by the transcription factor NFkappaB or by
estrogen receptor, depending on the cell type 5,28,29. The c-myb gene exhibits
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quite complicated alternative RNA splicing that can produce dozens of different
transcripts encoding different versions of c-Myb protein with unique
transcriptional activities 19. This makes the c-myb gene multifaceted and capable
of encoding subtly different transcription factors in different situations or cell
types. At the post-transcriptional level the c-myb mRNAs are tightly controlled by
a system of microRNAs, mostly that bind to the very long 3’-UTR region 30-34.
However, the most sophisticated and least understood regulation occurs after
translation. The c-Myb protein is subject to at least 10 and probably many more
post-translational modifications, all of which have the ability to change the activity
or stability of the protein or to affect which proteins c-Myb is able to interact with
and therefore which genes it can regulate. Thus, the c-myb gene and the c-Myb
protein lie at the intersection of many different regulatory pathways feeding into
such diverse mechanisms as the control of transcription, alternative RNA
splicing, translation and protein activity and stability.

Questions to be addressed
It has been over 30 years since v-myb was first discovered in a virus that
caused leukemia in chickens. The diverse studies and approaches undertaken
by numerous laboratories have uncovered a myriad of complexities related to the
expression and regulation of c-Myb, but several important questions remain
unanswered. It is still not clear how c-Myb regulates both differentiation and
proliferation, two processes that seem contradictory. Although c-Myb is a DNAbinding transcription factor 26, it is still not clear which Myb-regulated target genes
3

are the most important ones for the oncogenic activity of v-Myb, or whether Myb
proteins regulate different genes in tumors than in normal cells. Although the
turnover of c-Myb protein is tightly regulated, whether higher intracellular levels of
c-Myb protein lead to a different outcome in terms of gene expression patterns,
changes in differentiation or increased proliferation remains to be determined.
The goal of this review is to address these and related questions in order to shed
light on the most important and most relevant discoveries, and to set a
framework for future studies on c-Myb and its role in normal cells and tumors.

The Two Faces of Myb: A Regulator and An Oncogene
Myb as a critical regulator in normal cells
Like many transcription factors, c-Myb has a highly conserved DNA binding
domain (Figure 1A) 35, recognizes and binds to specific sequences in DNA 26 and
activates the expression of specific target genes 26,36,37. The unique feature of cMyb is that a few mutations can convert it into a transforming protein that
regulates a completely different spectrum of target genes 36. Trying to understand
the normal functions of c-Myb and how they become corrupted in the oncogenic
v-Myb has been the motivation behind many of the studies involving the Myb
proteins.
Because the viruses expressing v-Myb caused leukemias, much of the work
involving c-Myb has focused on its functions in hematopoietic cells. Early studies
showed that anti-sense oligos targeting c-Myb could block in vitro hematopoietic
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cell differentiation 21 and that homozygous disruption of the murine c-myb gene
causes a dramatic failure of definitive erythro- and myelopoiesis 22. Since then, cMyb has been intensively investigated in the context of the hematopoietic system
where it has been shown to regulate progenitor cell expansion and differentiation
of a number of lineages. A variety of mutant alleles and conditional knockout
mouse models have facilitated the study of c-Myb in hematopoiesis. For
example, inducible c-myb knockout systems have shown that precise expression
levels of c-Myb are required at distinct differentiation steps of each hematopoietic
cell lineage 38. Tissue-specific deletion of c-Myb in lymphoid progenitors has
demonstrated the importance of c-Myb expression during B-cell 39 and T-cell
development 40,41. In addition, low levels of c-myb expression lead to a
myeloproliferative phenotype resembling a stem cell disorder 42, suggesting that
c-Myb is required for proper differentiation and proliferation of hematopoietic
stem cells.
Presumably, c-Myb is required in these diverse cell types because it
regulates specific genes. Indeed, c-Myb appears to regulate some genes, such
as c-Kit 43-46 in many cell types while other genes, such as Bcl-2 47,48, may only
be targets in specific lineages. Many other c-Myb targets have been identified in
hematopoietic cells, including the first identified target mim-1 26, the stem cell
antigen CD34 49, the T-cell receptor delta 50, the cell cycle regulatory genes
CDC2 51 and CCNB1 52 and the MYC oncogene 53. Although many of these
target genes play important roles in hematopoiesis or even in oncogenesis, none
of the genes that have been identified have provided more than a partial
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explanation for what the role of c-Myb is in hematopoietic or other cell types, nor
have they led to a good explanation for why c-Myb should have oncogenic
activity.
Recent studies have also demonstrated an important need for c-Myb
expression in the normal development of some epithelial and other tissues. In
situ hybridization studies have shown that c-myb is expressed at high levels in
hematopoietic cells in developing embryos, but also in neural retina and in
respiratory epithelial cells 54. In the colon, c-Myb is required for colonic crypt
homeostasis, including the integrity, normal differentiation, and steady-state
proliferation of colon epithelial stem cells and progenitors 48,55,56. Interestingly, cMyb expression has been found to be important for neural progenitor cell
proliferation and for maintenance of neural stem cell niche 57, and an involvement
of c-Myb in melanocytes links it to the functions of neural crest cells 44. Clearly,
the c-myb gene is widely expressed, and the c-Myb protein plays a role in many
cell types, not just hematopoietic cells. As conditional knockout systems are
expanded to other cell lineages, it seems likely that the number of tissues that
require c-Myb for normal development will increase.
One complication of determining the role of the c-Myb protein in normal
tissues is the presence of two related transcription factors, A-Myb (MYBL1) and
B-Myb (MYBL2), which are often co-expressed with c-Myb. The three Myb
proteins have nearly identical DNA binding domains 58 and bind the same DNA
sequences in vitro and in reporter plasmids 59. However, they are biologically
distinct, since mice lacking A-Myb or B-Myb have completely different
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phenotypes than those lacking c-Myb 22,60,61. The genes encoding the three Myb
proteins are all induced by activating the estrogen receptor in MCF-7 breast
cancer cells 62, making this system a good one for studying the activities of all
three proteins. Microarray studies have shown that the three Myb proteins induce
almost totally non-overlapping sets of target genes when ectopically overexpressed in MCF-7 cells. This suggests that the similar DNA binding domains
are not enough to determine the specificities of the Myb proteins. Instead, the
large transcriptional trans-activation and protein-protein interaction domains
(Figure 1A) must play a role by helping to steer each of the transcription factors
to specific target genes. Thus, it seems likely that the products of the three genes
have completely different functions, although they likely evolved from a single
progenitor Myb gene similar to the one in Drosophila 63, which is involved in
chromosome condensation and genome stability 64,65.

Myb unveiled becomes an oncogene
The AMV and E26 viruses expressing different versions of v-Myb are both
strongly oncogenic, capable of transforming immature avian hematopoietic cells
in vitro and inducing leukemias in animals 24,27,66,67. In addition, both forms of vMyb can induce leukemias in mice when expressed from mouse retroviruses
68,69

. However, both v-Myb proteins are truncated and mutated derivatives of wild

type c-Myb (Figure 1A), lacking the N-terminus and C-terminus of c-Myb while
retaining the highly conserved DNA binding domain and more than half of the Cterminal domain, including the region required for transcriptional transactivation
7

70

. In contrast to v-Myb, full-length c-Myb is only capable of weak transformation

in vitro 71,72 and does not induce leukemias in animals, not even in transgenic
mice that over-express c-Myb in all tissues 73. However, C-terminal deletion
mutants of c-Myb are much more potent oncogenes and do induce leukemias in
mice 74,75. In addition, leukemias induced by retroviral insertions into the c-myb
gene express either N- or C-terminal truncations of c-Myb 76,77, suggesting that
truncation of one end or the other of c-Myb is necessary for conversion into a
potent oncogenic form. These results lead to the conclusion that c-Myb is subject
to auto-inhibition or repression, which can be relieved by deletion of one end or
the other, or both.
Researchers studying the differences between v-Myb and c-Myb have
focused on the idea that the two proteins have quantitatively different activities:
that they have essentially the same activities but the v-Myb protein is derepressed, lacking the negative controls that keep c-Myb in check. However, this
viewpoint now appears to be incorrect, since several types of evidence point to a
qualitative difference in the activities of c-Myb and v-Myb. The first hint should
have come from the study of the first identified Myb target gene, mim-1, which is
activated by c-Myb and the v-Myb protein from E26 virus, but not the v-Myb
encoded by AMV 26,27. Instead, researchers focused on the fact that all the Myb
proteins can bind the same DNA sequences and activate the same reporter gene
plasmids as evidence that they must regulate the same genes. It is now clear
that the results from reporter genes are misleading and fail to distinguish
between the different Myb proteins. However, microarray assays clearly show
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that the different Myb proteins activate completely different sets of target genes
36,37,78

, suggesting that they are qualitatively and functionally distinct. These

conclusions have important implications for our understanding of how Myb
proteins work and what controls their specificities. If the DNA binding domains of
the Myb proteins are not sufficient to direct them to target genes, then proteinprotein interactions become much more important and explain why the different
Myb proteins have such different activities. However, protein-protein interactions
are subject to regulation by many mechanisms, including post-translational
modifications, suggesting that not only the activities, but also the specificities of
Myb proteins are highly regulated.

N-terminal deletions of c-Myb
N-terminal truncation appears sufficient to unleash at least some of the
transformation potential of c-Myb. Retroviral insertional mutagenesis that results
in a truncation of amino acids 1-20 of c-Myb has been found in non-bursal B cell
lymphomas caused by ALV (avian leukosis virus) in chickens 79. This deletion
occurs in recombinant retrovirus-induced rapid-onset tumors, including B-cell
lymphomas, sarcomas, and adenocarcinomas in animals 80, suggesting that the
N-terminal deletion is important for increasing the oncogenic activity of c-Myb.
The precise role of the N-terminus of c-Myb is unclear, but it has been reported
that deletion of the N-terminus can abrogate the ability of c-Myb protein to
cooperate with other transcription factors (Figure 1), such as Ets-1 81, which
raises the possibility that oncogenic activation of c-Myb is linked to the loss of
9

cooperation between Myb and other cofactors. Truncation of the N-terminus and
the first Myb repeat can cause a decreased affinity for DNA binding and affects
interactions between c-Myb and Cyclin D1 82,83. Moreover, mutant forms of c-Myb
with different N-terminal deletions display differences in transcriptional
transactivation activities and the ability to interact with C/EBPbeta 84. All the Nterminal deletions lack a conserved casein kinase II (CKII) phosphorylation site
that may influence DNA binding activity 85. However, mutagenesis of the CKII site
does not influence the oncogenic activity of c-Myb 82, suggesting that its
importance may be limited to specific target genes or cell types.
There is provocative evidence suggesting that modifications of the Nterminus of c-Myb protein may occur in vertebrates through unusual
transcriptional mechanisms. The first type of evidence is the identification of a
second promoter in the c-myb gene, located in the normal intron 1, which would
encode an mRNA lacking the normal exon 1 and a protein with a small Nterminal deletion lacking the CKII phosphorylation sites 86. The implication is that
alternative use of the second promoter in some cell types or in some
circumstances would produce a subset of c-Myb proteins lacking the N-terminus
and whatever negative regulatory controls it confers. The second type of
evidence suggests that some c-myb transcripts arise via a mechanism of transsplicing, starting at a completely different promoter located on a different
chromosome from the rest of the c-myb gene, but resulting in the production of a
chimeric transcript encoding a protein that lacks the normal N-terminus of c-Myb
87,88

. This line of evidence originated with the cloning and characterization of one
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of the first cDNAs for c-myb, which contained sequences from two different
chromosomes 89. Although the evidence for trans-splicing is compelling, it is not
clear how important that mechanism is in the biology of c-myb or whether
proteins encoded by the trans-spliced chimeric mRNAs have any role in
controlling cell fate or in regulating specific sets of genes. However, given the
complexity of c-myb gene regulation, it would be foolish to rule out trans-splicing
just because it is unexpected without proof that it is not important.

C-terminal deletions affect intra- and intermolecular interactions
All the transforming alleles of c-Myb, including both forms of v-Myb, have Cterminal deletions, suggesting that elements at or near the C-terminus play an
important negative regulatory role, perhaps by keeping the activity of the full
length protein in check. The fact that overexpression of full-length c-Myb cannot
efficiently transform cells in vitro or induce tumors in animals suggests that
negative regulation of c-Myb is inherent in its structure. In support of this idea,
the EVES motif (513aa-563aa) near the C-terminus of c-Myb (Figure 1A) has
been shown to interact with the N-terminal DNA binding domain 90,91. This
intramolecular interaction could form the basis for autoinhibition, explaining why
c-Myb fails to transform cells, even if grossly over-expressed. The EVES motif
overlaps a site of in vivo phosphorylation by p42 Mitogen-Activated Protein
Kinase (p42MAPK) 92 and is close to several sites of sumoylation and
ubiquitinylation. Thus, activation of signal transduction cascades, leading to
changes in p42MAPK activity and c-Myb phosphorylation could affect the
11

intramolecular interactions and transcriptional activity and/or stability of c-Myb
93,94

. Although the potential for these regulatory mechanisms has been

demonstrated, a direct link between signaling pathways, p42MAPK activity and
changes in the transcriptional or oncogenic activity of c-Myb has yet to be
demonstrated.
Recognition of the EVES motif in c-Myb led to the identification of a related
domain in the transcriptional co-activator p100, also known as Tudor-SN and
recently renamed SND1 95. The p100/SND1 protein appears to have multiple
functions: it is a transcriptional co-activator 96,97, a component of the RISC
complex involved in microRNA metabolism 98,99 and a key component of RNA
editing complexes 100,101. For c-Myb, the implication is that intramolecular
interactions within the c-Myb protein compete for the intermolecular interactions
with p100/SND190, which could also affect the interactions between c-Myb and
Pim-1 102, an oncogenic kinase that phosphorylates the DNA binding domain of
c-Myb 103. C-terminal truncations of c-Myb could disrupt the intramolecular
interaction, allowing other domains of c-Myb to recruit co-activators or corepressors, leading to changes in transcriptional activity. Three co-repressors
(Ski, N-CoR, and mSin3A) that bind to the DNA-binding domain of c-Myb form a
complex with TIF1beta that binds to the C-terminus 104. Deletion of the Cterminus decreases the interactions with these co-repressor complexes and also
weakens the co-repressor-induced negative regulation of Myb activity (Figure
1A). Meanwhile, the deletion of the C-terminus could also unmask binding sites
for other proteins in the DNA-binding domain or N-terminal domain, such as
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CBP/p300 105. These regulatory mechanisms are likely dependent on enzymes
that bind c-Myb and catalyze changes in protein conformation. Examples include
the peptidyl proline isomerases Cyp40, which binds c-Myb and induces a
conformational change that affects DNA binding activity 106 and Pin1, which binds
c-Myb in a phosphorylation-dependent manner 94. All these results paint an
increasingly complex picture of the interdependence of each domain of c-Myb
and the interplay of multiple cofactors in modulating its activity, and suggest that
multiple different regulatory pathways interface with c-Myb to control its activity.
Deletion of the C-terminus of c-Myb plays a major role in changing the
stability of the protein. Full-length c-Myb has a short half-life in most situations
107

, which is greatly extended in proteins with C-terminal truncations. Some

aspects of c-Myb activity are closely tied to the level of its expression 38,42, so
controlling the stability of the protein could play a critical role in regulating c-Myb
activity and cell fate in some situations. The regulation of c-Myb degradation is
linked to the presence of a PEST sequence 108, which targets the protein for
ubiquitinylation and degradation. The PEST sequence overlaps with the EVES
motif and the p42MAPK phosphorylation site, suggesting that the mechanisms
that target c-Myb to the proteasome are highly regulated by upstream signaling
pathways.
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Wnt signaling and regulation of c-Myb stability
The carboxyl terminal domain of c-Myb that is deleted in v-Myb plays a
major role in negative regulation of c-Myb activity. Retrovirus-induced truncation
of the C-terminus of c-Myb leads to a substantial increase in transactivation
70,109,110

and transformation activity 109. Several types of post-translational

modifications occur in the C-terminal domain of c-Myb, affecting stability,
subcellular location 111 or interactions with other proteins. For instance, activation
of the Wnt-1 signaling pathway leads to phosphorylation of c-Myb at multiple
sites, followed by ubiquitinylation, targeting to the proteosome and degradation
112

. The phosphorylation sites in the C-terminal domain are more critical for the

Wnt-1-induced degradation since the interaction of c-Myb with E3 ubiquitin
ligases, such as Fbxw7 113 can be enhanced by these modifications. The
oncogenic v-Myb protein lacks the phosphorylation and ubiquitinylation sites and
is relatively resistant to this degradation pathway (Figure 2), which may partially
explain the differential transforming activity of v-Myb vs c-Myb 114.
Although the number of proteins known to interact with c-Myb increases
each year, there is still relatively little information about how any of these
interactions affect the activity of c-Myb or whether the interactions are significant
for oncogenic activities. These limitations are mostly due to problems with the
available assays. A major problem is that most investigators assess the activity
of c-Myb only through transfection assays using plasmid-based reporter genes.
However, it has been clear since the identification of the very first c-Myb target
gene, mim-1, that reporter genes do not distinguish between the activities of
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different Myb proteins or between normal and oncogenic alleles of c-Myb 26,27.
Microarray studies have shown that c-Myb and v-Myb activate completely
different, almost completely non-overlapping sets of target genes in human cells
36,78

. It will most likely be necessary to study the effects of the Myb-binding

proteins in the context of real target genes in order to determine how they affect
c-Myb activity. A related problem is that it is not yet clear which Myb target genes
are linked to oncogenic activity. Some target genes, such as cyclin genes
(CCNA1, CCNE1, CCNB1), other proto-oncogenes (c-MYC and c-KIT) or
survival genes (BCL-2) seem likely to be important for transformation or
oncogenesis. However, no target genes have yet been linked directly to the
transformation activity of c-Myb or its oncogenic derivatives.

Structure and activities of the Myb DNA binding (SANT) domain
The 48 KDa v-Myb protein encoded by AMV, the 135 KDa Gag-Myb-Ets
protein encoded by the E26 virus, and the 75 KDa c-Myb protein are all nuclear
and bind to the same DNA sequence (PyAACG/TG) 115. All three share a highly
conserved DNA binding domain composed of two approximately 50 amino acid
long “Myb repeats”, each of which includes three tryptophan residues separated
by a characteristic spacing 116. This motif is present in three tandem repeats (R1,
R2, and R3) in c-Myb, the first of which is deleted in the AMV and E26
oncoproteins 117,118. The first repeat has been implicated in stabilizing the binding
to DNA 119 but it is not required for DNA binding 120 and deletion of the first repeat
increases the oncogenic activity of c-Myb 110. Thus, the core DNA binding
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domain includes only the second and third Myb repeats (residues 90-192) 120.
Four amino acid substitutions are present within the DNA-binding domain of AMV
v-Myb. These substitutions do not appear to alter the sequence specificity of
DNA binding 115, but do affect the ability of the protein to transform different cell
types, to regulate specific genes and to be regulated by other cellular proteins
27,106,121

.

Although it is named for its ability to bind DNA, the most conserved part of
c-Myb 58 is also important for a large number of protein-protein interactions. As
discussed above, the DNA binding domain is the site of intramolecular
interactions with the C-terminal EVES domain 90 and for intermolecular
interactions with the structurally related p100/SND1 co-activator protein 90,102.
The DNA binding domain is also the site of interactions with and phosphorylation
by protein kinases including Protein Kinase A 122 and Pim-1 103. The
tetratricopeptide repeat domain of Cyp40 interacts with the DNA binding domain
of c-Myb 106, as do the cell cycle regulator Cyclin D1 83 and the transcriptional corepressors Ski, N-CoR and mSin3A 104. The solution structure of the Myb DNA
binding domain 120 shows that both the structure and the outside surface of the
domain – which interacts with other proteins – is perfectly conserved amongst
vertebrate Myb proteins. Interestingly, several of the mutations in the oncogenic
v-Myb protein change surface residues in the DNA binding domain, suggesting
that they enhance the oncogenic activity by affecting interactions with regulators
122

or co-activators that change the specificity of the protein.
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In addition to recognizing specific promoters and binding to numerous
proteins, the DNA-binding domain of c-Myb is also involved in chromatin
remodeling and oncogenic mutations can abolish this function 38,123. This
suggests that the DNA binding domain may play somewhat of a catalytic role,
initiating changes in chromatin structure or histone modifications at regulated
promoters. Recently the Myb repeat found in the Myb DNA binding domain was
relabeled as a SANT domain, variants of which are found in several chromatin
remodeling enzymes 123-125. SANT domains are the critical DNA-and chromatin
recognition domains in regulators such as Swi3p, Ada2p, Rsc8p and TRF2 and
are responsible for recognition of histone tails. Thus, the DNA binding/SANT
domain of c-Myb may play an important role in epigenetic regulation of target
genes or in the initiation of chromatin remodeling in genes that become activated
or repressed.

The related proteins, A-Myb and B-Myb, are not oncogenic
In addition to c-Myb, all vertebrates also express two closely related
proteins with similar overall structures and only a few differences to the surface
residues of their DNA binding domains 58. They both have been shown to be
transcription factors 126,127, but neither has been shown to be an oncogene or to
have transforming activity. B-Myb (MYBL2) is expressed in all proliferating cells
and is required for cell proliferation in which it plays a role in cell cycle
progression 128. B-Myb and c-Myb have some similar effects in hematopoietic
cells 129, but they are regulated differently and are not interchangeable 130.
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Overexpressed or amplified B-myb has been reported in different types of human
malignancies 131,132, but since its expression is linked to proliferation,
overexpression of B-Myb may just signal that the tumor cells are dividing. It is
suspected that B-Myb plays a role in human cancer, but there is still no direct
evidence of its causative role. Although B-Myb recognizes the same DNA
sequence as c-Myb (PyAACG/T/G), it regulates completely different sets of
genes 37. B-Myb has been identified as a component of LINC (LIN complex), a
protein complex involved in the regulation of genes that are expressed in the
G2/M phase of the cell cycle 133. LINC is related to similar complexes dREAM
and DRM from Drosophila and C. elegans 133, suggesting that this function of BMyb is evolutionarily conserved and primordial. Thus, B-Myb appears to be the
vertebrate equivalent of the original Myb protein, only one of which is found in
lower organisms. Compared to B-Myb, c-Myb appears to be a specialized
version that has acquired oncogenic potential.
The other Myb family member, A-Myb (MYBL1), is the least well studied and
remains the most enigmatic. In lymphoid cells, A-Myb expression is normally
restricted to the proliferating B-cell centroblasts 134 and is not correlated with that
of c-Myb and B-Myb 129. Human A-Myb is a strong transcriptional activator 135
and is therefore more similar to the oncogenic v-Myb than to c-Myb. Transgenic
mice with overexpressed A-Myb develop hyperplasia of the spleen and lymph
nodes with over-expanded B lymphocyte populations 136, suggesting that A-Myb
may contribute to hyperplasia by increasing the rate of B cell proliferation. A-Myb
is overexpressed or deregulated in several subtypes of human B-cell neoplasia
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137

and there is evidence that A-Myb regulates important target genes such as

MYC 138. However, there is no direct evidence that A-Myb is oncogenic or that it
transforms cells in vitro or in animals. Although many studies of A-Myb activity
have focused on its role in hematopoietic cells, it is widely expressed and is often
co-expressed with c-Myb and B-Myb. For example, the expression of all three
Myb proteins is stimulated by estrogen in MCF-7 breast cancer cells 62.
Many types of proliferating cells co-express the A-Myb, B-Myb and c-Myb
proteins, and since all three proteins can bind the same DNA sequences and
activate the same plasmid-based reporter genes, there is a chance that the three
proteins regulate the same genes, perhaps in different phases of the cell cycle.
Alternatively, they might have different activities, for example one might activate
a promoter that the other represses. However, microarray studies showed that
the three Myb proteins activated essentially completely different sets of target
genes in human cells 37. Furthermore, swapping the DNA binding domains
between A-Myb and c-Myb did not alter their specificities, indicating that the other
parts of the proteins, not the conserved DNA binding domains, were most
important for determining which genes got regulated by the different Myb
proteins. The best explanation is that the DNA binding domain is required for
finding Myb binding sites, but the protein-protein interactions mediated by other
domains are required for cooperative interactions necessary to stabilize the
formation of transcription complexes. Thus, the other parts of the Myb protein
determine which promoters get favored, and essentially determine the
specificities and which genes get regulated. This has important implications for
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how the Myb proteins are regulated, since post-translational modifications and
mutations can affect protein-protein interactions and therefore determine which
target genes get activated in different situations.

Mutations change the transcriptional activities of c-Myb
Many studies have investigated the regions of the c-Myb and v-Myb proteins
involved in transcriptional activation, mostly using standard plasmid-based
reporter genes that give information about activity, but not specificity. Deletion
studies originally identified the transcriptional activation domain (residues 241325) of c-Myb as a conserved region downstream from the DNA binding domain
117,118

. However, other studies have shown that this small central domain is not

sufficient for transcriptional activation in the context of the native v-Myb protein 67.
Rather, a series of adjacent subdomains are required for transcriptional
activation by v-Myb, including a heptad leucine repeat or “leucine zipper” (LZ)
and the conserved FAETL motif 139,140. Substitution of specific leucines in the LZ
with proline residues can activate the protein for both transcriptional regulation
and for oncogenic transformation 141, suggesting that the LZ is involved in
negative regulation of c-Myb. In contrast, mutations in this region decrease the
activities of v-Myb 67,140. The results suggest that the central, transactivation
domain of c-Myb and v-Myb is a series of conserved motifs responsible for
mediating interactions with co-activators such as p300/CBP 142,143,144,145 as well
as other proteins whose functions are less well defined, such as p160 146. It is
likely that some of these interactions are more generic, affecting the
20

transcriptional activity of c-Myb measured in reporter gene assays, while others
are more specific and may only become evident when tested in a more
biologically relevant context or with specific sets of target genes.
As described above, the C-terminal domain of c-Myb plays an important role
in controlling which target genes are regulated in different situations. Deletions
and domain swap experiments have demonstrated this for panels of human
target genes 36, and this is the best explanation for the finding that A-Myb and cMyb regulate such different sets of genes, despite having nearly identical DNA
binding domains 37,59. The C-terminal domain of c-Myb, which includes the
transcriptional activation and LZ regions described above, contains numerous
sites of post-translational modifications, including sites of acetylation 147,148,
phosphorylation 92,112,122,149-151, sumoylation 93,111,152-154 and ubiquitinylation
107,113,155

and is the site of action of the proline isomerases Cyp40 and Pin1 that

have dramatic effects on c-Myb activity. It seems likely that the activity and
specificity of c-Myb is regulated by post-translational modifications, some of
which could change in real time, such as during the cell cycle. Thus, c-Myb is
likely to regulate different sets of target genes in different phases of the cell
cycle. However, such time-dependent changes may not be detectable using the
reporter gene assays or even the endogenous gene activation assays that have
been used for most studies involving Myb proteins.
Overall, this section has described the activities of c-Myb and v-Myb, and
how mutations can convert one into the other. The results from many laboratories
and numerous different types of experiments suggest that the activities of c-Myb
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are context-specific and affected by numerous post-translational modifications. It
seems likely that the mutations that distinguish v-Myb mimic a specific set of
modifications in c-Myb, for example by freezing v-Myb into a conformation that
stimulates proliferation. Alternatively, the v-Myb mutations may completely
change the activity of c-Myb, converting it into something more sinister. If the
latter is true, it would mean that v-Myb and c-Myb are as different in activities as
A-Myb, B-Myb and c-Myb, and that they are, for all intents and purposes,
completely different transcription factors. This is in contrast to the notion that vMyb is merely a constitutively activated or de-repressed version of c-Myb. The
possibility that the normal and necessary activities of c-Myb could be corrupted
by mutations into something qualitatively different is one of the defining features
of the Myb proteins, and sets it apart from other oncogenes and other
transcription factors.

Does Myb Regulate Differentiation, Proliferation or Both?
Reversible regulation of differentiation by v-Myb
In transformation assays, normal hematopoietic cells form small colonies in
semi-solid medium, but eventually stop dividing and differentiate into mature
myeloid, erythroid or lymphoid cells. When transformed by oncogenic v-Myb, the
cells become fixed at an immature stage of differentiation and continue
proliferating. As a result, they form large colonies of immature dividing “blast-like”
cells that can be isolated and expanded for weeks in tissue culture. However,
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transformation by v-Myb does not constitute a block in differentiation, but an
acquired phenotype induced by the oncogenic transcription factor. This is evident
from studies performed using a mutant v-Myb that is temperature-sensitive for
DNA binding and for transformation 25,156 and which transforms cells reversibly.
Thus, the ts (temperature sensitive)-v-Myb transformed cells remain immature
until shifted to the non-permissive temperature, which inactivates v-Myb and
allows the cells to differentiate and stop proliferating. If shifted back to the lower
temperature the cells de-differentiate, become immature again and resume
proliferating 156. These results suggest that the active v-Myb induces a change in
the transcription profile, which leads to proliferation and the adoption of an
immature phenotype. When v-Myb is inactivated the cells resume their preprogrammed differentiation pathway and become mature, non-proliferating cells.
Thus, v-Myb affects both differentiation and proliferation simultaneously. In
contrast, cells transformed by the v-Myc oncogene differentiate almost
completely, but retain their ability to proliferate, forming large colonies of mature
monoblast-like cells 157,158. The v-Myc oncogene stimulates proliferation without
blocking or affecting differentiation. If v-Myc is introduced into cells that are
transformed by the ts-v-Myb oncogene, the doubly-transformed cells become
temperature-dependent for differentiation, since the ts-v-Myb controls their
differentiation state, but continue proliferating at both temperatures, due to the
activity of v-Myc 158. This highlights the differences between v-Myb and v-Myc,
but also shows the unique nature of v-Myb and its complex functions, which
affect both differentiation and proliferation.
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Myb target genes and transforming activities are lineage- and
differentiation-specific
The c-Myb protein is expressed in many cell types, including all proliferating
hematopoietic cells and most types of proliferating epithelial cells 7,8,54,159.
However, evidence of transformation by the v-Myb proteins is restricted to
hematopoietic 157 and some neural crest cells 44. Since Myb proteins are
transcription factors, the oncogenic activity is presumably linked to the activation
or repression of specific target genes. However, Myb proteins must cooperate
with other transcription factors in order to regulate cell type-specific genes. The
best example of this is activation of the mim-1 gene, the first identified target
gene for c-Myb 26, which is activated by the combinatorial effects of c-Myb plus
C/EBPbeta (also called NF-M) that binds adjacent to c-Myb on the mim-1
promoter 160,161. Thus, c-Myb can only activate the mim-1 gene in cells that
already express C/EBPbeta. However, co-transfection of c-Myb plus C/EBPbeta
into other cell types, such as fibroblasts, can lead to activation of the endogenous
mim-1 gene 161.
Interestingly, the two different v-Myb oncogenes encoded by the AMV and
E26 leukemia viruses transform related, but quite distinct types of cells. Both
types of transformed cells are immature myeloid cells and require the cytokine
cMGF for growth and survival 162 although AMV-transformed cells produce some
cMGF and are therefore less cytokine-dependent, due to autocrine stimulation
121

. Only the E26 transformed cells express the mim-1 target gene, which is
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activated by the E26 form of v-Myb and by c-Myb, but not by AMV v-Myb. The
latter protein has three point mutations in its DNA binding domain that disrupt a
protein interaction surface and prevent it from activating the mim-1 gene 27. As
shown in Figure 1B, the two v-Myb proteins have quite different structures. The
AMV protein is truncated at both ends compared to c-Myb, and has 11 point
mutations that contribute to its oncogenic potential 82,121 and affect which target
genes it regulates 36,78. The E26 protein is fused to the retroviral Gag protein at
the N-terminal end and a portion of another transcription factor, Ets1, at the Cterminal end. The E26 virus transforms more immature Myeloid Erythroid
Progenitor (MEP) cells 163. Interestingly, the ability to transform these immature
cells in vitro requires both the Myb and Ets proteins, but still works when they are
expressed in trans as separate proteins 164. However, the induction of leukemias
in animals requires that the proteins be fused 165, suggesting that the fusion
protein has unique activities, required for leukemia induction, that are not
provided by the separate transcription factors. Indeed, there are even specific
target genes that are only activated by the Myb-Ets fusion protein, and not by the
two proteins expressed separately 166.
If transformation by v-Myb or mutants of c-Myb requires the activation of
specific target genes, then combinatorial effects could explain why v-Myb only
transforms hematopoietic cells and not other cell types. A number of c-Myb target
genes have been identified that may be linked to transformation or
leukemogenesis, including c-kit 43, 45, 167, 168, CD34+ 169, 170, GATA-1 168 and Flt-3
168,171

. All of these genes are expressed in hematopoietic stem/progenitor cells
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but not other cell types and could explain the restriction of v-Myb oncogenic
activity to hematopoietic cells. The ability of Myb proteins to activate these genes
likely depends on combinatorial interactions with other transcription factors,
cofactors, or accessory proteins that influence Myb protein specificity and the
genes that are regulated in each cell type 172. This again highlights the
importance of protein-protein interactions in gene regulation by Myb proteins.
Mutations in c-Myb that disrupt interactions with C/EBPbeta affect the ability to
activate the mim-1 gene 27 and other target genes 36, suggesting that proteinprotein interactions are important for Myb protein specificity and for
transcriptional activity. This opens up new possibilities for identifying possible
drugs targeting specific interactions between Myb proteins and other cooperating
factors linked to transformation, that might inhibit the activities of “bad” oncogenic
Myb proteins in transformed cells, while leaving “good” c-Myb functional in
essential normal cells.

Myb is a key regulator of stem cell fate
Several types of evidence indicate that c-Myb is a key regulator of
proliferation and differentiation in stem cells, and that it plays a central role in the
determination of cell fate. In the hematopoietic system, the earliest evidence for
an important role of c-Myb came from experiments using antisense
oligonucleotides that showed the importance of c-Myb in normal hematopoiesis
21,173

and from the mouse knockouts showing that c-myb gene expression is

required for definitive hematopoiesis in mammals 22. More recent studies have
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used conditional knockout systems to demonstrate that c-Myb is also critical for
adult hematopoietic stem cells 174. These studies showed that c-Myb affects all
the hematopoietic lineages, suggesting either that it functioned at the earliest
stem cell stage or was required in all the lineage-specific progenitors, or both.
Another type of early evidence came from transformation studies, which showed
that even single amino acid changes in v-Myb led to the induction of completely
different phenotypes in the transformed cells 27, suggesting that the oncogenic
Myb protein was playing a decisive role by shifting or determining the extent and
direction of differentiation along different pathways.
The importance of c-Myb in hematopoietic stem cells has been
demonstrated in several different systems. The c-myb mRNA is highly expressed
in pluripotent hematopoietic stem cells 175 and the products of c-Myb target
genes c-Kit 176 and CD34 169,170,177 are used as cell surface antigens to isolate
hematopoietic stem cells and immature progenitors. In mice, two different
mutagenesis studies designed to find genes involved in stem cell regulation
identified mutations in c-myb 178,179, suggesting that even minor changes in the cMyb protein can have dramatic effects on the balance between differentiation
and proliferation in stem cells. However, the absolute levels of c-Myb are also
important, since mice engineered to express low levels of c-Myb displayed
myeloproliferative defects resembling stem cell disorders 42. Very similar studies
have been performed using the zebrafish model, where the c-myb gene is a key
marker of hematopoietic stem cells 180 and imaging studies have been used to
follow the development of c-myb positive hematopoietic stem cells 181. Thus, the
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importance of c-Myb expression for hematopoietic stem cell proliferation and
differentiation has been conserved throughout vertebrate evolution.
Although the role of c-Myb in hematopoietic stem cells has been best
documented, several studies have shown that c-Myb plays an important role in
stem cells from other tissues, including epithelial stem cells in colonic crypts 56
and neural stem cells in adult brain 57. Recent progress in the stem cell field has
led to procedures for generating induced Pluripotent Stem (iPS) cells from adult
fibroblasts, keratinocytes and other tissues 182,183. One of the important inducer
genes used for the generation of iPS cells, c-Myc, is a known target gene for cMyb 53 and bioinformatics approaches have identified c-Myb as a likely regulator
of pluripotency and “stemness” in iPS cells 184, but so far no direct tests of the
role of c-Myb, or the effects of oncogenic variants such as v-Myb, on the
formation of iPS cells have been reported.

Myb target genes may change during differentiation and the cell cycle
Several c-Myb target genes important for stem cells or early progenitors
have been identified, including c-Kit 176 and CD34 169,170,177, suggesting that cMyb is required for the expression of genes that are important in stem cells and
the earliest progenitors. However, c-Myb is also required for the expression of
mim-1 26, myeloperoxidase 185 and other genes that are expressed in mature
cells 186. Ironically, the mature cells express little or no c-Myb, which is primarily
expressed in the immature proliferating cells. This suggests that c-Myb may be
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involved in the initial activation of genes that are kept active by other transcription
factors in the mature cells. Although the mechanisms remain poorly defined, it is
clear that c-Myb regulates different genes in the immature and more mature
cells, another example of its context-specific regulation activity. As described in a
previous section, c-Myb regulates genes in combinations with other transcription
factors, and its targets change as the presence or absence of the other factors
change during differentiation.
Recently, c-Myb was shown to regulate the expression of Cyclin B1, a cell
cycle regulatory gene involved in G2/M transition 52. These results are important
because they suggest a mechanism for c-Myb regulation of the cell cycle and
proliferation. The c-Myb protein has also been shown to form complexes with
Cyclin D1 83 and with the cyclin-dependent kinases CDK4 and CDK6 187, which
also affect c-Myb transcriptional activity via a mechanism that involves p27Kip1
187

. These results raise the possibility that c-Myb activity and specificity could be

regulated during the cell cycle. For example, c-Myb might regulate different sets
of target genes in different cell cycle compartments. Cell cycle regulation could
be controlled by phosphorylation or other post-translational modifications, or by
the presence or absence of specific co-regulators, such as E2F or Rb. There is
ample evidence that the related transcription factor B-Myb is regulated by
association with Rb and other cell cycle-regulated proteins 133,188 and that B-Myb
transcriptional activity can be regulated by Cyclin-dependent kinase
phosphorylation 189,190. However, direct evidence that c-Myb activity is regulated
during the cell cycle is still unavailable.
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Mechanisms Affecting c-Myb Activity and Specificity
Activation of the c-myb gene in tumors
The control of c-myb transcription is complex and can be affected by several
different mechanisms. Overexpression or rearrangement of the c-myb gene has
been reported in patients with head and neck carcinomas, breast cancer,
melanoma and leukemias 14-16,191, implicating activated alleles of c-myb in the
development of human tumors. However, the c-myb gene promoter is GC rich,
resembling a constitutively expressed promoter from a housekeeping gene 192,
suggesting that expression of the gene is controlled through unconventional
mechanisms. Early studies in murine hematopoietic cells demonstrated a direct
correlation between the relative abundance of c-myb mRNA and the level of
transcriptional arrest in intron 1 (Figure 1A) 29,193. Attenuation of transcription
was linked to the rapid down-regulation of c-myb mRNA that occurs during the
induced differentiation of human colorectal cancer (CRC) cell lines 9 and
sequence analysis of primary CRC tumor samples revealed frequent mutations in
a poly-T tract disrupting a proposed stem-loop motif in intron 1. The mutations
reduced transcriptional attenuation and allowed greater gene expression,
suggesting that disruption of the attenuation mechanism plays an important role
in the elevated levels of c-myb mRNA in CRCs 10. In human breast tumors, cmyb was found to be over-expressed in estrogen receptor positive samples and
run-on transcription assays showed that c-myb transcriptional elongation was
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directly regulated by estrogen/ER signaling 5. These results show that
attenuation or control of elongation is an important mechanism for regulating the
levels of c-myb in normal and tumor cells.
Elevated levels of c-myb mRNA can also be caused by genomic alterations,
such as reciprocal translocations or genomic amplification. In human T-cell acute
leukemia (T-ALL), recurrent chromosomal translocations t(6;7)(q23;q34)
involving the TCRB and c-myb loci were identified (Figure 1B) 16. These
translocations were reciprocal and balanced, and led to the juxtaposition of the cmyb proto-oncogene near the TCRB regulatory sequence, which suggested
deregulated expression. Chromosomal translocations involving the c-myb gene
were also reported in other types of human tumors: the t(6;9)(q22-23;p23-24)
translocation in adenoid cystic carcinomas (ACC) of the breast and head and
neck consistently resulted in fused MYB-NFIB transcripts predominantly
consisting of MYB exon 14 linked to the last coding exon of NFIB (Figure 1B) 6.
This leads to loss of c-myb exon 15, which encodes the 3’-UTR, where several
highly conserved target sites for microRNAs (miR15a/16 and miR-150) are
located (Figure 1B). Thus, the translocation appears to deregulate c-myb by
removing the microRNA binding sites.
The human c-myb locus was recently found to be flanked by 257-bp Alu
repeats that can mediate c-myb gene tandem duplication by homologous
recombination between related elements on sister chromatids 17. This Alumediated c-myb tandem duplication could be one of the reasons for genomic
duplication of c-myb gene frequently reported in human T-ALL 16,18, MYST3-
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linked AMLs 194, BRCA1-mutated breast cancer 4 and some other types of
cancer. Intriguingly, comparative studies on healthy individuals and patients with
T-ALL showed that this tandem duplication also occurs spontaneously during
normal thymocyte development and is clonally selected during the molecular
pathogenesis of human T-ALL. So rearrangement or duplication of the c-myb
gene may occur frequently, but is apparently not sufficient to induce
leukemogenesis or transformation without other cooperating events.

Alternative RNA splicing as a novel mechanism for unleashing c-Myb
oncogenicity
Alternative RNA splicing provides a mechanism for encoding multiple
different transcripts from a single gene and represents an important molecular
mechanism of gene regulation in physiological processes such as developmental
programming as well as in disease. Recent studies using next-generation
sequencing technologies have shown that up to 94% of human genes undergo
alternative RNA splicing 195, suggesting that this mechanism is important for
adding to the complexity of expressed transcripts. In cancers, splicing is
significantly altered. Many cancer-associated splice variants arise from genes
with an established role in oncogenesis, and their functions can be oncogenic.
The c-myb gene contains 15 classical exons and 6 alternative exons (Figure 1B).
It undergoes extensive alternative splicing producing dozens of different splice
variants that encode many different isoforms of c-Myb protein 19. Alternative
splicing in c-myb RNAs has been detected in both normal and tumor cells and in
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several species 196-200. Recent studies revealed an array of c-myb variant
transcripts, expressed in highly regulated, lineage-specific patterns, that are
formed through the use of alternative exons 8A, 9A, 9B, 10A, 13A and 14A
(Figure 3A) 19. All of these identified splice variants encode Myb proteins sharing
the same DNA binding domain but having unique transcriptional activation and
C-terminal domains. Several lines of evidence have shown that relatively minor
changes in the transcriptional activation domain and/or negative regulatory
domain of c-Myb can dramatically affect its transcriptional activity, raising the
possibility that the variant c-Myb proteins encoded by these splice variants may
display unique transcriptional activities. Indeed, the variant c-Myb proteins
encoded as a result of alternative RNA splicing have quantitative and qualitative
differences in their transcriptional activities 19.
Perhaps the best characterized of the alternatively spliced c-myb transcripts
includes alternative exon 9B (previously named 9A) that encodes the p89 variant
of c-Myb with a 121-amino-acid in-frame insertion in the transcriptional activation
domain (Figure 3A) 201-203. Overexpression of this alternatively spliced isoform in
avian hematopoietic cells resulted in increased transactivation and
transformation activity 204. The murine homologue of this variant enhanced cell
survival in hematopoietic cell assays in which wild-type c-Myb accelerated cell
death 205. The 9B variant is conserved throughout vertebrates, suggesting that it
plays an important role. However, a targeted knockout of the 9B/p89 variant had
no apparent phenotype 206, so it is possible that the variant has specialized
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functions or that the loss of the variant might be compensated for by other forms
of c-Myb.
Recent studies showed that the patterns and relative levels of c-myb splice
variants changed dramatically in a lineage-specific manner during the in vitro
differentiation of CD34+ cells 19, suggesting that the alternative splicing of c-myb
transcripts is highly regulated in hematopoietic cell differentiation and that the
ratios or the relative levels of alternatively spliced c-Myb variants play a role in
lineage-specific functions of hematopoietic cells. Some alternative exons contain
stop codons or cause a translation frame-shift, so the encoded variant proteins
have C-terminal deletions, similar to the oncogenic v-Myb (Figure 3A) 19. Since
the alternative splicing of c-myb transcripts produces a family of transcription
factors, it is possible that aberrant or increased alternative splicing in tumors
could lead to the production of truncated variants of c-Myb with transforming or
leukemogenic activities. This would represent a novel mechanism of activation of
an oncogene via alternative RNA splicing. Unfortunately, there is very little
information about how alternative splicing is regulated, although some splicing
factors have been shown to have oncogene like activities when over-expressed
207

.

Regulation of c-myb expression through microRNAs
MicroRNAs (miRs) are a large and growing class of ~22 nucleotide-long
non-coding RNAs which function as repressors, negatively regulating the
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expression of their target genes, in all known animal and plant genomes 208 209. In
many cases, miRNAs bind to the 3’-UTRs of the mRNAs they regulate 209. The cmyb gene encodes an mRNA with an extensive 3’-UTR that contains binding
sites for several different microRNAs, and there are several examples of
microRNAs that appear to regulate the turnover or translation of c-myb mRNA.
For example, the microRNA miR-150, which binds the c-myb 3’-UTR, was found
to be down regulated in granulocytes that over-expressed c-myb and that were
isolated from patients with primary myelofibrosis (PMF)210. The implication is that
aberrant expression of miR-150 in the PMF patients led to over-expression of cmyb mRNA and subsequent defects in granulocyte differentiation. Similar studies
have uncovered an important control circuit in which miR-150 plays a critical role
in the regulation of c-myb during the development of B-cells 33 and other
hematopoietic lineages32,211. The link between miR-150 and c-myb has even
been conserved in zebrafish 31. In addition to miR-150, the c-myb 3’UTR also
contains binding sites for several other microRNAs 30,34,212. These results indicate
that deregulation of c-Myb expression by aberrant expression of microRNAs
could be another mechanism of activating c-Myb in tumors.
Like the c-Myb protein, which is regulated by many different mechanisms,
the c-myb gene is controlled at all possible levels, from regulation of the
promoter, to control of transcriptional elongation, to alternative RNA splicing, to
microRNAs that control the fate of the mRNAs. Each of these is a potential
regulatory circuit that can respond to various extracellular cues or activated
signaling pathways. Thus, the regulation of c-myb expression is a complicated
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and rich area of study, and offers many opportunities for potential intervention in
the design of novel therapeutic approaches.

Perspective
One of the most surprising and provocative results that has come out of
studies of c-Myb and v-Myb is the finding that the activities of Myb proteins are
variable and context-dependent and controlled by their interactions with other
proteins. Thus, c-Myb regulates different target genes in different cell types, in
immature vs. mature cells and perhaps even during different parts of the cell
cycle. On the one hand, this realization seems obvious, since c-Myb is expressed
in so many different cell types. However, there were expectations that c-Myb
would be a “master regulator” of hematopoiesis or that it would have one or a few
key targets that would explain its ability to become an oncogenic transforming
protein. On the contrary, c-Myb has turned out to regulate hundreds of target
genes, and to regulate different sets of genes in different cell types 36,37,78,186. The
oncogenic activity of v-Myb may be linked to its ability to regulate different genes
than c-Myb, or to do so at different times or in different circumstances than cMyb. And oncogenic activity may be a combined effect of activating dozens or
hundreds of genes, rather than one key target. The other big surprise about cMyb is the large number of proteins it interacts with, and the large number of
post-translational modifications that affect it. Dozens of Myb-binding proteins
have been identified, including cell cycle regulators, transcription factors,
transcriptional co-activators and modifying enzymes. Although some of these
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interactions have been shown to affect the activity of c-Myb, it is not at all clear
how all these potential interactions relate to one another. For example, do these
interactions happen simultaneously in the same cell? Do they happen on the
same c-Myb protein or do they define subpopulations of c-Myb with distinct
protein partners and activities? It seems clear that the study of c-Myb needs to
progress from the discovery phase and into a more systematic study of how the
protein is regulated in a time- and context-dependent manner.
Despite more than 25 years of research, the question of what makes v-Myb
a transforming protein remains unanswered. This is the central question, and the
reason that studying c-Myb is significant and unique. We have learned that the
v-Myb protein is lacking the C-terminal domains that cause c-Myb to be rapidly
degraded and that promote its intramolecular auto-inhibition, that the v-Myb
mutations affect protein-protein interactions and that v-Myb and c-Myb regulate
different sets of genes, but we do not understand why v-Myb is an oncogene,
what genes it regulates in transformed or leukemic cells or how those genes
contribute to oncogenesis. Answering these questions may require using new
technologies, like genome-wide chromatin immunoprecipitation assays, in order
to identify all the v-Myb targets in transformed cells. A related question is whether
mutants or splice variants of c-Myb that are expressed in tumors can mimic the
activity of v-Myb, which appears to be so different from that of c-Myb. It will be
necessary to understand the transforming activity of v-Myb in order to answer
these questions about c-Myb and derivatives of it.
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Although the transforming potential of c-Myb is still not understood, it has
become clear that the regulation of c-Myb is extremely complex and involves
many different pathways and regulators. The regulation of c-Myb activity involves
changes in c-myb gene expression, changes in alternative splicing, regulation by
microRNAs and then a myriad of post-translational modifications and protein
interactions. It seems that c-Myb plays the role of integrator, at the intersection of
many different signaling and regulatory pathways. With so many variables
affecting its expression and activity, it should be no surprise that the activities of
c-Myb are also complex. Hopefully the application of new technologies will
illuminate the role of Myb proteins in transformation and oncogenesis, provide an
understanding of how post-translational modifications and protein-protein
interactions control c-Myb and help explain its important roles in determining cell
fate and controlling differentiation and proliferation.
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Figure Legends
Figure 1. Myb genomic and protein structures.
(A) A diagram of the c-Myb protein structure shows the major functional
domains including the highly conserved DNA binding domain (DBD) near the Nterminus, transcriptional trans-activation domain in the middle, and the C-terminal
negative regulation domain. Shading indicates the most highly conserved
portions of the protein and known sites of post-translational modifications are
marked with asterisks. Structural details are labeled below the diagram. The DNA
binding domain is comprised of Myb repeats R1, R2 and R3 and is also the
binding site for a number of proteins including Ets-1, Cyp40, p100, c-Ski, N-CoR
and mSin3A, as indicated. The central transactivation domain (TAD) is the
interaction site for p300/CBP. The negative regulatory domain (NRD) extends
from the LZ/FAETL region to the EVES motif and includes the binding sites for
p160, Pin1 and TIF1beta. Arrows indicate potential intramolecular interactions.
The lower section shows the structures of the AMV v-Myb and E26 Gag-Myb-Ets
proteins. Compared to c-Myb, both have N- and C-terminal truncations. AMV vMyb also has 11 point mutations (empty circles) that change its activity. (B) The
c-myb gene contains 15 core exons (black boxes above the line) and 6
alternative exons (under the line). Important features of the gene are labeled
(from left to right): The two promoters (bent arrows) upstream of exons 1 or 2, the
translation attenuation site in intron 1 (star), a frequent site of chromosomal
translocation in tumors (//) and the 3’ untranslated region encoded by exon 15
containing microRNA binding sites.
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Figure 2. Wnt signaling affects c-Myb stability and activity.
c-Myb protein is phosphorylated and degraded by Wnt-1 signal via the
pathway involving TAK1, HIPK2 and NLK. Wnt-1 causes the nuclear entry of
TAK1, which then activates HIPK2 and NLK. NLK directly binds to c-Myb DNA
binding domain with HIPK2, resulting in the phosphorylation of c-Myb at multiple
sites (indicated by P), which enhances the interaction of c-Myb with Fbw7, a
ubiquitin ligase, and as well as the interaction with the SCF complex, leading to
ubiquitinylation of c-Myb and degradation by the proteasome. Mutations in the
DNA binding domain of v-Myb decrease the affinity for HIPK2, and the C-terminal
truncation removes NLK phosphorylation and ubiquitinylation sites, helping vMyb to evade this regulatory mechanism.

Figure 3. Alternative splicing as a novel means of activating c-Myb.
(A) The diagrams depict the protein structures of wild type c-Myb,
alternatively spliced isoforms 9B, 8A, 9A, 10 and 9S/10 and AMV v-Myb. The
DNA binding domain (DBD), transactivation domain (TAD) and negative
regulatory domain (NRD) are labeled at the top. The numbers on the right
indicate amino acid residues from c-Myb plus novel amino acids encoded by the
alternative exons. (B) Different versions of Myb protein have different protein
structures, permitting them to interact and cooperate with distinctive sets of
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transcription factors or cofactors to form stable transcription complexes at
different promoters.
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Chapter 2: Aberrant c-myb alternative splicing in leukemias
Alterations of the C-terminal domains, through post-translational
modifications, mutations or deletions, have been implicated by many studies to
impact the activities of c-Myb. Such mutations can direct c-Myb to different
promoters and transform it to a potent oncoprotein. As discussed, the c-myb
gene undergoes extensive alternative splicing, leading to the expression of
variant forms of c-Myb protein. The variant c-Myb proteins contain the same DNA
binding domain, but have changes in the C-terminal domains. With the
identification of additional c-Myb target genes and the availability of assays that
can detect differences in the genes targeted by different versions of c-Myb, it has
become clear that many of these variant Myb proteins have distinct
transcriptional activities and activate different sets of genes than the “wild type” cMyb. Alternative splicing of c-myb RNAs appears to be tightly regulated in
hematopoietic cell differentiation. It is plausible that alternative RNA splicing
provides a mechanism for producing specific variants of c-Myb with unique
functions in hematopoiesis. By shifting the pattern of c-myb alternative splicing,
hematopoietic progenitor cells could produce a different repertoire of c-Myb
proteins and express a different subset of c-Myb target genes than more
differentiated cells. Thus, if the alternative splicing process skews, oncogenic
forms of c-Myb could be produced, which could potentially affect the normal
hematopoiesis and induce leukemias.
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We hypothesized that aberrant c-myb alternative splicing could correlate
with the formation or the outcome of leukemias. We developed a polony assay to
characterize c-myb alternative splicing in several cell types, including a small
cohort of leukemia samples. We also tested whether some of the c-myb splice
variants that are generally expressed more in leukemias correlate with the
activation of the genes that are potentially targeted by Myb proteins and play
important roles in leukemias. Our data demonstrate that the levels of c-myb
splice variants are more prevalent in leukemia patients and imply that some
splice variants that encode Myb proteins with truncated C-terminal domains could
be oncogenic and contribute to leukemogenesis.
Author Contribution
The following paper discusses our observations in a small cohort of
pediatric pre-B-ALL with 4 independent authors Ye E. Zhou (YEZ), John P’
O’Rourke (JPO), Jeremy S. Edwards (JSE) and Scott A. Ness (SAN). YEZ
performed the research. JPO provided the preliminary data on c-myb splice
variants in different cell types detected by qRT-PCR. JSE provided expertise and
materials for the polony assay. SAN mentored YEZ, provided funding and
supervised all the research. SAN also approved the manuscript for publication.
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Abstract
The c-Myb transcription factor, a key regulator of hematopoiesis, has an Nterminal DNA binding domain and a large C-terminal domain responsible for
transcriptional activation, negative regulation and protein-protein interactions that
control its target gene specificity. Overexpression and rearrangement of the cmyb gene has been reported in patients with leukemias and other types of
cancers, implicating activated alleles of c-myb in the development of human
tumors. Alternative RNA splicing-produced variant c-Myb proteins with different
C-terminal domains and unique transcriptional activities have been detected in
both normal and tumor cells and in several species; however, no link was
established between the aberrant splicing of c-myb and leukemias. Here, by
performing a detailed, single molecule-based polony assay, we monitored c-myb
splicing variants in both leukemia patient samples and normal donors. We found
that c-myb alternative RNA splicing was elevated and much more complex in a
small cohort of pediatric precursor B-ALL samples than in CD34+ hematopoietic
progenitor cells from normal donors. The results revealed that leukemia samples
express more than 60 different c-myb splice variants, most of which have
multiple alternative splicing events and were not detectable by conventional
microarray or PCR approaches. For example, the single molecule assay
detected 21 and 22 splice variants containing the 9B and 9S exons, respectively,
most of which encoded unexpected variant forms of c-Myb protein. Furthermore,
the detailed analysis identified some splice variants whose expression correlated
with poor survival in a small cohort of precursor B-ALL samples. Our findings
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indicate that single molecule assays can reveal complexities in c-myb alternative
splicing that have potential as novel biomarkers and could help explain the role of
c-Myb variants in the development of human leukemia.
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Introduction
The c-myb gene encodes a transcription factor that is absolutely required for
normal hematopoiesis 22 including the differentiation of stem cells into committed
progenitors 179, the normal development of myeloid and erythroid lineages 22,38
and for B-cell and T-cell differentiation 40,213. The c-Myb protein has a highly
conserved DNA binding domain near its N-terminus and a large C-terminal
domain required for transcriptional activation as well as negative regulation
74,78,90

. In addition, mutations or modifications of c-Myb can change its activity,

converting the normal regulator into a potent oncoprotein that transforms
immature myeloid cells in tissue culture and induces leukemias in animals (for
review see 214). Activated alleles of the c-myb gene have been identified in
numerous human malignancies, including several types of leukemias as well as
colon, breast and head and neck tumors 6,16,18. Thus, c-Myb activities are
conflicting, affecting both differentiation and proliferation and from normal
regulator to transforming protein. These duplicities may be due to the fact that
relatively minor changes can completely change the activity and specificity of cMyb. For example, individual point mutations change its ability to regulate
specific target genes 26,27. Furthermore, microarray studies have shown that cMyb regulates totally different sets of target genes than v-Myb, a truncated,
mutated and oncogenic allele of c-Myb encoded by Avian Myeloblastosis Virus
36

. Most of the differences in the activity of v-Myb are due to changes in the large

C-terminal domain, which appears to control target gene specificity by affecting
protein-protein interactions 78. The implication is that the activity of c-Myb is
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highly variable and subject to change through mechanisms that alter its Cterminal domain, such as post-translational modifications, mutations or deletions.
Such modifications can target c-Myb to different promoters and convert it from a
normal regulator into a potent transforming protein.
One of the mechanisms affecting the C-terminal domains of c-Myb is
alternative RNA splicing. The human c-myb gene is located on chromosome
6q22-q23 and spans 15 exons plus 6 alternative exons (Figure. 1A).
Interestingly, all of the alternative exons are in the region of the gene encoding
the C-terminal domains that affect target gene specificity. Alternatively spliced cmyb transcripts have been detected in both humans and animals and in
numerous tissues 19,200,204,215,216 and some c-myb splice variants with altered Cterminal domains have increased transforming activities 204,205,217. Our own
studies showed that alternative splicing of c-myb is tightly regulated during the
differentiation of primary human hematopoietic progenitor cells and that levels of
alternatively spliced c-myb transcripts are elevated in leukemia samples
compared to normal bone marrow cells 19, suggesting that c-myb alternative
splicing could be a whole new mechanism of unmasking its oncogenicity and
play a role in leukemogenesis.
These initial observations prompted us to further investigate c-myb
alternative splicing profiles in leukemia patient samples and to evaluate its
clinical relevance in terms of prognosis. The conventional way to monitor
alternative splicing variants is by using real-time PCR, microarray, or short-gun
sequencing. However, any exons combinatorial information regarding individual
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c-myb transcript is lost in these methods. In order to circumvent this problem, we
applied a polony assay that allows for quantitative profiling complex alternative
splicing at the single-molecule level 218 to analyze the c-myb splicing patterns in
13 pediatric pre-B ALL patient samples and correlate the expression levels of the
splice variants with the survival of these leukemia patients. We also tested
whether c-Myb splice variants that are more highly expressed in leukemias are
able to associate with the level of some oncogenes that are normally
overexpressed in leukemia. Our results showed that alternative splicing of c-myb
RNAs is complex and that leukemias produce elevated levels of c-Myb splice
variants that can be potentially associated with clinical outcome, implicating
deregulation of c-myb splicing could contribute to leukemogenesis.

Results
Alternative splicing of c-myb transcripts is complex and combinatorial
The transforming activity of c-Myb has often been linked to deletions or
mutations in its C-terminal domains 219, which can lead to the regulation of
different sets of target genes 36. Our previous studies showed that alternative
splicing of c-myb transcripts is highly regulated in hematopoietic cell
differentiation and in leukemias, and could lead to the production of variant c-Myb
proteins with different C-terminal domains 19. We set out to determine whether
the shift in the patterns of c-myb alternative splicing could be a novel mechanism
for activating c-Myb oncogenicity in leukemias. However, we were faced with a
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complication due to the complexity and combinatorial nature of c-myb alternative
RNA splicing. As shown in Figure 1A, the c-myb gene spans 41 kb on
chromosome 6q and contains 15 exons that compose the wild type transcript,
plus 6 alternative exons (8A, 9A, 9B, 10A, 13A and 14A). The complexity is
increased further by exons that have multiple splice donor sites. For example, as
shown in Figure 1B, exon 9 can also be spliced as an 85 nt shorter “9S” version.
The normal exon 9 and the short 9S form can be joined to exons 9A, 9B or 10
(labeled a, b, c and d, e, f, respectively), so just this small portion of the gene
produces 6 different splice variants. All six variants encode different versions of
the c-Myb protein, with identical N-terminal DNA binding domains (shaded black
in Figure 1C), but different C-terminal domains that affect transcriptional activity
and that control which target genes get regulated 19,36,37,78. Analysis of chicken
and mouse bone marrow has shown that the use of the 9S splice site is
conserved in other vertebrate species, suggesting that it is an integral and
important part of the c-myb gene (Supporting information Figure S1). For
simplicity, we designate the 9S exon spliced to exon 10 as the 9S/10 splice
variant, and so on.
Our previous studies 19 had also identified a large number of transcripts
containing more than one alternative splice event, e.g. a transcript including exon
8A that also has exon 9S spliced to exon 10. These combinatorial transcripts are
problematic, because the usual methods of measuring alternative splicing do not
assess them correctly. For example, a real-time PCR (QPCR) assay measuring
the 9S/10 splice junction would not distinguish whether exon 8A was also present
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in the same transcript, but the presence or absence of exon 8A produces
markedly different protein products (Figure 1D). Almost all c-myb alternative
splicing occurs in the exon 6-11 region, which is too long to be analyzed using
currently available next-generation DNA sequencing technologies. Therefore, in
order to determine what c-Myb protein products were being produced in different
samples, we had to find a quantitative methodology that would determine the
levels of expression as well as the structures of the c-myb transcripts.
Detection of c-myb alternative splicing variants using a polony-based
assay
To produce a quantitative and complete picture of c-myb alternative splicing,
we adopted a single molecule analysis procedure utilizing polonies, or PCR
colonies 218. In the polony procedure (Figure 2A), mRNA samples are converted
to cDNA by reverse transcription, the mixture of individual cDNA template
molecules are then seeded into and immobilized in a thin polyacrylamide gel
containing primers and other reagents necessary for PCR amplification. In situ
PCR is conducted directly in the gel, which prevents the PCR products from
diffusing away, so that each template produces a “ PCR colony”, or polony, each
of which arose from the same template cDNA. The structures of the polonies are
then interrogated through sequential rounds of hybridization with fluorescently
labeled, exon-specific probes. To test the sensitivity of this assay on detecting a
rare splice variant, we generated polonies from a region of the c-myb transcript
spanning exons 6 to 11, where the majority of alternative splicing occurs. We
used a mixture of wild type c-myb cDNA plus an alternatively spliced cDNA
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containing exon 8A mixed in at different molar ratios (e.g. 5000:1). After in-gel
amplification to produce the polonies, multiple rounds of hybridization were
performed sequentially with fluorescently labeled probes specific for different
exons or splice junctions (Supplemental Table S2). The microscope slide was
scanned after each round of hybridization to record which polonies were positive
for each probe. Since each polony was generated from a single template cDNA
molecule and every polony had a fixed address on the polony slide, the
sequential hybridization steps produced a series of images that were converted
into an exon map for each polony (Supplemental Figure S2).
The Polony assay provides a distinct advantage over QPCR assays, which
only measure one exon or one splice junction at a time. The polony approach
can determine the structure of the entire cDNA molecule that served as the
polony template. This is critical for the analysis of c-myb alternative splicing,
since different splice variants produce different proteins with potentially unique
activities. For example, all splice variants that include exon 8A, which includes a
premature stop codon, produce the same protein, even if they also have
additional alternative exons downstream (e.g. 9S, 9B or 10A). The polony assay
can distinguish these complex splice variants to more accurately quantify which
versions of c-Myb protein would be produced. The QPCR approach cannot
distinguish a transcript that has only exon 10A from one that has both exons 8A
and 10A, so it does not accurately predict which proteins will be produced.
As shown in Figure 2B, the polony assay was highly sensitive and able to
detect one transcript containing alternative exon 8A in a background of more
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than 5,000 wild type c-myb transcripts. Thus, the assay is well suited for
detecting rare splice variants in a background of wild type transcripts. The
linearity of the polony assay was examined by seeding different amounts of wild
type c-myb plasmid templates. As shown in Figure 2C, the polony assay was
linear over a wide range of concentrations (r2=0.99). Thus, the polony approach
provides a sensitive and linear methodology for analyzing the structures and
relative expression levels of alternatively spliced c-myb transcripts, and it gives
more structural information that conventional QPCR approaches.
To test the polony technique using more relevant samples, we examined the
expression of c-myb transcripts in 2 human hematopoietic cell lines (K562 cells,
Jurkat cells) and 2 types of primary cells (peripheral blood leukocytes, PBLs, and
CD34+ progenitor cells) that were previously analyzed extensively for c-myb
splice variants by QPCR and shotgun cloning and sequencing 19. The four cell
types expressed wild type (WT) plus 10 additional splice variants of c-myb, some
of which have not been previously described (Table 1). The patterns of c-myb
splice variants identified by the polony assay were complex, demonstrating the
effectiveness of this assay to detect multiple splice events in a single transcript.
For example, the 9B/10A splice variant, an alternatively spliced c-myb transcript
containing both alternative exons 9B and 10A, was detected in both K562
(0.53%) and Jurkat (1.07%) leukemic cell lines, but not in two primary human
hematopoietic cells. The 9S/10/10A splice variant, which includes the short (9S)
version of exon 9 spliced to exon 10, plus an alternative exon 10A, was
detectable in Jurkat (0.36%) and CD34+ cells (0.09%) but not in the other cell

56

types. Approximately 10%-15% of the c-myb transcripts in these samples were
alternatively spliced variants and the polony assay detected levels of alternative
exons 8A, 9A, 9B and 10A that were similar to the results obtained previously
using either QPCR or direct shotgun sequencing techniques 19. We conclude that
the polony assay provides quantitative information about c-myb alternative
splicing that rivals or exceeds the results obtained using QPCR, and that it offers
a valuable and powerful alternative for quantifying transcripts with complex
structures.
Comparison of the polony and QPCR assays
The results described above demonstrated the usefulness of the polony
assay for following patterns of alternative RNA splicing and suggested that the
polony assay could provide different and more extensive information than QPCR.
We next applied both QPCR and the polony assay to monitor c-myb expression
and alternative splicing patterns in a small cohort (n=13) of pediatric precursor BALL patient samples. RNA samples from each patient were converted to cDNA,
which was used for QPCR assays or used to seed the polony assays, which
were interrogated by probes for various c-myb exons. Up to 1500 polonies per
slide, or 3000 polonies in two replicate measurements, were queried for each
patient sample. As shown in Figure 3A, the QPCR and polony assay results for
the total amount of c-myb transcripts in the patient samples correlated quite well
(r2=0.946), suggesting that both assays were similarly efficient and were equally
linear. This confirms the results described above showing that both the QPCR
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and polony approaches are very sensitive and provide quantitative results, at
least for measuring the total levels of c-myb expression.
However, the differences between the two methods were more dramatic
when they were used to measure the expression of individual c-myb splice
variants. As shown in Figure 3B, the QPCR and polony assays agreed only
modestly (r2=0.815) when they were used to assay the levels of the 9B splice
variant. The situation was much worse for the 9S/10 splice variant (Figure 3C),
where the results from the assays failed to correlate (r2=0.243). Thus, although
the two methods gave highly similar results for the total expression of c-myb,
they gave quite different results for some splice variants, and the variation
appeared to be sample specific, producing much more scatter in the leukemia
sample plots, rather than some sort of systematic difference.
The differences in the QPCR and polony assay results for individual splice
variants can be explained when the details of the polony results are scrutinized
(Supplemental Table S3). While QPCR measures only the relative abundance of
each exon, such as 9B, or each splice junction, such as 9S/10, the polony assay
measures the structure of each template and the data are converted into
predicted protein structures. As shown in Supplemental Table S3, the polony
assay detected a total of 21 different splice variants that contained exon 9B, only
one of which is predicted to produce the 9B splice variant protein, which includes
residues 1-401 of c-Myb, followed by a novel 121 amino acid in-frame insert
followed by residues 402-640 (abbreviated: 1-401, +121aa, 402-640). Similarly,
the polony assay detected 22 different splice variants that included the short 9S
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exon, only two of which produce the 9S/10 protein (1-372, +2aa). Thus, the
QPCR assay overestimates the number of splice variants that will produce the
9B and 9S/10 protein products because it fails to take into account the other
changes in the transcript. Indeed, if the polony assay data are compiled in order
to simulate the QPCR assay results by pooling all the enumerated splice variants
that contain the 9S/10 splice junction, the results of the two assays again
correlate quite well (r2>0.88, Figure 3D). Thus, the polony assay detects all the
different splice variants containing specific exons and provides a more detailed
glimpse of the spectrum of proteins produced as a consequence of alternative
RNA splicing.
Identification of alternatively spliced variants of c-myb in pediatric B-ALL
Using the polony results (Supplemental Table S3), we compared the total
levels of wild type and alternatively spliced transcripts in the leukemia samples,
which revealed that c-myb alternative splicing was highly increased in the
leukemias compared to normal CD34+ cells. In 3 normal donor samples
(progenitor CD34+ cells), the combined expression level of c-myb splice variants
was approximately 5%-15% of the total c-myb transcripts (Figure 4A). However,
the splice variants were much more abundant in the 13 pediatric leukemia patient
samples, accounting for 25% to 60% of the total c-myb transcripts, suggesting
that alternative splicing of c-myb transcripts occurs much more frequently in
leukemias than in normal hematopoietic cells.
The polony assay detected 61 different splice variants of c-myb in the
leukemia samples (Supplemental Table S3). They can be categorized as: (a)
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exon deletions, in which one or more exons are skipped (for example, Del8;
Del9; Del10; Del8/Del9; Del8/9/Del10); (b) partial exon deletions by the activation
of cryptic exonic splice sites (for example, 85 nucleotides of partial exon 9
deletion (9S)); (c) inclusion of one or more alternative exons (for example, 8A;
9A; 9B; 10A); (d) combinations of these splicing events (for example, 9S/9A;
Del8/9S/9B; Del8/9/9B/10A; 9B/10A; 8A/10A). Some of these variants are
predicted to encode the same variant c-Myb proteins, since the introduction of a
premature termination codon is encoded by the upstream alternative exon(s) (8A,
9A, and 10A). Truncation of the c-terminus of c-Myb activates its leukemogenic
activities 74,109, so these variant proteins could be expected to have increased
transforming activities. The c-terminus of c-Myb protein also contains the major
site of ubiquitination, and truncated variants are more stable 107, so the shorter
proteins produced by the splice variants could also be expected to be more
stable than wild type c-Myb protein.
The expression levels of the 13 most abundant splice variants in the normal
CD34+ and leukemia samples (each accounting for more than 1% of the total cmyb transcripts) are shown in Figure 4B. The results revealed highly variable
levels of each of these splice variants amongst the patient samples. For
example, the levels of the 9S/10 transcript varied 6-fold in these 13 patients (from
1% to 6% of the total c-myb transcripts), the level of the 9B form ranged from 2%
to 16% of the total transcripts, and the 10A transcript varied from 5% to 15% of
the total. On average, the splice variants were far more abundant in patient
samples than in normal CD34+ cells. In addition, the splicing repertoires of c-myb
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were distinct in patient samples compared to healthy CD34+ cells and each
patient displayed a unique pattern of splice variants: some patients expressed
more than 25 c-myb isoforms, while others only expressed 12 splice variants
(Supplemental Table S3). Taken together, these data confirm that overall
alternative splicing of the c-myb gene was significantly elevated in leukemia
samples compared to normal CD34+ cells, suggesting that alternative splicing of
c-myb could be linked to prognosis or patient outcome.
Alternative splicing of c-myb as a potential prognostic marker
The higher rates of alternative splicing in leukemias suggested that
expression of particular c-myb splice variants could be a potential prognostic
signature. Analysis of the alternative splicing data (Supplemental Table S3)
showed that only wild type c-Myb and 5 splice variant proteins: Del8, 8A, 9S/10,
9A and 10A were expressed in all the leukemia samples. By analyzing the levels
of expression in leukemias and normal samples (Figure 4B) we identified three
splice variants: Del8, 9A and 9S/10 that were consistently expressed more highly
in the leukemias than in the normal CD34+ progenitor cells. Next, we used the
polony exon profiling data to group the 13 patients based on whether they
expressed above or below the median level of each of the most commonly
expressed splice variants. The survival data for these patients were then
analyzed to see if the groupings, based on splice variant expression, correlated
with better or worse outcome. As shown in Figure 5A, the patients displaying the
highest and lowest levels of total c-myb displayed similar survival curves,
indicating that the absolute level of c-myb expression did not affect outcome in
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this context. Similar results were obtained for the majority of the splice variants
analyzed (not shown). However, the groups of patients with high and low levels
of expression of the 9S/10 splice variant, which is generated through the use of
an alternative splice donor site in exon 9 and which encodes a truncated version
of c-Myb protein (Figure 1C), were quite striking. As shown in Figure 5B, the
patients with below median expression of variant 9S/10 all survived at least 8
years (solid line), while the patients with above median expression of 9S/10 had
significantly lower survival (p<0.05). In contrast, high levels of the c-myb 9B
variant, which has been implicated in altered regulation of apoptosis in some cell
types 205, was associated with increased survival (p=0.265) (Figure 5C). Although
these results are from a small cohort of patients, they suggest that increased
levels of the 9S/10 splice variant could be a negative prognostic factor for
pediatric precursor B-ALL and that analysis of c-myb alternative splicing could
prove to be a useful prognostic marker for leukemias such as precursor B-ALL.
Analysis of the expression of c-myb splice variants relationship with the
expression of oncogenic genes in pediatric B-ALL patient samples
The 9S/10 splice variant of c-myb is formed through the use of an
alternative splice donor site located 85 nucleotides upstream of the normal splice
site, which connects a shortened exon 9 to exon 10. This variant encodes a
truncated c-Myb protein with a unique C-terminus whose structure is reminiscent
of the v-Myb protein encoded by Avian Myeloblastosis Virus, Compared to cMyb, the v-Myb protein is truncated at the N- and C- termini and is modified by
several point mutations that unleash its oncogenic potential and its ability to
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transform myelomonocytic cells 121. Several c-Myb target genes are involved in
regulating cell proliferation, for example cell cycle regulator CCNA1 36 and
transcription factor c-MYC 220; as well as genes important in metastasis, such as
CXCR4 36. Some of these genes have been linked to aggressive childhood pre-B
ALL and high frequencies of relapse 221-224. We tested whether the aberrant
expression of the 9S/10 splice variant could be correlated to the expression
levels of these target genes in pediatric pre B-ALL leukemia patients.
Quantitative RT-PCR was used to compare the expression levels of MYC,
CCNA1, and CXCR4 to the level of splice variant 9S/10 measured by polony
assay (Figure 6). However, the data showed no clear correlation between the
expression of the 9S/10 splice variant and the expression of these Myb target
genes, suggesting that there is no simple, direct relationship between the level of
splice variant 9S/10 and overexpression of these genes.
Discussion
The c-myb gene is organized in way that the vast majority of alternative
RNA splicing occurs in exons encoding the C-terminal domains of c-Myb protein,
generating a family of transcription factors with the same N-terminal DNA binding
domains but differences in the C-terminal domains affecting transcriptional
activity, negative regulation and target gene selection 19,36,78. Here, we have
adapted a polony assay to detect the complex and combinatorial alternative
splicing events in c-myb transcripts and to quantitatively measure the changes in
the patterns of c-myb alternative splicing in different cell lines and in leukemia
patient samples. We found that c-myb alternative splicing is greatly increased in
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precursor B-ALL samples, the pattern of c-myb alternative splicing is more
complex in leukemia patients than in normal CD34+ cells, and the pattern is
distinct in each patient sample, suggesting that activation of alternative RNA
splicing is a mechanism that could contribute to leukemogenesis. By analyzing a
small cohort of patient samples, we identified a splice variant, 9S/10, whose
expression correlated with poor survival. Although confirmation will require
detailed analyses of larger patient cohorts, the results are intriguing and suggest
that patterns of c-myb alternative splicing have the potential to provide an
independent means of classifying patients into different treatment groups, similar
to gene expression profiling 225. Interestingly, the latter approach compares total
levels of mRNAs, but our analyses (Figure 5) showed that total c-myb levels did
not correlate with patient survival, while levels of some individual splice variants
(e.g. 9S/10) did. This may explain why microarray assays did not identify c-myb
as a component of the classifier distinguishing high risk patient groups, even
though c-Myb is a key regulator of proliferation and differentiation in
hematopoietic and other cells 214.
A key difference in our study compared to previously reported analyses of
alternative splicing is our use of a single molecule polony assay to analyze the
various c-myb transcripts. Unlike microarrays or QPCR, which only measure the
relative levels of expression of specific exons or splice junctions, the polony
assay provides structural information over the entire length of the template
cDNA. Thus, the polony assay can identify transcripts that contain both an
upstream variation, such as inclusion of exon 8A, and also a downstream
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variation, such as inclusion of exon 9B. The other methods can detect each of
these events but cannot determine whether both splice variations are present in
the same, or in different RNA molecules. In this example, since exon 8A
introduces a premature stop codon, mRNAs that include exon 8A either alone or
in combination with exon 9B produce the same truncated protein. Thus, the
polony assay is better able to predict which types of variant c-Myb proteins will
be produced in a given sample. At present, even next-generation sequencing
methods are limited to reading less than 1 kb of DNA sequence per run, so they
are insufficient to determine the structure of the entire region of the c-myb
transcript that becomes altered by alternative RNA splicing. Until next-generation
methods are developed that can determine the structures of entire cDNAs, single
molecule approaches such as the polony assay will remain the best alternative
for following complex changes in alternative splicing.
An important question concerns why the alternative splicing patterns differ in
leukemias compared to normal cells, and why they vary amongst different patient
samples. There is little information about the regulation of alternative splicing in
leukemias, although the levels of specific splicing regulatory factors are altered in
tumors, can affect the alternative splicing of some genes, including c-myb, and
can act as oncogenes in some situations 207. Several types of regulatory
pathways, including transcriptional and post-transcriptional regulation and
signaling cascades leading to post-translational modifications can affect the
activities of factors controlling alternative RNA splicing 226. Many of these
pathways can be modified in leukemias, which could lead to changes in splicing
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patterns. In addition, histone modifications can affect alternative RNA splicing 227,
implicating important leukemia-associated oncogenes that affect histone
modifications in the control of alternative splicing 228,229. Thus, the regulation of
alternative splicing is a relatively unstudied area that could be affected by many
of the known oncogene pathways and that could play an important role in tumor
development or progression.
Perhaps the most profound result from our study is that leukemias express
such a large fraction, in some samples up to 60%, of c-myb transcripts that are
alternatively spliced products (Figure 4). Thus, a large fraction, or perhaps even
a majority of the c-Myb proteins in these samples are likely to be variant forms,
rather than the expected wild type c-Myb. Interestingly, the two leukemia cell
lines we analyzed, K562 and Jurkat cells, were much more similar to normal cells
than to the leukemia samples in this respect, since they only expressed 10-15%
of alternatively spliced c-myb transcripts (Table 1). Neither of these cell lines was
derived from a precursor B-ALL, so the high level of alternatively spliced products
we observed in the leukemias could be specific to precursor B-ALL. Alternatively,
the cell lines may be a poor model system for studying the expression of c-myb
variants. Analysis of additional leukemia types will be necessary to distinguish
these possibilities.
Overall, our study explored the possibility of quantitatively monitoring c-myb
alternative splicing in different samples by polony assay. The increased c-myb
alternative splicing events in leukemia patient samples and the survival analyses
suggested a tight link between the regulation of alternative splicing, the
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production of variant c-Myb proteins and their possible roles in leukemogenesis.
Further investigation of more patients using the polony assay or related
techniques will be needed to shed light on the clinical value of following c-myb
alternative splicing in leukemia samples, which could potentially be used as a
unique type of biomarker.

Materials and Methods
Cells, tissue culture and patient samples
Human erythroleukemia K562 cells (CCL-243, ATCC, Manassas, VA) and
human Jurkat T-cells (TIB 152, ATCC, Manassas, VA) were maintained in
RPMI1640 medium (GIBCO, Carlsbad, CA) with 10% Fetal Bovine Serum (PAA,
Morningside QLD Australia). Buffy coat blood samples were purchased from
United Blood Services (Albuquerque, NM) and peripheral blood leukocytes were
purified by Ficoll (Amersham, Piscataway, NJ) density centrifugation and cultured
in Iscove’s Modified Dulbecco’s Medium (IMDM from GIBCO) with 10 U each of
interleukin-2 (IL-2; PeproTech, Rocky Hill, NJ) and phytohaemagglutinin per ml
for 4 days prior to RNA isolation. Cytokine-mobilized CD34+ cells (purchased
from the Fred Hutchison Cancer Research Center Large-Scale Cell Processing
Core) were cultured in IMDM supplemented with BITS serum substitute, IL-3 (20
ng/ml), IL-6 (20 ng/ml), Stem Cell Factor (100 ng/ml), and FLT-3 ligand (100
ng/ml) (all from Stem Cell Technology, Vancouver, Canada). Pre-B-ALL Patient
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bone marrow RNA samples were obtained from the Children’s Oncology Group
Cell Bank.
RNA expression and structure assays
Total RNA was isolated using RNeasy mini kits (Qiagen, Valencia, CA),
cDNA was synthesized using a first-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA), SYBR green-based real-time PCR used a Maxima qPCR kit
(Fermentas, EU) and Taqman probe-based QRT-PCR used Taqman Universal
PCR Master Mix (Applied Biosystems/Life Technologies, Foster City, CA),
according to the manufacturers protocols. PCR reactions were performed in
quadruplicate using primers described in Supporting Information Table S1. The
results of relative gene expression assays were normalized to the level of
GAPDH, and the data were analyzed using the comparative threshold cycle
method 234.
Polony amplification
A variety of cell lines and cell types, and 13 pediatric precursor B-ALL
samples (provided by COG) were used for the c-myb alternative splicing patterns
studies. After reverse transcription (as described above), the polony amplification
was performed as previously described (218. Briefly, the three-step procedure
involves application of the gel matrix on a slide, infusion of PCR reagents and in
situ PCR in a Slide Cycling ‘16/16’ Dual PCR Block (MJ Research, MA). Gel mix
[10 mM Tris-HCl pH 8.3, 50 mM KCl, 0.01% gelatin, 1.5 mM MgCl2, 6%
acrylamide, 0.35% DATD, 0.035% Bis-acrylamide, 1 µM acrydite modified primer
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(Table S2), 0.1% Tween-20 and 0.2% BSA] was freshly prepared, ammonium
persulfate (APS) and TEMED were added to a final concentration of 0.087%
each and 15 µm thick gels were poured on glass microscope slides that had
been partially coated with Teflon masks (Erie Scientific), which served as
spacers between the glass surfaces and glass coverslips (22 mm x 30 mm,
Fisher Scientific). The gels were allowed to polymerize in a dedicated pre-PCR
hood for 15 min. The slides were washed 20 min in ddH2O, dried under the hood
for about 25 min and 23 µl of polony amplification mix [10 mM Tris-HCl pH 8.3,
50 mM KCl, 0.01% gelatin, 0.2% BSA, 0.1% Tween-20, 1.33 µl primer (Table
S2), 200 µM dNTP, 0.335 U Jumpstart Taq and desired amount of template] was
poured on the slides and covered with a coverslip. The slides were covered with
mineral oil utilizing adhesive incubation chambers (Secure Seals SA 500,
GRACE Bio-Labs), then cycled in a PTC-200 twin tower thermocycler as follows:
denaturation (3 min at 94 °C), amplification for 48-52 cycles (30 sec at 94 °C, 45
sec at 62 °C, 3 min at 72 °C), extension (6 min at 72 °C), chill to 4 °C. After
cycling, mineral oil was washed off by rinsing the slides in hexane.
Denaturation and Hybridization
After polony amplification, the unattached strand of DNA was removed by
incubating the slides (after removing the glass cover slip) in pre-warmed
denaturing buffer (70% formamide, 1 x SSC) at 70 °C for 15 min. The slides were
subsequently washed in ddH2O for 3 min, 2 x 4 min each in wash buffer 1E (10
mM Tris-HCL pH 7.5, 50 mM KCL, 2 mM EDTA, 0.01% Triton X-100) and 90 µl
of annealing mix [0.5 µM of each hybridization probe (4 probes at a time), 6 x
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SSPE, 0.01% Triton X-100] (all of the probes were listed in Table S2) was added
over the gel and sealed with a frame seal chamber (HybriWell HBW2240,
GRACE Bio-Labs). The slides were heated at 94 °C for 6 min, followed by 58 °C
for 15 min. Free probes was removed by washing the slides 2 x 4 min in wash
buffer 1E. Following the first cycle, subsequent denaturation steps were
performed at 65 °C for sequential exon hybridization. Denaturation in the
denaturing buffer will result in removal of the fluorophore labeled exon probes
and therefore is done before the annealing of a new exon probes.
Image Acquisition and Data Analysis
All images of gels were acquired on a ScanArray 5000 instrument (Perkin
Elmer) at 10 µm resolution using four lasers (635 nm, 532 nm, 488 nm, 594 nm).
Gels were scanned after hybridization with labeled probes, as well as after probe
stripping (to assess background signal). The myb-exon probed polony slide
images were processed with Matlab to generate a composite. Colocalization of
polonies allowed us to detect the exon context of the original molecule. A grid
was overlaid on the images and a systematic random approach was performed
to select fields for analysis. A total of 250–1500 polonies per case were counted
in this fashion to provide estimates of expression. For each case, there were at
least two slides created and counted. All counts were performed without
knowledge of diagnosis.
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Sensitivity and linearity of the polony assay
PCR products containing unique alternative exons were cloned in frame in a
human c-Myb expression vector (pCDNA3; Invitrogen). To assess the alternative
splice variant detection sensitivity of the polony assay, we performed the polony
assay on different molar ratio of mixtures of wild-type c-myb transcript plasmid
and the plasmid containing unique alternative exon 8A. To evaluate the
quantitative ability of the polony assay, we serially diluted the wild-type plasmid
from 5 x 10-2 ng/µl to 6 x 10-4 ng/µl, and used 1 µl from each dilution to perform
the polony assay.
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Figure Legends
Figure 1. Alternative splicing in the c-myb gene
(A) Structure of the human c-myb gene. The diagram shows the exon
structure of the human c-myb gene, which spans more than 41,000 nucleotides.
The arrow marks the major transcription initiation site and exons 1-15, which are
included in the wild type version of c-Myb, are indicated above the line. The
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highly conserved DNA binding domain of c-Myb is encoded by exons 4-6, and
the C-terminal domains that control transcriptional activity and specificity are
encoded by exons 7-15, as indicated. The latter region also includes the 6
alternative exons, shown below the line. (B) Alternative splicing in exons 9-10. A
cryptic splice donor site in exon 9 generates a short (9S) version lacking 85 nt
(shaded). Both the long and short forms of exon 9 can be spliced to alternative
exons 9A or 9B or to exon 10. (C) Diagrams of wild type c-Myb and the 9A, 9B,
9S/9A, 9S/9B and 9S/10 splice variants. The structure of the v-Myb protein
encoded by Avian Myeloblastosis Virus is shown for comparison. The highly
conserved Myb DNA binding domain is shaded black. The variant proteins lack
the normal C-terminus of c-Myb and have unique regions, indicated by shaded
boxes. The numbers on the right summarize the structures of the proteins with
the included amino acids (aa) and the changes relative to wild type c-Myb. (D)
Structures of the proteins encoded by splice variants 8A, 8A/9S/10 and 9S/10.
These variants are described in the text. Labels and numbering are as in panel
(C).

Figure 2. Sensitivity and linearity of the polony assay
(A) Outline of polony assay. Gene-specific primers are used to convert
mRNA to cDNA, which is then seeded into a thin acrylamide gel containing
primers, enzymes and other components necessary for in situ PCR, which
results in the formation of “PCR colonies”, or polonies. The polonies are fixed in
the gel, but can be interrogated by sequential hybridization with specific
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fluorescently labeled oligonucleotides. (B) Sensitivity of polony assay. Plasmids
containing cDNAs for wild type c-myb or the 8A splice variant were mixed in a
ratio of 5,000:1. After in situ PCR, the slide was hybridized sequentially with
fluorescently labeled probes specific for exon 8, exon 8A or exon 11. The full
polony slide is shown at left and the enlargement at right shows a single detected
exon 8A-containing splice variant (white). In the false color image the polonies
containing only exons 8 and 11 appear Cyan in color, the polony containing all
three exons appears white. (C) Linearity of polony assay. Different amounts of
wild-type c-myb plasmid were used as template in the polony assay and the
number of polonies detected with the exon 11 probe was plotted against amount
of plasmid template used in the assay. The assay was very linear, as shown by
the correlation coefficient r2, which was 0.99.

Figure 3. Comparison of exon-specific (QPCR) to single molecule (polony)
assays
Scatter plots compare the levels of different c-myb splice variants detected
by bulk QPCR or single molecule polony-based assays for (A) total c-myb
transcripts or (B-C) the 9B or 9S/10 splice variants, respectively. The QPCR and
polony assays agree nicely (r2=0.946) for total c-myb transcripts, but the results
for the 9B variant agree only modestly (r2<0.82) and the results for the 9S/10
variant did not correlate well (r2<0.25). (D) Compiling the polony data by
combining all the detected transcripts that contain the 9S/10 exon produces data
that correlate much better (r2>0.88) with the QPCR data. Thus the differences in
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the two assays are due to the exclusion of variants in the polony results that are
predicted to produce different protein products, which are detectable in the
polony assay but not by QPCR.

Figure 4. Alternative splicing of c-myb transcripts in normal and leukemic
cells
(A) Rates of c-myb alternative splicing in normal cells and leukemias.
Polony assays were used to measure the levels of normal and alternatively
spliced c-myb transcripts in normal CD34+ progenitors from healthy donors (n=3)
or in pediatric precursor B-ALL patient samples (n=13). The black and gray
sections of each bar indicate the fractions of alternatively spliced or wild type
transcripts, respectively. (B) Patterns of c-myb alternative splicing in pediatric
precursor B-ALL samples. Dots indicate levels of wt or splice variant expression,
as a fraction of total c-myb transcripts detected, as determined by polony assay
for pediatric precursor B-ALL samples (n=13, filled circles) or CD34+ cells from
normal donors (n=3, empty diamonds). Each symbol represents the average of
duplicate measurements and the horizontal bars represent the median values for
the leukemia samples.
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Figure 5. Survival plots for patients grouped by c-myb variant expression
levels
Precursor B-ALL patients (n=13) were grouped according to their
expression above (dotted line) or below (solid line) the mean expression level for
(A) wild type c-myb or (B) the 9S/10 variant or (C) the 9B variant. The plots show
overall survival curves, with p-values as indicated.

Figure 6. Relationship between the 9S/10 splice variant’s expression level
(measured by polony assay) and the Myb target genes’ expression levels
Patient RNA samples were analyzed by QRT-PCR to assess the expression
level of the CCNA1, MYC, and CXCR4 genes, relative to the GAPDH control
gene and the patient sample that has the lowest expression. Scatter plots
correlate the levels of 9S/10 splice variant in each patient detected by polony
assay with the levels of the CCNA1 (A), MYC (B), and CXCR4 (C) genes
measured by QRT-PCR, respectively. R is the observed correlation coefficient.

Supporting Information Legends
Figure S1. Conservation of the c-myb 9S/10 splice variant.
(A) Comparison of the cryptic splice site in exon 9 from human, mouse and
chicken and the predicted C-terminal amino acids in the corresponding c-Myb
9S/10 variant proteins. The 5’ splice site (gt) is bolded. All the predicted proteins
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terminate with two serine residues (in bold). B) Expression of the c-myb 9S/10
variant in primary chicken and mouse bone marrow cells. RNA samples isolated
from the chicken cell line HD3, primary chicken bone marrow or primary mouse
bone marrow were subjected to RT-PCR using a forward primer spanning the
unique 9S/10 splice junction and a reverse primer found in exon 10. Nucleotide
sequencing of the PCR product confirmed that it was the expected splice junction
product from the 9S/10 splice variants.

Figure S2. Polony exontyping of c-myb transcripts.
(A) Scheme of c-myb alternative splicing. 11 exons including constant and
alternative ones were analyzed in this experiment. The same slide was
sequentially hybridized with 11 different fluorophore-labeled exon probes. The
probed exons are shown in different colors. Exon8: red; Exon 8A: green; Exon
10A: blue. All four possible alternative splicing isoforms are indicated. (B)
Individual and merged images hybridized with exon 8, exon 8A and exon 10A are
shown. Different combinations were identified as indicated. White polonies are
transcripts with 8A+10A+8, purple are transcripts with 8+10A, and yellow are
transcripts with 8A+8.

76

77

78

79

80

81

82

83

84

Tables
Table 1. Expression of c-myb splice variants in different cell lines
Description

Accession No.

Exontyping

K562

Jurkat

PBL

CD34+

Del9

AY787448

6-7-8-10-11

ND

1.78%

ND

0.26%

Del8

AY787447

6-7-9-10-11

1.33%

ND

1.05%

0.45%

9S/10

AY787470

6-7-8-9S-10-11

2.13%

0.36%

1.83%

0.89%

Del10

NA

6-7-8-9-11

0.27%

ND

ND

0.09%

Del8/9A

NA

6-7-9-9A-10-11

0.27%

ND

ND

ND

9A

AY787464

6-7-8-9-9A-10-11

0.54%

0.36%

0.52%

0.18%

9B

AY787467

6-7-8-9-9B-10-11

6.91%

5.69%

2.09%

2.09%

9B/10A

NA

6-7-8-9-9B-10-10A-11

0.53%

1.07%

ND

ND

9S/10/10A

AY787471

6-7-8-9S-10-10A-11

ND

0.36%

ND

0.09%

10A

AY787450

6-7-8-9-10-10A-11

2.66%

4.63%

6.54%

2.84%

8A

AY787454

6-7-8-8A-9-10-11

1.06%

1.43%

3.40%

3.76%

WT

AY787475

6-7-8-9-10-11

84.57%

84.34%

84.55%

89.35%

Table 1 Legend
Expression of c-myb alternative splicing isoforms measured by polony assay and
expressed as percentage of the total detected c-myb transcripts. ND: not detected. NA:
not applicable, since these products were only detected using the polony assay, their
sequences have not been determined and no accession numbers are available.
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Supporting Information Tables
Table S1. Primers used for QRT-PCR.
SYBR Green Detection
Name
c-myb 9S/10

Sequence
Forward

5’-CCTCGCCAGCAAGTTCTTA

Reverse 5’-GGTGGAAGTTAAAGAAGGCATTT
c-myb 9B/10

Forward

5’-TTCAACTCCCAAGCGTTCC

Reverse 5’-AAAGAAGGCATTTCCAAGTCTG
CCNE1

Forward

5’-CCATCCTTCTCCACCAAAGA

Reverse 5’-CTGGAGGTGGCTGGTGTACT
c-MYC

Forward

5’-CAGCTGCTTAGACGCTGGAT

Reverse 5’-ACCGAGTCGTAGTCGAGGTC
GAPDH

Forward

5’-GCTGTGTGGCAAAGTCCAAG

Reverse 5’-GGTCAGGCTCCTGGAAGATA

Taqman Expression Assay
Primer

Catalogue Number

CXCR4

HS00607978_s1

c-myb

Hs00193527_m1
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Table S2. All primers used to perform polony amplification and exonprofiling
Name

Sequence (5’-3’)

Gene specific reverse primer

AGAAGACGAGTGTGGTGACC

Myb_Forward

Acrydite/GGAAGGTCGAACAGGAAGGTTATCTG

Myb_Reverse

CTAGATGAGAGGGTGTCTGAGGTAGCA

Myb_E6R

Alexa532/TAGTCGTTGTTAACAGTGGGCTGG

Myb_E7R

Alexa488/GGTATGGAACATGACTGGAGAC

Myb_E8R

Alexa647/TTTATTCGCTTTTCCTTCTCAGGG

Myb_E8AR

Alexa594/CTGCCCAGTCGCTAAAGATGTC

Myb_E9R

Alexa532/CATGAGGTCTGGTGTGGTCGGCAA

Myb_E9AR

Alexa488/TGAGCAGTTGCTCTATTATACTGC

Myb_E9BR

Alexa594/CTACAGTCTCCAGTGGCTAAGG

Myb_E10R

Alexa532/CAGTCAATTTGTGACCAATGAG

Myb_E10AR

Alexa594/ATTCCTGGGGATGTCAGAAGAG

Myb_E11R

Alexa488/GAATGGTGTAGGAGTTCTTGGA

Myb_E(9-9S)R

Alexa647/TTAACATTATCCAGAATGGTGCC

87

Table S3. The expression level of c-myb splice variants detected by polony assay in 13 pediatric pre-B ALL
sample
Isoform

Protein Size

Exontyping

611859

612296

610319

610190

610856

610761

609266

611159

610194

612110

609941

609963

611551

1

Del8/Del9

1-281, 402-640

6-7-10-11

0.14%

ND

ND

ND

ND

ND

ND

ND

0.24%

ND

ND

0.47%

ND

2

Del8/Del10

1-281, 371-402

6-7-9-11

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.16%

ND

3

Del8

1-281, 317-640

6-7-9-10-11

4.20%

12.54%

3.18%

5.21%

3.54%

1.05%

4.29%

5.51%

2.59%

3.25%

0.92%

5.94%

0.73%

4

Del9

1-316,402-640

6-7-8-10-11

0.36%

0.57%

1.03%

1.74%

1.29%

3.14%

0.51%

1.48%

ND

0.12%

0.23%

1.25%

2.00%

5

Del10

1-402

0.21%

0.28%

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.16%

0.36%

6

WT

61.85%

62.96%

62.30%

77.43%

51.13%

74.22%

56.31%

51.91%

57.46%

40.14%

60.32%

63.28%

70.24%

7

Del8/9S

1-640
1-281, 317-372,
+2aa

6-7-8-9-11
6-7-8-9-1011

0.14%

1.71%

ND

0.35%

0.96%

0.35%

0.25%

0.64%

0.47%

ND

0.23%

0.78%

ND

8

Del8/9S

0.07%

ND

ND

ND

2.57%

ND

ND

ND

ND

ND

ND

ND

ND

9

9S/10

2.42%

3.42%

2.43%

4.17%

1.93%

4.53%

5.81%

2.54%

5.05%

2.88%

5.28%

4.53%

6.17%

10

9S/10

1.07%

0.28%

0.19%

ND

1.93%

1.05%

0.25%

0.21%

0.47%

0.36%

1.83%

ND

0.18%

0.36%

ND

ND

ND

ND

ND

0.25%

ND

0.35%

0.36%

ND

ND

0.18%

0.07%

N/A

0.09%

ND

ND

ND

0.25%

ND

0.12%

0.24%

ND

ND

ND

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

ND

ND

0.28%

ND

0.19%

ND

0.32%

0.35%

0.25%

ND

0.24%

0.60%

ND

ND

0.36%

ND

ND

ND

ND

0.32%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.64%

ND

0.25%

ND

0.12%

ND

0.23%

ND

ND

0.14%

ND

ND

ND

ND

ND

1.01%

ND

ND

0.12%

ND

ND

ND

1.57%

0.85%

2.43%

0.35%

2.25%

1.39%

1.26%

1.27%

2.35%

5.77%

2.75%

1.56%

1.09%

11

Del8/9A

12

Del8/9A

13

Del8/9A

14

Del8/9A

15

9S/9A

16

9S/9A

17

9S/9A

18

9S/9A

19

9A

1-372, +2aa

1-281, 317-402,
+M

1-372, +16aa

1-401, +M

6-7-9S-10-11
6-7-9S-1010A-11
6-7-8-9S-1011
6-7-8-9S-1010A-11
6-7-9-9A-1011
6-7-9-9A-9B10-11
6-7-9-9A-1010A-11
6-7-9-9A-9B10-10A-11
6-7-8-9S-9A10-11
6-7-8-9S-9A9B-10-11
6-7-8-9S-9A10-10A-11
6-7-8-9S-9A9B-10A-11
6-7-8-9-9A10-11
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Isoform

Protein Size

20

9A

1-401, +M

21

9A

22

9A

23

Del8/8A

24

Del8/8A

25

Del8/8A

26

Del8/8A

27

Del8/8A

28

Del8/8A

29

8A

30

8A

31

8A

32

8A

33

8A

34

8A

35

8A

36

8A

37

8A

38
39

1-281, +34aa

1-316, +34aa

Exontyping
6-7-8-9-9A9B-10-11
6-7-8-9-9A10-10A-11
6-7-8-9-9A9B-10-10A11
6-7-8A-9S10-11
6-7-8A-9-1011
6-7-8A-9-1010A-11
6-7-8A-9-9A10-10A-11
6-7-8A-9S9B-10-10A11
6-7-9-9A-1010A-11
6-7-8-8A-9S10-11
6-7-8-8A-911
6-7-8-8A-910-11
6-7-8-8A-9S9A-10-11
6-7-8-8A-99A-10-11
6-7-8-8A-9S9B-10-11
6-7-8-8A-99B-10-11
6-7-8-8A-99A-9B-10-11

611859

612296

610319

610190

610856

610761

609266

611159

610194

612110

609941

609963

611551

0.57%

ND

0.65%

ND

ND

ND

0.51%

1.27%

1.65%

3.13%

0.23%

ND

0.54%

0.64%

0.28%

ND

ND

0.64%

0.35%

ND

0.42%

0.12%

1.92%

0.92%

ND

0.54%

0.21%

ND

ND

ND

0.96%

ND

ND

0.21%

0.47%

0.72%

0.23%

ND

ND

ND

ND

0.28%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.21%

0.28%

0.19%

ND

ND

ND

ND

ND

ND

ND

0.23%

0.47%

ND

0.36%

ND

ND

ND

0.64%

ND

ND

0.21%

0.24%

ND

0.23%

ND

0.73%

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

ND

ND

ND

0.07%

ND

ND

ND

0.32%

ND

0.25%

0.21%

ND

ND

0.23%

ND

ND

0.21%

ND

0.19%

ND

ND

ND

0.25%

ND

ND

ND

0.92%

ND

ND

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

5.69%

0.28%

3.55%

0.35%

ND

ND

1.77%

2.33%

0.12%

0.12%

6.65%

ND

ND

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.14%

ND

0.09%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.14%

ND

0.09%

ND

ND

ND

0.25%

0.21%

ND

ND

ND

ND

ND

0.07%

ND

0.19%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

6.72%

ND

8A

6-7-8A-10-11
6-7-8-8A-1010A-11

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

8A

6-7-8-8A-9S10-10A-11

0.14%

0.28%

ND

ND

0.32%

0.35%

ND

ND

0.35%

0.12%

0.23%

ND

0.18%
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Isoform

Protein Size

40

8A

1-316, +34aa

41

8A

42

8A

43

8A

44

8A

45

8A

46

8A

47

Del8/9S/9B

48

Del8/9S/9B

49

Del9/10A

50

Del9/10A

51

9S/9B

52

9S/9B

1-281, 317-372,
+50aa

1-316, 402-449

1-372, +50aa

53

9B/Del10

54

9B

1-401, +121aa,
402
1-401,+121aa,
402-640

55

Del8/10A

1-281,317-449

56

Del9/Del10/10A

1-316,+13aa

57

Del10/10A

1-401,+13aa

58

10A

1-449

Exontyping
6-7-8-8A-910A-11
6-7-8-8A-99A-10-10A11
6-7-8-8A-9S9B-10-10A11
6-7-8-8A-9S9A-10-10A11
6-7-8-8A-910-10A-11
6-7-8-8A-9S9A-9B-10-11
6-7-8-8A-99B-10-10A11
6-7-9S-9B10-11
6-7-9S-9B10-10A-11
6-7-8-1010A-11
6-7-8-1010A-11
6-7-8-9S-9B10-11
6-7-8-9S-9B10-10A-11
6-7-8-9-9B11
6-7-8-9-9B10-11
6-7-9-1010A-11
6-7-8-10A-11
6-7-8-9-10A11
6-7-8-9-1010A-11

611859

612296

610319

610190

610856

610761

609266

611159

610194

612110

609941

609963

611551

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.24%

0.24%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.24%

0.24%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.18%

1.21%

1.42%

0.56%

2.43%

1.61%

3.14%

0.51%

0.21%

4.82%

2.16%

2.75%

0.94%

6.72%

ND

ND

0.19%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.07%

ND

ND

ND

0.96%

ND

ND

ND

0.71%

1.56%

ND

ND

0.18%

ND

ND

ND

ND

0.32%

ND

1.01%

ND

0.24%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

0.16%

ND

ND

ND

ND

ND

ND

0.35%

ND

0.21%

ND

ND

ND

ND

ND

ND

ND

0.09%

ND

0.32%

ND

ND

ND

ND

ND

ND

ND

ND

0.21%

ND

0.37%

ND

0.32%

0.70%

1.52%

1.27%

2.00%

1.80%

0.69%

3.28%

ND

0.14%

ND

ND

ND

0.64%

ND

0.25%

0.21%

0.12%

0.84%

0.23%

0.16%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

ND

ND

3.13%

1.99%

10.10%

2.08%

7.40%

2.44%

10.35%

15.68%

10.81%

16.35%

4.59%

ND

3.63%

0.71%

1.14%

0.19%

ND

0.96%

0.35%

1.52%

0.64%

0.24%

0.60%

ND

0.63%

0.36%

ND

ND

ND

ND

ND

ND

ND

ND

ND

0.12%

ND

0.63%

ND

0.07%

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

ND

11.60%

11.11%

10.57%

5.21%

14.79%

6.27%

9.60%

10.81%

5.99%

10.34%

9.17%

9.69%

5.26%
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59

9B/10A

60

Del8/9S/9A

61

Del8/9B

1401,+121aa,402449
1-281,317372,+16aa
1-281,317401,+121aa,402640

6-7-8-9-9B10-10A-11
6-7-9S-9A10-11
6-7-9-9B-1011

0.71%

ND

1.12%

ND

ND

ND

0.36%

0.28%

ND

0.35%
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2.57%

ND

0.51%

2.33%

1.53%

4.21%

0.92%

0.31%

0.36%

ND

ND

ND

ND

ND

ND

ND

ND

0.16%

ND

0.35%

0.32%

ND

1.01%

0.21%

0.59%

0.96%

ND

ND

ND

Chapter 3: Next-Generation multiplex sequencing of c-myb
alternative splicing in a cohort of pediatric B-ALL samples:
Implications for clinical applications

Introduction
As predicted from the early studies demonstrating that activation of
the c-myb gene is leukemogenic in several animal species, it has now
become clear that the c-myb gene is also deregulated in human
leukemias. Recent studies revealed that a subset of T-ALL shows
selective amplification and overexpression of c-myb mediated by somatic
homologous recombination between Alu-elements flanking the c-myb
locus 16-18. A Myb-Tcrb fusion resulted from t(6,7)(q23:q34) translocations
was also identified in a novel subgroup of T-ALL associated with very
young age and a proliferation/mitosis gene expression signature 16.
However, these mutations on the c-myb gene are not associated with
prognosis or other clinical parameters of the cancer patients. The c-myb
gene can undergo extensive alternative splicing in different cell lines, cell
types, some leukemias and other types of human cancers, producing a big
repertoire of c-myb splice variants encoding multiple forms of variant cMyb proteins 19. Our previous findings (see details in Chapter 2) showed
that c-myb alternative splicing is more prevalent in pre-B-ALL leukemia
samples than in normal cells, and the level of some splice variants could
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be tightly correlated with clinical outcome of these leukemia patients,
suggesting that aberrant c-myb alternative splicing may be a mechanism
of activating the c-myb gene and unleashing its oncogenicity and could
potentially be useful as a novel biomarker in pre-B-ALL.
Our preliminary data are very promising, but are based on analyzing
a very small cohort of leukemia samples. We need to confirm these results
using a larger data set. To have 80% statistic power, we would need to
analyze at least 100 pre-B-ALL patient samples. However, it is not feasible
to use a traditional polony assay to analyze such a large set of samples. It
is important to develop a high throughput assay. Here, we describe two
methods that have multiplex and high-throughput capacity to monitor cmyb alternative splicing at a scale and ease heretofore unattainable. In the
bead based polony assay, each c-myb cDNA molecule was amplified with
an agarose bead within an emulsified microdroplet. After amplification,
each agarose bead was bound by thousands of copies of DNA identical in
sequence to the original molecule. Therefore, each bead in this assay was
like the “PCR colony” in the traditional polony assay, representing each
individual starting cDNA molecule. Exon-structure of each cDNA molecule
could be simply assessed by hybridizing with exon-specific probes via
automatic polony sequencing system. Simultaneous analysis of many
samples could be easily accomplished by adding barcodes to patient
samples in the process of cDNA synthesis, and the identity of each cDNA
molecule (each agarose bead) could be interrogated by hybridizing with
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barcode-specific probes. We applied this method to analyze 4 leukemia
patient samples in parallel and the results suggest this method has highthroughput capacity and could efficiently exontype mRNA transcripts in
multiple samples.
We have also addressed the possibility of adapting Next-Generation
Sequencing methods (NGSMs) into our application by developing a novel
method to construct the barcode-labeled mRNA libraries for each
individual c-myb mRNA molecule in each patient. We further adopted
dual primer emulsion PCR method, which combines the emulsion PCR
and bridge amplification on beads, to amplify the short DNA fragment
libraries for paired-end next generation sequencing. We named this novel
approach “barcoded-mRNA-Seq”. This method can map out an entire
cDNA molecule, which fills up an important niche in the applications of
Next-Generation Sequencing Methods (NGSMs) for profiling alternative
splicing of the genes. We applied “barcoded-mRNA-Seq” to sequence cmyb alternatively spliced variants in a large cohort of pediatric pre-B-ALL
patient samples. We showed the utility, throughput, accuracy and
robustness of this approach using different quality control methods.
Overall, our work provides important clues to the molecular pathogenesis
of pre-B-ALL this high malignant leukemia and opens up new avenues for
improved diagnosis and identification of novel targets for pharmaceutical
interventions.
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Results
BEAMing (beads, emulsion, amplification and magnetics), a high
throughput method to detect c-myb alternative RNA splicing
In general, new polony sequencing (from beads) has replaced the
use of the original polony assay (in situ DNA amplification) in an
acrylamide gel matrix. One of the key innovations was developed by Bert
Vogelstein’s lab at Johns Hopkins University, which was the emulsion
PCR technology 235, which is also used by 454 as well as by Applied
Biosystems’ SOLiD system. However, there still remain a few specific
applications for the original polony approach. The most common reason
for using the original polony method is to study long PCR amplicons. It is
currently difficult to generate long amplicons (>1 kb) using the bead-based
polony sequencing method. Due to the amplicon size limitations, the
traditional polony assay is currently the best method for assaying large
amplicons, such as characterizing the splicing patterns in long transcripts.
In the previous chapter, I applied the in situ amplification polony assay to
monitor c-myb alternative splicing in a small cohort of pediatric pre-B ALL
patient samples. The results revealed that aberrant c-myb alternative
splicing could be a novel biomarker in pre-B-ALL.
In order to further confirm the preliminary data and establish
statistically significant links between the patterns or the levels of c-myb
splice variants and clinical parameters, we need to analyze a large set of
patient samples. Since the traditional polony assay could only analyze one
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sample at a time and each sample needed to be hybridized with 3 rounds
of exon probes manually, it was not feasible to apply that method to
analyze a large set of patient samples. Emulsion PCR or BEAMing
(Beads, Emulsion, Amplification and Magnetics) is a higher throughput
adaptation of the polony assay suitable for analyzing a large set of
samples. BEAMing is essentially a bead-based polony assay, which can
amplify individual DNA molecules and simultaneously attachesthe PCR
products to beads within emulsion droplets 235. BEAMing permits the
analysis of >107 beads simultaneously coated with DNA, which greatly
increases the throughput of the polony-based assays. However, in
traditional BEAMing, the size of the beads is 1 µm and the size of the
emulsion microdroplets are about 10 times bigger than the beads, which
highly restricts the size of the amplicon that could be amplified within the
emulsion droplet 236.
To address this problem and adapt this high-throughput assay in our
analysis, we modified the traditional BEAMing and developed a novel
bead based polony assay. In this bead base polony assay procedure,
mRNA samples are converted to cDNA by reverse transcription, in which
mRNA samples from different patients are labeled with unique barcodes
(Figure 1). These labeled mRNA samples are then mixed and subjected to
emulsion PCR. Emulsion PCR is conducted directly on the beads within
the microdroplet. Ideally, each microdroplet only contains one bead with
one cDNA molecule, so that the DNA products on each bead are amplified
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from one single molecule and each bead with DNA products is similar to a
“PCR colony” in traditional polony assay. However, unlike the traditional
emulsion PCR, our approach uses 30 µm agarose beads instead of the
traditionally used 1 µm magnetic beads and amplifies individual molecule
in 100 µm (in diameter) emulsified microdroplets. With these
modifications, 1.0-1.5 kb DNA amplicons could be easily amplified on the
beads within the droplets, allowing us to map out the exon structure of the
entire c-myb mRNA molecules. The structure and the identity of the DNA
(from which patient) on individual bead could be interrogated by
hybridizing with fluorescently labeled, exon-specific and barcode-specific
probes. This entire exontyping process is very similar as the one
described in traditional polony assay (see details in Chapter 2) but can be
performed by an automated system.
To test the high-throughput and multiplex exontyping abilities of the
agarose bead based polony assay, we examined the expression and the
pattern of c-myb transcripts in 4 pediatric leukemia patient samples that
have been previously investigated by traditional polony assay. In brief, cmyb cDNA samples were synthesized from 4 pediatric pre-B-ALL patient
bone marrow RNA samples and were labeled with 4 different barcode
sequences through reverse transcription. These cDNAs were then briefly
amplified (8-10 cycles) with a forward primer complementary to exon 6
and a reverse primer specific to the universal T7 sequence T7 in the
reverse primers used in the reverse transcription (Figure 1). After PCR, all
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of the cDNA molecules were linearly amplified without PCR artifacts and
the generated DNA molecules all contained the corresponding patient
barcode sequences. The PCR products from the 4 leukemia patients were
then mixed and subjected to the following emulsion PCR and exontyping.
Emulsion PCR, beads immobilization and mounting the flow cell onto
the microscope stage were performed as described in “Materials and
Methods” section (Figure 2A). To determine the structure of the DNA on
the beads, 4 cycles of 3 to 4 fluorescent probes, which included 11 exon
specific probes and 4 barcode specific probes (Table 1), were sequentially
flowed through the polony sequencing system to hybridize with the beads.
The images were obtained after each cycle of hybridization to record
which beads were positive for each probe. The majority of the beads only
showed one color after hybridizating with 4 specific barcode probes,
indicating that the DNA products coupled to the bead were amplified from
a single molecule (Figure 2B). The whole exontyping process was
automated and was completed in 20 hours. After image acquisitions, a
series of images generated from the sequential hybridization steps were
translated into an exon map for each bead. Total 49 c-myb splice variants
including the wild type c-myb transcript were detected in these 4 patients.
Approximately 30-40% of the total c-myb transcripts in these samples
were alternatively spliced variants. The patterns and the levels of c-myb
splice variants identified by the bead based polony assay were very
similar to the ones detected by the traditional polony assay (Table 2). For
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example, the 9S/10 splice variant, the level of which has been correlated
with poor leukemia prognosis, was detected in all 4 patients and the
detected level in each patient was consistent with the previous results
from the polony assay (Table 2). With this bead based polony assay, the
profiles of c-myb splice variants in 4 patient samples could be obtained in
one single experiment. We conclude that the bead based polony assay
could be a powerful tool for multiplex profiling c-myb alternative splicing in
a large set of patient samples.
Whole molecule c-myb exontyping by next generation sequencing
I. Generating individual short DNA fragment libraries
Compared to the original polony assay, the bead-based polony
sequencing method can generate more readouts and works under more
automated conditions. However, to perform the emulsion PCR with
agarose beads, to recover and enrich the beads after emulsion PCR and
immobilize them to the coverslips, is still difficult and time-consuming.
Also, the cost and the capacity of the bead based polony sequencing
cannot match the capabilities of newer next generation sequencing
technologies. Since vast quantities of genetic data could be obtained
affordably and with relative ease through these next generation
sequencing methods, we were prompted to explore the feasibility of the
use of these new tools in profiling c-myb alternative splicing in a large
cohort of patient samples.
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Next generation sequencing methods (NGSMs) have been widely
used in different applications, such as ChIP-Seq 237 238 239, genome
sequencing 240
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, and exon and transcriptome sequencing 238,240,242,243.

The value of next generation sequencing technologies is in the highthroughput ability and low cost for sequencing a large number of samples
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. At present, next generation sequencing platforms use slightly different

technologies for sequencing, such as pyrosequencing, sequencing by
synthesis or sequencing by ligation. However, most platforms adhere to a
common library preparation procedure, with minor modifications. The
procedure includes fragmenting the DNA (sonication or nebulization),
followed by DNA repair and end polishing (blunt end or A overhang) and,
finally, platform-specific adaptor ligation. Each short DNA fragment in this
library is sequenced and reassembled to generate final results. However,
these short DNA fragments in the library are derived from different DNA
molecules, the final results can only represent the general DNA sequence
information but not the sequence information of individual DNA molecule.
While adequate for genome sequencing and exon profiling, this technique
cannot map the exon combination of each individual mRNA transcript. To
apply next generation sequencing methods to single molecule exontyping,
we prepared a complex pool of sequencer-ready libraries for each
individual mRNA transcript as described in “Materials and Methods”
section. First, RNA samples were converted into cDNA. In the process of
reverse transcription, every mRNA molecule from different patients was
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labeled differently by using reverse primers containing 7 random
nucleotides (N7) and a 2 nucleotides patient barcode (BC) (there are a
total of 8 different patient barcodes). After reverse transcription, these
cDNA samples were amplified for 10-12 cycles, which ensures that all of
the cDNA molecules were amplified simultaneously without bias and the
PCR products arising from each cDNA molecule still contained the original
barcode information. In this PCR reaction, an optimized amount of dUTP
was included in the mix, which resulted in the generated PCR products
containing randomly incorporated uracil moieties in the sequence. After
PCR, the products were treated with UDG/APE1, which removed the
uracil moieties and fragmented the DNA. This step is similar to the
shearing step in the common way of making DNA libraries. The size of
these fragments was from 200 bp to 2 kb, with the barcodes retained at
one end (Figure 3 and Figure 5A).
The DNA fragments were end polished, A-tailed and then ligated to
an adaptor (AcuI-Inside Adaptor). After ligation, the DNA fragments that
contained barcode information were selectively amplified with specific
primers (Figure 3 and Figure 4). These PCR products were then
circularized by intramolecular hybridization and ligation. The newly
generated circular DNA molecules all contained the barcode information.
The circularized DNA molecules were digested with AcuI to linearize
them and were further ligated to the polonator-specific adaptors (FDV and
RDV). The ligation products were amplified for 12-15 cycles with adaptor

101

specific primers (Figure 3). The resulting 180 bp PCR products were
isolated and purified from the polyacrylamide gels (Figure 5E). These
isolated products were the finalized DNA libraries and were the templates
for the next generation sequencing reactions. Every DNA molecule in this
library should contain a fragment of c-myb sequence and a barcode
sequence identifying which patient and which original cDNA it was derived
from. To test this, the final products were cloned in TA vectors and
sequenced by Sanger sequencing method. The results showed that the
template DNA fragments contained the FDV or RDV adaptor sequence on
each end, the myb sequence and the barcode sequence, which flanked an
inside DNA segment generated by circularization (Figure 7). The c-myb
sequences span from exon 6 to exon 15 of the c-myb mRNA, and the
barcode sequence showed which mRNA molecule the c-myb sequence
originally derived from and which patient it was from (Figure 3 and Figure
7).
II. Dual Primer Emulsion PCR (DPePCR)
For the emulsion PCR step, we adapted the bridge amplification
method used by Illumina. Instead of coupling both reverse and forward
primers onto the solid phase, we coupled the primers to the magnetic
beads (Dual-Primer emulsion PCR). Since the amplicons were confined to
the droplets, the amplification efficiency was increased by including free
primers in the aqueous phase (Figure 6A). With 120 PCR cycles, a single
DNA fragment in an emulsion drop could be amplified effectively (Figure
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6B and Figure 6C). After amplification, the dsDNA bridges were formed on
the bead inside the emulsion droplets. These DNA bridges could be
denatured, but the proximity of the complementary strands led them to
immediately re-hybridize, which blocked annealing of the sequencing
primers. To overcome this problem, during library construction, some
enzyme restriction sites (MmeI, AcuI or SnaBI) were included, so that the
amplified products could be digested before sequencing. Here, we placed
a restriction site SnaBI at the middle part of inside adaptor (Figure 6C).
After digestion with SnaBI, the DNA bridges were cut into two DNA
fragments that were both on the bead (Figure 6D) and then they were
made single-stranded (Figure 6E). This provided the accessibility of both
DNA strands to the sequence primers and the DNA products could be
sequenced by standard sequencing by ligation (SBL).
The SBL sequencing strategy for Dual Primer ePCR (DPePCR)
beads is similar to the one for standard ePCR beads. The only difference
is that because there were two different paired-end fragments on the
beads, both fragments could be sequenced independently from both the
3’-5’ and 5’-3’ directions using four different sequence primers (Figure 6E).
To validate the DNA bridges forming on the bead after DPePCR, the
beads were treated with 0.1 M NaOH (no restriction enzyme digestion).
After denaturing, a FAM-labeled oligo (complementary to the outside
adaptor, FDV-FAM) was annealed to the bead-bound DNA fragment. The
results indicated that the FAM-oligo could not hybridize to the DPePCR
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products, which suggests the formation of double-stranded DPePCR
product was in a bridged conformation (data not shown). Following
restriction enzyme digestion, we were able to anneal the sequence
primers and successfully sequenced the DNA on the beads from both
ends of the fragment.
Theoretically, the DNA products on each bead arise from a singe
molecule, which is the critical requirement for all of the next generation
sequencing platforms. To validate the clonal amplification, we performed
SBL on the DPePCR beads in solution. When sequenced, the beads
showed a single color during each SBL cycle, which indicated that the
DNA molecules on the beads were clonal products of a single template
molecule (Figure 6F).
III. Sequencing By Polonator
RNA from a total of 145 pediatric B-ALL patients was labeled with
unique barcodes and grouped into 21 samples containing 4-8 differently
labeled patient RNA samples. These 21 samples were converted into 21
libraries and further amplified on the beads for sequencing. The libraries
were analyzed using sequencing by ligation method on the G007
Polonator (Westborough, MA.USA). The flow cell used in the Polonator
contains 8 wells, which can simultaneously holds 8 samples. Prior to
sequencing, the beads were treated with BS3 reagent, which provides
covalent bond to the amino group on the amine-functionalized glass
coverslip of the flow cell. The beads were then flowed in the individual
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wells in which they were allowed to attach. Any unattached beads were
removed by flushing the flow cell. A total of 4 sequence primers were
sequentially flowed in (See Table 3), and each sequence primer could be
used to sequence 6 to 7 nucleotides (Figure 8). The Polonator could
capture and process four-color images of fluorescent beads in real time.
After all of the SBL runs, the base calling program decoded the color of
the beads to the corresponding nucleotide. For each cycle, each bead was
dim in three of the four fluorescent colors, and bright in one, allowing an
accurate base call to be made. The Polonator base caller output a
separate read file for each well on the flow cell, with each read file
containing ~ 20 million reads. For each bead, the optimal read length was
approximately 26 bases, in which 13 bases were the DNA sequence of the
c-myb gene and the other 13 bases (with 4 bases overlap) were the
barcode sequence (Figure 7).
To be able to generate the final profile of c-myb alternative splicing in
145 patients, sophisticated bioinformatics tools are needed to analyze the
raw data and reassemble the single molecule sequence. Preliminary data
analysis has been run on the raw data files generated from 21 libraries.
Briefly, all the beads with signals were first categorized into individual
molecules from each patient using the 9 bp barcode. Then the bowtie
program was used to align back the 13 bases read of c-myb sequence to
the individual reference exon sequence of c-myb mRNA245. The beads
with the reads that hit on the same exon were categorized into the same
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exon group. After preliminary data processing, the reads of the beads for
each library were categorized into different groups in which c-myb tags hit
back to the same exon sequence and shared the same barcode
sequence. Since a sequencing library was prepared and subjected to
extensive amplification (PCR in the library preparation), the bias could be
increased. We plotted the abundance of the tags of these reads found in
each exon against the entire sequence of the exon (Figure 9). The plots
showed that there were a few “hotspots” found but the majority of these
tags were evenly distributed along the entire exon sequence, suggesting
no obvious bias in the construction of the sequencing libraries.
Further analysis is needed to determine the combinatorial exon
information of individual mRNA molecule and the abundance of the mRNA
transcripts for each patient. Analysis of this large cohort of leukemia
patient samples will allow us to generate statistically significant results,
which will be important for evaluating whether c-myb alternative splicing
could be used as a signature to either classify leukemia patient sample or
a biomarker to predict the outcome of leukemia patients.
Discussion
Several lines of evidence show that c-myb, a key regulator of normal
hematopoiesis, can be activated through multiple mechanisms and is a
bona fide oncogene in human cancers. Our previous study showed that
compared to normal hematopoietic cells, leukemia patients express a
different and more diverse set of c-myb splice variants encoding a family
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of c-Myb proteins with different C-terminal domains and different
transcriptional activities. Importantly, the expression levels of some splice
variants correlate with clinical outcome. The above findings indicate that
aberrant alternative splicing of c-myb mRNA could be a novel and
unexpected mechanism for expressing activated forms of c-Myb protein
that participate in leukemogenesis and profiling c-myb splice variants
could provide a unique and novel approach of classifying leukemias.
However, current methods, such as QRT-PCR and in-situ polony assay,
are not feasible to profile c-myb splice variants in large numbers of patient
samples, which points to the need for new and improved methods of
exontyping. Here, we have developed two bead-based methods, and both
methods utilized emulsion PCR and were capable of simultaneous
exontyping many RNA (cDNA) samples. One method was combined with
automated polony sequencing stage to exontype c-myb splice variants by
hybridization. The other method was coupled to the next–generation
technology to sequence c-myb splice variants. We successfully applied
both methods to analyze c-myb splicing patterns in several patient
samples in parallel.
The polony assay is a method for in-situ amplifying a large number of
distinct individual DNA molecules, which is ideal to analyze long
amplicons and map the transcript splicing patterns at the single molecule
level. Bead based emulsion PCR is a method to amplify individual DNA
molecules on beads. Each bead coated with DNA can be considered as a
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polony in the traditional polony assay. These beads cannot overlap, which
makes the image analysis easier than traditional polony assays.
Furthermore, DNA on the beads is more concentrated than gel-base
assays, increasing the signals to noise ratio. Overall, this approach allows
us to simultaneously analyze >107 beads with DNA, which greatly
increases the throughput of the polony-based assays. However, there is a
critical limitation of current bead based technology; it is not possible to
generate DNA coated beads with amplicons longer than a few hundred
bases. In order to solve this problem, we replaced the traditional 1 µm
magnetic beads with 30 µm agarose beads and generated microdroplets
with the diameter around 100 µm, which were stabilized by the
surrounding “microfines” during emulsifying. With these modifications, the
larger surface area of the beads and the increased size of the
compartments allowed the amplification of amplicons up to 1.5 kb and
binding them to the beads via emulsion PCR. Compared to traditional
polony assay, this bead-based method can be coupled with the automated
polony sequencing system and the entire exontyping process can be run
automatically. In addition to the automated system, which reduces a lot of
manual labor and accelerates the exontyping process, multiple parallel
analyses could further facilitate the throughput. Here, molecular barcoding
of each patient and identifying them later through hybridization with
specific probes were shown useful for this purpose. cDNA samples from 4
different patients were added with unique barcodes and mixed for the
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bead-based polony assay. A total of 2x105 beads with DNA were queried
and the profiles of c-myb alternative splicing in 4 patient samples were
obtained simultaneously in one run.
Another way to increase the throughput would be to utilize nextgeneration sequencing methods. Next-generation sequencing methods
(NGSMs) have been applied to a wide range of fields in biology and
medicine. In addition, NGSMs have changed the scope and speed of
standard sequencing methods by several orders of magnitude. In spite of
the massive amounts of throughput generated in a single run, the main
drawback to NGSMs is the relatively short read lengths. For profiling a
single gene transcriptome, which means reading out the exon composition
of an entire mRNA transcript up to several kilobases, the current NGSMs,
even Roche 454 GS FLX with read length up to 600 bp, are not sufficient.
In order to broaden the application scope of these NGSMs and adapt
them in our research, we developed a novel protocol for the construction
of sequencing libraries for each individual c-myb cDNA molecule. Nextgeneration sequencing libraries for amplification-based methods comprise
short DNA (50 bp-300 bp) templates usually called “sequencing features”.
In our prepared libraries, these sequencing features contain a short
fragment from c-myb transcripts and the barcode sequence that indicates
which cDNA molecule and which patient this c-myb fragment is originally
from. By ligating to platform-specific adapters, these sequencing features
could be amplified using the adapter sequence as priming sites or
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hybridization targets. Here, we used Polonator G.007 sequencing to
separately but in parallel sequence each of the millions of single clonally
amplified targets. The generated read length from the Polonator is 26 bp.
For relatively less complex c-myb gene transcriptome, short reads of the
c-myb gene are sufficient to generate an alignment for individual c-myb
mRNA transcript according to their barcode information. Our data showed
that the generated short reads of c-myb are at high coverage of the c-myb
gene, indicating there was no bias during library construction. Our results
also suggest that these short reads of c-myb could be easily grouped,
based on the reads of the barcode, into individual cDNA molecule for each
patient, and these grouped reads could be mapped back to each exon of
the c-myb gene. Hence, the exon combinatorial information of individual
molecule could be mapped out and c-myb alternative splicing could be
profiled for each patient.
Next-generation sequencing could generate volumes of data that are
both a blessing and a curse. We faced the common and major problem
that often happens using next generation sequencing; that is, the handling
of massive amounts of sequencing data. It is necessary to develop
effective bioinformatics tools to assist us in analyzing the raw data and
generating the final profiles of c-myb alternative splicing in patients. With
the data processed, the clinical value of c-myb alternative splicing will be
evaluated by correlating alternative spliced isoforms with critical clinical
parameters of these patients. Compared to the previous agarose bead
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based polony assay, this NGSM provides a more efficient and costeffective means to profile c-myb alternative splicing in multiple samples
simultaneously. Adaptation of our sequencing library protocol may allow
us to perform a comprehensive profiling of alternatively spliced
mammalian transcriptomes.
Overall, our study has explored the possibility of multiplexed profiling
c-myb alternative splicing in large amounts of samples by combining
molecular barcodes, emulsion PCR with polony sequencing system/next
generation sequencing platforms. The bead based polony assay breaks
the limitation of conventional emulsion PCR that requires the analyzed
amplicon shorter than 300 bp. The novel way of constructing libraries for
next generation sequencing (“barcoded mRNA-Seq”) circumvents certain
limitations of RNA sequencing, in which the analysis of the full sequence
of individual mRNA molecule is impossible. In a single experiment,
“barcoded mRNA-Seq” provides a wealth of qualitative as well as
quantitative information that cannot be obtained by any other method.
Indeed, “barcoded mRNA-Seq” is a promising tool in the analysis of a
single gene transcriptome or whole transcriptomes in a disease across
hundreds of individuals for clinical purpose. With this unique application,
NGSMs could be used as a powerful tool in the studies that evaluate
aberrantly expressed splice variants as a disease biomarker or the studies
that discover new oncogenic forms of proteins as targets for developing
novel therapeutic strategies.
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Materials and Methods
I. Bead-based Polony assay
cDNA sample preparation
Patient bone marrow RNA samples were obtained from the
Children’s Oncology Group (COG) Acute Lymphocytic Leukemia (ALL)
Cell Bank. c-myb cDNA was synthesized by using a first-strand cDNA
synthesis kit (Invitrogen, Carlsbad, CA). In order to monitor c-myb
alternative splicing in several patient samples in parallel, the reverse
primers used in cDNA synthesis were comprised of the c-myb genespecific reverse primer followed by a 20 bp barcode sequence and a
universal T7 primer for the later amplification and emulsion PCR (Figure
1). Different patient RNA samples were reverse transcribed with unique
reverse primers having their own barcodes (Table 1). The generated
cDNAs were concentrated and purified through MiniElute columns
(Qiagen, Valencia, CA) and were then subjected to PCR (8-10 cycles of
94 °C for 30 sec, 58 °C for 35 sec, 72 °C for 1min 45 sec) in a 50 µl
reaction consisting of 5 units of Jumpstart (Sigma, St Louis, MO), 1x PCR
buffer, 2.5 mM MgCl2, 200 µM dNTPs, and 200 nM of reverse primer T7
Rev and forward primer SN-3 Forward. These products were the final
templates for emulsion PCR.
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Preparation of DNA Primer Coupling Beads
Packed beads from a 1 ml N-hydroxysuccinimide ester (NHS)activated Sepharose HP affinity column (Amersham Biosciencese,
Piscataway, NJ) were activated as described in the product literature
(Amersham Pharmacia Protocol # 71700600AP). In brief, 1 ml of 1 mM
amine-labeled c-myb primer (5’-Amine-3 sequential 18-atom hexaethyleneglycol spacers CCTATCCCCTGTGTGCCTTG-3’) (IDT
Technologies, Coralville, IA, USA) in standard coupling buffer (0.2 M
NaHCO3, 0.5 M NaCl, pH 8.0), was injected into the column at a speed of
0.5 ml/min. The column was then sealed and incubated at room
temperature for 30 min, allowing the amine labeled primers to couple to
the beads. After coupling, the column was washed with buffer A (0.5 M
ethanolamine, 0.5 M NaCl, pH 8.3) and buffer B (0.1 M NaOAC, 0.5 M
NaCl, pH 4) alternatively 12 times each to remove the uncoupled primers
and deactivate the uncoupled NHS group on the beads. The packed
beads were removed from the column, resuspended in 2 ml Wash 1E
buffer [10 mM Tris-Cl (FisherScientific), 50 mM KCl (Sigma, St.Louis,
MO), 2 mM EDTA (USB Corporation, Cleveland, OH), 0.01% Triton X-100
(Dow Chemicals, Midland, MI)] and stored at 4 ºC until needed.
PCR Reaction Mix Preparation and Formulation
To reduce the possibility of contamination, the PCR reaction mix was
prepared in a UV-treated laminar flow hood. For each emulsion PCR
reaction, 175 µl of reaction mix [1x Platinum HiFi Buffer (Invitrogen,
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Carlsbad, CA), 0.25 mM dNTPs (Promega, Madison, WI), 3.5 mM
MgSO4 (Invitrogen, Carlsbad, CA), 0.1% BSA (NEB, Ipswich, MA), 0.01%
Tween-20, 0.003 U/µl thermostable pyrophosphatase (NEB, Ipswich, MA),
0.05 µM forward primer SN-3 and 0.95 µM biotinylated-reverse primer T7
rev (Invitrogen, Carlsbad, CA) and 0.15 U/µl Platinum Hi-Fi Taq
Polymerase (Invitrogen, Carlsbad, CA)] were prepared in a 1.5 ml tube. 15
µl of the reaction mix was removed and stored in an individual 200 µl PCR
tube for use as negative control. Both the reaction mix and the negative
controls were stored on ice until needed. Additionally, 240 µl of mock
amplification mix [1x Platinum HiFi Buffer (invitrogen, Carlsbad, CA), 2.5
mM MgSO4 (invitrogen, Carlsbad, CA), 0.1% BSA, 0.01% Tween-20] for
every emulsion were prepared in a 1.5 ml tube, and similarly stored at
room temperature until needed.
Emulsification and Amplification
The emulsification process creates a heat-stable water-in-oil
emulsion with approximately 1,000 discrete PCR microreactors per µl,
which serve as a matrix for single molecule, clonal amplification of the
individual molecules in the target library. The reaction mixture and the cmyb forward primer-coupled beads for a single reaction were emulsified in
the following manner: 160 µl of PCR reaction mix was mixed with 10 µl
coupled agarose beads (>106), then 2 µl of desired amounts of cDNA
samples was added into the PCR-bead mixture. 400 µl of emulsion oil [50
% (w/w) DC 5225C Formulation Aid (Dow Chemical Co., Midland, MI),
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25% (w/w) DC 749 Fluid (Dow Chemical Co., Midland, MI), and 25% (w/w)
AR20 Silicone Oil (Sigma, St Louis, MO)] were dispensed into a flattopped 2 ml centrifuge low retention tube (Bioexpress, Lodi, CA). The 240
µl of mock amplification mix was then added to 400 µl of emulsion oil, the
tube was capped and placed on a TissueLyser (Qiagen, Valencia, CA).
The emulsion was homogenized for 5 min at 25 HZ to generate the
extremely small emulsions, or “microfines”, that confer additional stability
to the reaction.
After the microfines were formed, the combined beads and PCR
reaction mix were briefly mixed and added. The mixture was then placed
on the TissueLyser and homogenized for 4 min and 30 sec at 15 HZ. The
lower homogenization speed created water droplets in the oil mix with an
average diameter of 100 to 150 µm, which is sufficiently large to amplify
longer amplicons (>1 kb).
The total volume of the emulsion was approximately 800 µl contained
in one 2 ml flat-topped low retention tube. The emulsion was dispensed
into 7-8 separate PCR tubes each containing roughly 100 µl. The tubes
were placed in an MJ thermocycler along with the 15 µl negative control
made previously. The following cycle times were used: 94 ºC for 4 min, for
Hotstart initiation; 60 cycles of 30 sec at 94 ºC, 2 min at 58 ºC, 1.5 min at
68 ºC, for amplification; 13 cycles of 30 sec at 94 ºC, 6 min at 63 ºC, for
hybridization extension. After completion of the PCR program, the
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reactions were removed and the emulsions either broken immediately or
the reactions stored at 4 ºC before initiating the breaking process.
Breaking the Emulsion and Recovery of Beads
The emulsion of amplified material in each PCR tube was removed
and combined in a 2 ml flat-topped low retention tube. 100 µl AR2 silicon
oil (Sigma, St Louis, MO) was added to each PCR tube to remove the
remaining emulsion solution into the same 2 ml tube. The tube was
vortexed and then centrifuged at high speed for 2 min. The supernatant
was removed and 1 ml of AR2 silicon oil was added to the tube. The tube
was mixed on a vortex and spun in a benchtop centrifuge and the
supernatant was removed. This silicon oil wash step was repeated 6
times. Then 1 ml of isopropyl alcohol (General Chemical Corp,
Parsippany, NJ) was added to the tube and vortexed until mix well. The
tube was then spun at high speed for 1 min and the supernatant was
removed. This washing step with isopropyl alcohol was repeated 6 times
as well. After isopropyl alcohol cleaning, 1 ml of 80% Ethanol/1x
Annealing Buffer (80% Ethanol, 20 mM Tris-HCl, pH 7.5, 5 mM
Magnesium Acetate) was used for washing, which was repeated 3 times.
Then the beads were washed with 1 ml of 1x Annealing Buffer with 0.1%
Tween (0.1% Tween-20, 20 mM Tris-HCl, pH 7.5, 5 mM Magnesium
Acetate) 3 times. The beads were finally washed with 1 ml Wash 1E
Buffer 3 times and ddH2O 2 times. The final clean beads were
resuspended in 200 µL EB buffer and stored at 4 ºC until needed.
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Enrichment of the Beads
Up to this point the beads were comprised of both beads with
amplified DNA products, and null beads with no amplified product. The
enrichment process was utilized to selectively capture beads with
amplified DNA while rejecting the null beads. In brief, the clean agarose
beads were washed with Bind and Wash Buffer (B+W Buffer) (10 mM TrisHCl, pH 7.5, 1 mM EDTA, 2 M NaCl) 3 times and resuspended in 150 µl
B+W Buffer. While washing the agarose beads, 30 µl well-resuspended
Dynabeads M-280 streptavidin beads (Invitrogen, Carlsbad, CA) was also
washed with B+W Buffer 3 times and resuspended in 100 µl B+W Buffer.
The washed magnetic bead solution was added into the washed agarose
beads. The bead mixture was mixed by gentle flicking and mixed at room
temperature for 1 hr, allowing the streptavidin beads to bind to the
biotinylated DNA strand on the agarose beads. The bead mixture was
then spun at 2,000RPM for 3 min, after which the beads were gently
flicked until the beads were resuspended. Then 300 µl of B+W Buffer was
added and incubated at room temperature for 5 min. Following the
incubation, the bead mixture was placed onto a DynaMag-2 magnetic
Particle Concentrator (MPC) (Invitrogen, Carlsbad, CA), and the beads
were left undisturbed for 2 min to allow the beads to pellet against the
magnet, after which the supernatant (containing the null agarose beads)
was carefully removed and discarded. This step was repeated 4 times with
300 µl B+W Buffer to ensure removal of all null agarose beads. To remove
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the biotinylated DNA strand and the magnetic streptavidin beads from the
selected agarose beads, the bead mixture was resuspended with 0.1 M
NaOH and incubated at room temperature for 5 min. Then the bead
mixture was vortexed and placed on MPC. The supernatant, containing
the enriched agarose beads with the immobilized DNA strands, was
transferred to a separate 1.7 ml low retention tube. The NaOH wash was
repeated additional time and the supernatant was combined with the first
supernatant. The beads attached on the MPC were discarded. The
supernatant containing the enriched beads was placed on the MPC again,
and the supernatant transferred to a fresh 1.5 ml tube, ensuring maximal
removal of remaining magnetic streptavidin beads. The final enriched
beads were washed with 500 µl Wash 1E Buffer 2 times and resuspended
in 200 µl Wash 1E Buffer. The average yield for the enrichment process
was 30% of the original beads added to the emulsion.
Fluorescent labeled Probe Hybridization
Before immobilizing the beads to the coverslip, the enriched beads
were checked for the signals on the attached DNA. 30 µl of the enriched
beads were used to do hybridization with different fluorescent labeled
probes, either specific to different exons or to the patient barcode
sequences. The hybridization step was mainly carried out as follows: a
mixture of different fluorescent labeled probes was added to the enriched
bead solution to make the final concentration of each of these probes 1
µM. The beads-probes mixture was mixed on a vortex and placed in a MJ
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thermocycler (BioRad, Hercules, CA) for the following 3-stage
hybridization program: 4 min at 94 °C, 10 min at 58 °C, and 10 min at 42
°C. Upon the completion of the hybridization program, the beads were
washed with 100 µl EB buffer 2 times and resuspended in 20 µl EB Buffer.
The images of these labeled beads were then recorded with a fluorescent
microscope (Nikon, Melville, NY) (Figure 1).
Bead Immobilization
The large size of the agarose beads (30 µm) makes it really difficult
to attach to the coverslip using traditional chemical conjugation of the
hydroxyl- group on the DNA to the amine group on the coverslip.
Therefore, the best way to immobilize the agarose beads to the coverslip
is by using a polyacrylamide gel. 40 µm thick 6% polyacrylamide gels
containing the agarose beads were prepared as described 218, except that
polymerization was initiated by addition 1.25 µl 5% TEMED (BioRad,
Hercules, CA) and 1.875 µl 1% ammonium persulphate solution (EM
Science, Gibbstown, NJ). In order to allow the beads to settle onto the
surface of the gel, the coverslip was inverted during polymerization. The
whole polymerization was performed in a vacuum chamber. The coverslip
with the immobilized beads was placed into a flow cell and then mounted
to the Polony sequencing system, consisting of a fluorescent microscope,
automated stage, automated filter wheels and external shutters, PIFOC
objective Z-control, 1 megapixel camera, autosampler, syringe pump, and
flow cell with temperature controller.
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Exontying on the polony sequencing system
The polony sequencing system has been successfully used for
bacterial genome sequencing (unpublished data by Jeremy Edwards
group). The cyclical delivery of exontyping reagents into the flow cell and
washing off the exontyping reaction byproducts from the cell was achieved
using an automated fluidics system. The controller program was written in
MATLAB, specifying the reagent name (wash buffer, exon probes,
annealing buffer and so on), flow rate and duration of each step, and
specific temperature for each step. The whole program ran as following:
Wash the flow cell with 500 µl Wash 1E 3 times; flow in 400 µl 70%
formamide and denature at 56 °C for 12 min; wash with 500 µl H2O at 30
°C; flush the flow cell with Wash 1E at 42 °C for 6 min; flow in 500 µl 3x
SSPE [diluted from 20x SSPE buffer (Ambion, Austin, TX)] with 0.01%
Tween-20 with 4 different fluorescent labeled exon probes (2 µM of each
exon probe) or barcode probes, anneal at 90 °C for 12 min and 60 °C for
35 min; wash with 500 µl H2O once and 4 times of 500 µl 0.1x SSPE
(Ambion, Austin, TX) with 0.01% Tween-20 at 45 °C; the duration time of
each wash within the hybridization step was 4 min. For each hybridization
step, the total run time was about 120 min.
Image Acquisition
The bright field image for each flow cell was recorded preceding the
entire exontying run. After acquiring the bright field image, the flow cell
was fixed with no movement during the exontyping process. Based on the
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fixed position of the flow cell, the image analysis software could determine
the location (in CCD pixel coordinates) of each bead within the flow cell. In
operation, the entire coverslip was defined as an imaging area and was
split into several frames (400 pixel X 400 pixel). For each frame, the
attached CCD moved up and down to autofocus on the beads in this
frame, set the image position for this frame and then recorded the image.
This autofocusing and recording process was repeated across the entire
imaging area. Then, after hybridization, based on the previously recorded
image position of each frame, the CCD went across the entire imaging
area and recorded the fluorescent images of each frame. All of the images
of the same frame were overlapped and processed in the same way as
described in Chapter 2. Image analysis was also carried out in the same
way as described in Chapter 2.
II. Whole molecule c-myb exontyping by Next-Generation
Sequencing
Sample preparation and library construction
Total RNA of patient samples was provided by the Children’s
Oncology Group (COG). c-myb cDNA was synthesized with a genespecific reverse primer (Oligo AcuI -7mer-2BC-RT) using a first-strand
cDNA synthesis kit (Invitrogen, Carlsbad, CA). This gene-specific primer
consists of a specific sequence complementary to the c-myb gene, 2
barcode nucleotides for labeling each patient, 7 random nucleotides for
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labeling each cDNA molecule synthesized from the patient samples, and 6
nucleotides of AcuI restriction sites. Approximately 8 X 10-4 pmol of cDNA
from each patient was first subjected to PCR (12-15 cycles of 94 °C for 30
sec, 58 °C for 35 sec, 72 °C for 1 min 35 °C) in a 50 µl reaction consisting
of 5 units of Jumpstart (Sigma, St Louis, MO), 1x PCR buffer, 2.5 mM
MgCl2, 200 µM dNTPs, 10 µM dUTP, and 200 nM of reverse primer RevOligo AcuI and forward primer SN-3-For. This process resulted in
amplification of all splice variants of c-myb between exon 6 and exon 15
(~1.4 kb) with randomly incorporated dU moieties. The PCR products
were treated at 37 °C for 60 min, 80 °C for 20 min with 5 units of a Uracil
DNA Glycosylase (UDG) (NEB, Ipswich, MA) /APE1 (Enzymatics, Beverly,
MA) cocktail to create random fragments with average size of about 700
bp. The products generated from 5 to 8 patient samples with different
barcodes were mixed and purified with MiniElute column (Qiagen,
Valencia, CA). Approximately 0.3 pmol of purified DNA was treated with
1.5 µl End-Repair enzyme mix (Epicentre Biotechnologies, Madison, WI)
and incubated at 25 °C for 45 min and 75 °C for 15 min in a reaction
consisting of 1x End-Repair buffer, 100 µM dNTP Mix, and 100 µM ATP,
to create 5’ phosphorylated blunt termini. The end-repaired DNA
fragments were then 3’-A tailed with 7.5 units Bsu DNA polymerase (NEB,
Ipswich, MA). These A-tailed, blunt-ended DNA fragments were ligated to
10-fold molar excess of synthetic inside adaptor (AcuI-Inside Adaptor) for
30 min at 25 °C in a reaction containing 50 mM Tris-HCl (pH 7.8), 10 mM
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MgCl2, 1 mM ATP, and 1,000 units of T4 DNA ligase (Enzymatics,
Beverly, MA). The AcuI-Inside Adaptor has one terminus with 4 bases of
3’- protruding and the other terminus with 5’-T overhang and 3’-phosphate.
In this T4 DNA ligation reaction, 5’-T overhang terminus of the inside
adaptor was ligated to 3’ A overhang DNA termini, producing an
intermediate structure. And the ligated DNA products had both termini with
4 bases of 3’- protruding. The DNA was incubated for 30 min at 37 °C
with 10 units of ExonIII (NEB, Ipswich, MA), heat inactivated at 75 °C for
20 min, then incubated with 10 units of Exon I (NEB, Ipswich, MA) at 37
°C. This process is to degrade unincorporated inside adaptors and
unligated DNA, and only the ligated DNA with 3’-overhang (4 bases) on
both termini, which is resistant to ExoIII, would survive.
Half of the ligated DNA was subjected to PCR (25-30 cycles of 95 °C
for 30 sec, 58 °C for 30 sec, 72 °C for 1 min 30 sec) in a 400 µl reaction
consisting of 20 units of PfuTurbo Cx (Stratagene, La Jolla, CA) 1x pfu
Turbo Cx buffer, 200 µM dNTPs, and 200 nM Circularization-U primer
sets. This process selectively amplified the DNA fragments containing the
random 7 bases and barcode sequences on the left side and inside
adaptor AcuI-In on the other side, to produce PCR product incorporating
dU moieties at specific locations within both termini. The PCR products
were treated with 10 units of a UDG/APE1 cocktail to create both termini
with complementary 3’ overhangs. Approximately 1.2 pmol Minielutepurified DNA was diluted to a concentration of 3 nM in a reaction
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consisting of 16.5 mM Tris-OAc (pH7.8), 33 mM KOAC, 5 mM MgOAc,
and 1 mM ATP, heated to 55 °C for 10 min, and cooled to 16 °C for 10
min, to favor intramolecular hybridization (circularization). The reaction
then was incubated at 16 °C for 1h with 5400 units of T4 DNA ligase
(Enzymatics, Beverly, MA) to form monomeric dsDNA circles containing
two AcuI sites right next to the inside bridge formed by intramolecular
hybridization. The circle was incubated at 37 °C for 30 min with 100 units
of Exonuclease III/Exonuclease I to eliminate residual linear DNA.
Approximately 0.6 pmol of this purified circle was digested at 37 °C
for 1h with 12 units of AcuI (NEB, Ipswich, MA) according to the
manufacturer’s instruction to generate linear dsDNA structures containing
the bridge flanked by two DNA fragments of either 14 bases or 16 bases,
in which one is part of the c-myb gene and the other contains the 7
random bases and 2 bases of the patient barcode. The digested DNA was
end-repaired with 1.5 µl End-Repair Enzyme Mix as above, incubated for
30 min at 37 °C in a reaction containing 1 mM dATP and 7.5 units of Bsu
DNA polymerase (NEB, Ipswich, MA) to add 3’ A overhang. The resulting
5’ phosphorylated, 3’ A overhang DNA was incubated for 1 h at 25 °C in a
reaction containing 50 mM Tris-HCl, 10 mM MgCl2, 5 mM dithiothreitol, 1
mM ATP and 1500 units of T4 DNA ligase, and two 10-fold molar excess
of adaptors FDV and RDV, of which both were designed to ligate to the
3’A overhang of the DNA, thereby yielding a ligated DNA product with 4
bases of 3’ protruding termini. The ligated DNA products were treated with
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10 units of Exonuclease III, and then with 10 units of Exonuclease I to
eliminate the unincorporated adaptors and the inefficiently ligated DNA
(either unligated DNA or the DNA with only one end ligated to the
adaptor). PCR was performed on the resulting DNA with primers FDV-BCPCR and RDV-BC-PCR (12-15 cycles of 94 °C for 30 sec, 64 °C for 20
sec, 72 °C for 20 sec) in a 400 µl reaction consisting of 40 units of
Jumpstart (Sigma, St Louis, MO), 1x Jumpstart buffer, 2.5 mM MgCl2, 200
µM dNTPs and 200 nM each PCR primer, to specifically amplify the
ligated DNA containing both FDV and RDV adaptors. After MiniElute
purification, the PCR products were run on a 10% polyacrylamide gel
(BioRad, Hercules, CA), and the DNA fragments with the length of
approximately 180 bp, which contain both FDV and RDV adaptors, and
the inside bridge formed by circularization, were extracted from the gel
and recovered by phenol-chloroform precipitation.
Library Construction QC
To assess the efficiency of each step, intermediate constructs were
assayed by PCR amplification with Jumpstart DNA polymerase (Sigma, St
Louis, MO) and specific primer sets. To check the efficiency of the ligation
to inside adaptor, PCR 1 was performed with the inside adaptor-specific
primers (Figure 5B). To check the efficiency of the reaction of
circularization, PCR 2 was performed on the circular DNA product after
being ligated by T4 ligase or the generated DNA products without using
T4 ligase (Figure 5C). To check whether the circle dsDNA was efficiently
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digested by AcuI, PCR 3 was performed on the linearized DNA with the
inside bridge-specific primers but no PCR product was generated (Figure
5D).
To assess library construct structure and coverage bias, the final 180
bp library DNA was PCR-amplified (PCR 4) with Jumpstart Taq DNA
polymerase (Sigma, St Louis, MO) and FDV- and RDV-adaptors specific
PCR primers (Figure 5E). These PCR products were then cloned with
pCR®2.1 TA cloning kit (Invitrogen, Carlsbad, CA), and plasmid mini-prep
(Qiagen, Valencia, CA) was used to extract DNA from independent
colonies. Sequence information was collected from these DNA products
by DNA sequencing service (Health Science Center, UNM, NM) and
blasted against the c-myb gene sequence (Accession Number: U22376).
Coupling of dual-biotinylated primer to the streptavidin beads
As previously described 246, to bind the PCR primers to Myone
streptavidin beads (Invitrogen, Carlsbad, CA), 240 µl MyOne streptavidin
beads solution were mixed with 240 µl B+W buffer by inversion. The
beads were then placed on MPC to remove liquid by pipetting. The beads
were washed twice with 480 µl B+W buffer, then resuspended in 480 µl
B+W buffer. 2.4 µl FDV2-dual biotin primer (1 mM) and 2.4 µl RDV2-dual
biotin primer (1 mM) were then added into beads solution. The mixture
was mixed briefly and incubated at room temperature for 20 min with
mixing. After incubation, the beads were washed three times with 600 µl
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B+W Buffer. The final pellet beads were resuspended in 640 µl TE and
stored at 4 °C.
Dual Primer Emulsion PCR
Emulsion PCR was performed as described 246. 2 µL aliquots of
constructed library (at the appropriate concentration to allow a single
molecule per drop) was mixed with 265 µl Dual Primer emulsion PCR
(DPePCR) master mix (see “Dual Primer ePCR Master Mix” table), 13 µl
Taq B (Enzymatic, Beverly, MA), 0.1 µM FDV-BC-PCR and 0.1 µM RDVBC-PCR and 12 µl Dual Primer beads. The mixture was added to 1 ml
silicone oil phase (see details in “Silicone Oil Phase”) in a 2-ml tube and
put on a Tissuelyser II (Qiagen, Valencia, CA) to emulsify (13.5 Hz for 3
min). The DPePCR emulsion mixture was equally dispensed into PCR
tubes and amplified in a MJ thermocycler (94 °C 3 min, 100 cycles of 90
°C 15 sec, 58 °C 2 min, 72 °C 45 sec, 20 cycles of 90 °C 15 sec, 60 °C 5
min, then 72 °C for 15 min). For the same library, to be able to fill up one
lane on the flow cell, 10 of the above reactions are required. The emulsion
beads were broken and cleaned using the protocol in the “Breaking
Emulsion”. Finally, all of the beads were suspended in 1 ml TE containing
0.1% Triton X-100.
The DPePCR beads were digested with 5 µl SnaBI (5000 U/ml)
(NEB, Ipswich, MA) in 1x NEBuffer 4 by incubating at 37 °C for 60 min.
After SnaBI digestion, the beads were washed 2X with 1x NXS [10 mM
Tris·HCl (pH 7.5), 1 mM EDTA (pH 8.0), 100 mM NaCl, and 1% Triton X127

100] and TE with 0.1% Triton. The beads were then treated with 0.1 M
NaOH for 5 min to single strand DNA and washed 2 times with 1x NXS
and TE with 0.1% Triton. The beads were finally resuspended in 25 µl 1x
PBS buffer (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4• 2H2O, 1.76
mM KH2PO4, pH 7.4) before loading onto the flow cell for polonator
sequencing.
Polonator Sequencing
To test the sequencing before loading the beads onto the flow cell,
the beads with DNA products were checked by in-solution sequenceing by
ligation method. For sequencing of the FDV strand in 3’-5’ direction, the
beads were annealed with 10 µM sequence primer 5’phosphorylatedSequence primer FDV-Minus at 75 °C for 5 min, 55 °C for 5 min and 25 °C
for 10 min, and washed three times with Wash 1E buffer. Then 1 µl T4
DNA ligase (600 unit/µl) and 200 µl ligation buffer [2 µl of each nonamer
(300 µM)(IDT, Coralville, IA) for one queried position and 200 µl 1x DNA
quick ligase buffer (Enzymatics, Beverly, MA)] were added to the beads
and incubated at room temperature for 30 min. The beads were then wash
with 2 times 1x NXS buffer and TE/0.1% Triton X-100, and resuspended in
50 µl TE/0.1% Triton for observation on fluorescent microscope.
The DPePCR beads were interrogated from the FDV and RDV strand
respectively using the same strategy from both the 3’-5’ and 5’-3’
directions. As describe in Polonator sequencing protocol, during the run, a
series of sequencing primers (see details in Table 3) are flowed through
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the cells, where they hybridize to the FDV strand or RDV strand. For 3’-5’
direction sequencing, the sequence primers have 5’-phosphorylated
modification. While for 5’-3’ direction sequencing, the sequence primers
have no modification, however, the beads need to be capped with
dideoxynucleotide before hybridization and ligation (see details in
“Capping with dideoxynucleotide reaction”). Once a sequence primer is
hybridized, a mixture of fully degenerate nonanucleotides (‘nonamers’)
and T4 DNA ligase (600 unit/µl) is flowed into the cell; each of the
nonamer mixture’s four components being labeled with one of four
fluorophores (see Table 3), which correspond to the base type at the
query position. The fluorophore-tagged nonamers selectively ligate onto
the sequence primer, providing a fluorescent signal that identifies the
corresponding base on the DNA library tag.
Once the probes are ligated, fluorescently labeling the beads, the
polonator images the array in four colors. Each bead on the array will
fluoresce in only one of the four images, indicating whether there is an A,
C, G, or T at the position being queried. After imaging, the Polonator
chemically strips the array the annealed primer-fluorescent probe
complex, as well as residual enzyme, using 0.1 M NaOH.
After each cycle has been completed, and the primer-fluorescent
probe complex has been stripped, the sequence primer is replaced, and a
new mixture of fluorescently tagged nonamers is introduced, for which the
query position is shifted one base further into the library DNA tag. Seven
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bases are queried in this fashion, with the sequence performed from the 5’
end of the FDV side 14 base pair DNA library tag, followed by six base
reads with a different sequence primer from the 3’ end of this same 14
base pair DNA library tag, for a total of 13 base pair reads for this FDVside DNA library tag. This sequencing is then repeated for the 5’ and 3’
ends of the RDV side DNA library tag, resulting in another 13 base pair
reads.
Dual Primer ePCR Master Mixer

Reagent

Final Concentration

10 X EXT Buffer (FINNZYMES, Lafayette, CO)

1.2 x

MgCl2 (25 mM)

7 mM

dNTP (10 mM)

1 mM

FDV-PCR primer

0.1 µM

RDV-PCR primer

0.1 µM

Taq B enzyme

0.1 U/µl

Triton X-100 (10% (w/v))
BSA (10 mg/ml)

0.1%
1 mg/ml

Glycerol (50% (w/v))

5%

H2O

—

Silicone Oil Phase
The silicone oil phase is prepared by mixing 3.75 g AR 20 silicone oil
(Sigma, St Louis, MO), 7.5 g 749 Fluid (INCI name: cyclopentasiloxane
and trimethylsiloxysilicate; Dow Chemicals Co., Midland, MI) and 10 g
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5225C Formulation Aid (INCI name: clyclopentasiloxane and PEG/PPG18/18 dinethicone; Dow Chemicals Co., Midland, MI). The oil phase is
mixed on a vortex at high speed and 400 µl of oil mixture was immediately
dispensed equally into 2 ml low retention tube. Another 600 µl AR 21
silicone oil was added into this 400 µl mixture and mixed on a vortex to
make the final oil phase for emulsion PCR.
Breaking DPePCR emulsions
After PCR, all of the emulsion solution in the PCR tubes was
transferred into a low retention 2 ml tube, mixed and spun at 15,000 rpm
in a benchtop centrifuge. The beads were washed 12 times with 1 mL
isopropanol, and attached on MPC and the supernatant was removed.
After the isopropanol washes, the beads were then washed with 1 ml 80%
Ethanol/annealing buffer 4 times, then washed 4 times with 400 µl 1x NXS
buffer (combine all the same samples into new tubes at first wash). The
beads were finally washed with 2 times 800 µl TE buffer and 4 times with
800 µl TE buffer /0.1% Triton. After final wash, the beads were
resuspended in 1 ml TE buffer/0.1% Triton and stored at 4 °C until
needed.
Capping with dideoxynucleotide reaction
The beads were incubated with 15 µl (2.5 mM), 114 µl ddH2O, 15 µl
10 x Tailing buffer (NEB, Ipswich, MA), 4 µl 1.25 mM (each)
dideoxynucleotide mix (USB, Cleveland, OH), and 2 µl terminal
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transferase (20,000 U/ml) (NEB, Ipswich, MA) at 37 °C for 60 min. The
beads were washed 3 times with 500 µl 1x NXS buffer, 1x TE buffer with
0.1% Triton X-100, and 1x PBS.

Figure Legends
Figure 1. Molecular Barcoding Approach.
cDNA of each patient was tagged at the time of reverse transcription
with the barcoded reverse primers. The sequence adjacent to the 5’ end of
the barcode sequence is a universal PCR primer (T7), which is shared by
all the reverse primers. All of the PCR products from each individual
patient contain the corresponding barcode information, which can be
distinguished by hybridizing with the complementary fluorescently labeled
barcode probes.

Figure 2. Process schematic of bead based polony assay.
(A) The general steps of bead based polony technique are shown.
The agarose beads were conjugated to the forward primers. An aqueous
mix containing all of the necessary components for PCR, primers-coupled
beads, and template DNA was mixed with a silicone oil phase to create
emulsified microdroplets. These microdroplets were temperature-cycled
as in a conventional PCR. If a DNA template and a bead were present
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together in a single compartment, the oligonucleotides bound to the bead
acted as primers for amplification. After emulsion PCR, the microdroplets
were broken and the DNA products coupled beads were purified and
pooled together. By binding to the magnetic beads, the agarose beads
with amplified DNA products were enriched. These enriched beads with
coupled DNA were i immobilized to a coverslip by casting a
polyacrylamide gel. (B) The merged image hybridized with exon 11 (blue),
barcode 1 (green), and barcode 2 (red) is shown. Exon 11 was used as a
positive control, which should be present in every c-myb transcript.
Different combinations were identified as indicated: White beads are
transcripts with exon 11+ barcode 1 + barcode 2, indicating the DNA on
the beads was not clonal products from one single molecule; purple are
transcripts with exon 11+barcode 2; cyan are transcripts with exon
11+barcode 1; and blue are transcripts with exon 11 only, suggesting
these beads contained probably the DNA products from the other two
barcoded patient samples.

Figure 3. Process schematic of c-myb cDNA library construction.
see “Materials and Methods” for details.
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Figure 4. Oligos and intermediates in AcuI inside adaptor ligation.
Oligos and intermediates in AcuI inside adaptor ligation. Adatpor (in
grey shadow) is oriented as it would be in circle formation. 5’, 3’, and 5’phosphate oligo temini are indicated as 5, 3, 5-P, respectively.
Phosphodiester linkages to insert sequences are indicated by >- for the
top strand and <- for the bottom strand. Oligo names correspond to details
listed in Table 3.
Figure 5. Agarose gels of selected library construction intermediates.
M1 (Marker) for the gels contains 2000 bp, 1500 bp, 1000 bp, 500
bp. M2 (Marker) for the gel contains 400 bp, 300 bp, 200 bp, 100 bp. (A)
dUTP incorporation titration. Different ratios of dUTP:dNTP (1: 5, 1:20,
1:100) were used in the first PCR step. After amplification, the DNA
products were fragmented with UDG/APE1 and compared to the products
amplified with no dUTP (dUTP:dNTP=0) incorporation. (B) PCR 1. To
check the efficiency of AcuI inside adaptor ligation with fragmented DNA,
circularization U forward primer and circularization U reverse primer were
used to selectively amplify the adaptor ligated DNA product (AcuI-DNA).
(C) PCR 2. To check the intramolecular circularization of the DNA after
ExoIII and I nucleases digestion, a negative control experiment was set
up, in which T4 ligase was not included in the circularization reaction.
Circularization U-For and circularization U-Rev primers were used to
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amplify the DNA products from both reactions (W/ T4 and W/O T4 ligase).
(D) PCR 3. To check the efficiency of AcuI digestion of linearizing the
circle DNA, circularization U-For and circularization U-Rev primers were
used for PCR amplification. The generated PCR products (W/AcuI) were
compared to the PCR products from the circle DNA prior to AcuI digestion
(W/O AcuI). (E) PCR 4. After ligating to the outside adaptors FDV and
RDV, the ligated DNA products were amplified with FDV-BC-PCR and
RDV-BC-PCR primers. The PCR products (FDV-DNA-RDV) were
compared to the PCR products (FDV/RDV) arose from the negative
control ligation reaction in which there were only two adaptors but no
DNA. The 180 bp DNA products on the agarose gel were the PCR
products amplified from the final DNA libraries.
Figure 6. Dual Primer Emulsion PCR approach.
(A) Dual primer beads, diluted DNA fragment, ePCR reagents, and
both free primers were mixed with silicone oil phase. Ideally, each
microdroplet should only contain 1 bead, 1 DNA molecule and enough
reagents for clonal amplification. (B) After 1 cycle, the first DNA bridge
was formed inside the microdroplet and bound to the bead, which would
be used as the template for later DNA amplification on the bead. (C) After
120 cycles, the beads were covered with numerous DNA bridges that
were clonal products from a single molecule. (D) After breaking emulsion,
the beads were digested with SnaBI enzyme. This digestion site was at
the inside adaptor, which cut the DNA fragment into half. This digestion
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left one segment (c-myb sequence) of the fragment DNA on one strand
and the other segment (barcode sequence) on the other strand. (E) After
digestion, the beads were treated with NaOH to single strand the dsDNA,
which provides the accessibility of the DNA strand for sequencing.
Specific sequence primers were hybridized at both ends of the forward
and reverse strands (individually). (F) Merged images recorded after
hybridizing with sequencing primers and ligating to the nonamers. After
hybridizing with different sequencing primers, the SBL (sequencing by
ligation) sequencing strategy was used, followed by recording the images.

Figure 7. The final DNA library for DPePCR.
About 85 bp DNA fragments were ligated to FDV and RDV outside
adaptors. Since the ligation reaction is not oriented, the two adaptors
could be ligated to either side of the DNA fragments. The size of the final
DNA products in the library is about 180 bp, in which the inside DNA
sequence formed by circularization was flanked by two segments
containing 13 bp c-myb sequence and 9 bp barcode sequence,
respectively.

Figure 8. Polonator sequencing.
After emulsion PCR, the DNA on the beads was digested with SnaBI
and single-stranded. For 3’-5’ direction sequencing, sequence primers
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FDV-Minus and RDV-Minus were sequentially hybridized to the FDV or
RDV adaptor sequence of the DNA strands coupled to the beads. A set of
four fluorescently labeled nonamers competed for ligation to the
sequencing sequence primers. Specificity of the nonanonamer is achieved
by interrogating the 1st base (-1 position) in the ligation reaction. Multiple
cycles of denaturation, hybridization, and ligation are performed with the
number of cycles determining the eventual read length for the 3’-5’
direction. For 5’-3’ direction sequencing, sequence primers FDV-Plus and
RDV-Plus were individually hybridized to the sequence adjacent to SnaBI
digestion site. A set of four 5’phosphorylated fluorescent nonamers
competed to ligate to the plus sequencing primers. Specificity of the
nonamer was achieved by interrogating the 1st base (+1 position) in the
ligation reaction. The 5’-3 direction sequencing was performed the same
way as the 3’-5’ direction sequencing. The unknown sequences in the red
box are the interrogated bases.

Figure 9. Distribution of sequence coverage for each exon.
After decoding the barcode information of each bead and
categorizing the raw data into the groups with the same barcode, the cmyb tags were mapped back to different position at individual exon
sequence. The frequency of the tags found in the same position was
plotted against the entire sequence of the exon.
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Tables
Table 1. Primers for polony sequencing (bead-based) assay
Primers for Polony
Sequencing
Universal T7-Barcode1-RT
Universal T7-Barcode2-RT
Universal T7-Barcode3-RT
Universal T7-Barcode4-RT
T7 Rev PCR Primer
SN-3 Forward Primer
T7 Rev PCR Primer-biotin

Probes for Exontyping
Barcode 1 probe-cy3
Barcode 2 probe-cy5
Barcode 3 probe-FITC
Barcode 4 probe-TxRed

Sequence
5'-GTAATACGACTCACTATAGGGCGAATTGGGTAAAGGCACGTATCATATCCCTCTTTCCACAGGATGCAGGTT-3'
5'-GTAATACGACTCACTATAGGGCGAATTGGGTAACATATCCTAATACAGGCGCCTTTCCACAGGATGCAGGTT-3'
5'-GTAATACGACTCACTATAGGGCGAATTGGGTAGACGATCCTTATACTCGATGCTTTCCACAGGATGCAGGTT-3'
5'-GTAATACGACTCACTATAGGGCGAATTGGGTAGAAGACAGTTATACCCATGCCTTTCCACAGGATGCAGGTT-3'
5'-GTAATACGACTCACTATAGGGCGAATTGGGTA-3'
5'-GGAAGGTCGAACAGGAAGGTTATCTG-3'
5'-Biotin-GTAATACGACTCACTATAGGGCGAATTGGGTA-3'

Sequence
5'-Alexa 532-TAAAGGCACGTATCATATCCCTC-3'
5'-Alexa 647-TAACATATCCTAATACAGGCGCC-3'
5'-FAM-TAGACGATCCTTATACTCGATGC-3'
5'-Alexa 594-TAGAAGACAGTTATACCCATGCC-3'

The exon-specific probes are the same as the ones used in gel-based polony assay in Chapter 2.
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Table 2. The splice variants in 4 pediatric pre-B-ALL patient samples detected by the bead based polony assay
(ND: Not Detectable)
Isoform

Protein Size

Exontyping

610-194

610-856

610-319

1

Del8/Del9

1-281, 402-640

6-7-10-11

0.28%

ND

ND

611-551
ND

2

Del8/Del10

1-281, 371-402

6-7-9-11

ND

ND

ND

0.09%

3

Del8

1-281, 317-640

6-7-9-10-11

2.35%

3.89%

2.72%

0.68%

4

Del9

1-316,402-640

6-7-8-10-11

ND

1.29%

1.09%

1.56%

5

Del10

1-402

6-7-8-9-11

ND

ND

ND

0.19%

6

WT

1-640

6-7-8-9-10-11

58.63%

52.37%

64.50%

67.54%

7

Del8/9S

1-281, 317-372, +2aa

8

Del8/9S

9

9S/10

10

9S/10

11

Del8/9A

12

Del8/9A

13

Del8/9A

14

Del8/9A

15

9S/9A

16

9S/9A

17

9S/9A

18

9S/9A

1-372, +16aa

19

9A

1-401, +M

20

9A

21

9A

22

9A

23

Del8/8A

24

Del8/8A

25
26

6-7-9S-10-11

0.47%

0.96%

ND

0.19%

6-7-9S-10-10A-11

ND

2.57%

ND

0.09%

6-7-8-9S-10-11

4.17%

2.28%

1.93%

7.17%

6-7-8-9S-10-10A-11

0.82%

1.60%

ND

0.09%

6-7-9-9A-10-11

0.35%

0.09%

ND

ND

6-7-9-9A-9B-10-11

0.12%

0.19%

0.09%

ND

6-7-9-9A-10-10A-11

ND

ND

ND

ND

6-7-9-9A-9B-10-10A-11

ND

ND

ND

ND

6-7-8-9S-9A-10-11

0.24%

0.32%

0.19%

0.58%

6-7-8-9S-9A-9B-10-11

ND

0.32%

ND

0.19%

6-7-8-9S-9A-10-10A-11

0.12%

0.64%

ND

ND

6-7-8-9S-9A-9B-10A-11

ND

ND

ND

ND

6-7-8-9-9A-10-11

2.54%

2.25%

2.48%

2.09%

6-7-8-9-9A-9B-10-11

1.45%

0.09%

0.49%

0.36%

6-7-8-9-9A-10-10A-11

0.12%

0.64%

ND

0.54%

6-7-8-9-9A-9B-10-10A-11

0.47%

0.76%

ND

ND

6-7-8A-9S-10-11

ND

ND

0.29%

ND

6-7-8A-9-10-11

ND

ND

0.19%

ND

Del8/8A

6-7-8A-9-10-10A-11

0.24%

0.64%

ND

0.56%

Del8/8A

6-7-8A-9-9A-10-10A-11

ND

ND

ND

0.19%

1-372, +2aa
1-281, 317-402, +M

1-372, +16aa

1-281, +34aa
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Isoform

Protein Size

Exontyping

610-194

610-856

610-319

611-551

27

Del8/8A

1-281, +34aa

6-7-8A-9S-9B-10-10A-11

28

Del8/8A

6-7-9-9A-10-10A-11

0.12%

ND

ND

ND

ND

0.32%

ND

29

8A

ND

6-7-8-8A-9S-10-11

ND

ND

0.19%

30

8A

ND

6-7-8-8A-9-11

ND

ND

0.13%

ND

31
32

8A

6-7-8-8A-9-10-11

0.12%

ND

3.59%

ND

8A

6-7-8-8A-9S-9A-10-11

ND

ND

ND

33

8A

ND

6-7-8-8A-9-9A-10-11

ND

ND

0.09%

34

8A

ND

6-7-8-8A-9S-9B-10-11

ND

ND

ND

ND

35
36

8A

6-7-8-8A-9-9B-10-11

ND

ND

0.09%

0.19%

8A

6-7-8-8A-9-9A-9B-10-11

ND

ND

ND

0.24%

37

8A

6-7-8A-10-11

ND

ND

0.09%

ND

38

8A

6-7-8-8A-10-10A-11

ND

ND

ND

ND

39

8A

6-7-8-8A-9S-10-10A-11

0.35%

0.32%

ND

0.12%

40

8A

6-7-8-8A-9-10A-11

ND

ND

ND

ND

41

8A

6-7-8-8A-9-9A-10-10A-11

0.24%

ND

ND

ND

42

8A

6-7-8-8A-9S-9B-10-10A-11

0.24%

ND

ND

ND

43

8A

6-7-8-8A-9S-9A-10-10A-11

ND

ND

ND

ND

44

8A

6-7-8-8A-9-10-10A-11

4.82%

1.61%

0.56%

7.45%

45

8A

6-7-8-8A-9S-9A-9B-10-11

ND

ND

0.09%

ND

46

8A

6-7-8-8A-9-9B-10-10A-11

0.71%

0.96%

0.09%

0.09%

47

Del8/9S/9B

48

Del8/9S/9B

49

Del9/10A

50

Del9/10A

51

9S/9B

52

9S/9B

53

9B/Del10

54

1-316, +34aa

1-316, +34aa

1-281, 317-372, +50aa
1-316, 402-449
1-372, +50aa

6-7-9S-9B-10-11

0.24%

0.32%

ND

0.09%

6-7-9S-9B-10-10A-11

ND

ND

ND

ND

6-7-8-10-10A-11

ND

ND

ND

ND

6-7-8-10-10A-11

ND

0.32%

0.09%

ND

6-7-8-9S-9B-10-11

1.57%

0.19%

0.41%

ND

6-7-8-9S-9B-10-10A-11

0.47%

0.64%

ND

ND

1-401, +121aa, 402

6-7-8-9-9B-11

ND

ND

ND

ND

9B

1-401,+121aa, 402-640

6-7-8-9-9B-10-11

11.32%

7.50%

9.25%

4.24%

55

Del8/10A

1-281,317-449

6-7-9-10-10A-11

0.24%

0.96%

0.19%

0.36%

56

Del9/Del10/10A

1-316,+13aa

6-7-8-10A-11

ND

ND

ND

ND

57

Del10/10A

1-401,+13aa

6-7-8-9-10A-11

ND

ND

ND

ND

58

10A

1-449

6-7-8-9-10-10A-11

4.98%

13.87%

10.27%

5.26%
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Isoform

Protein Size

Exontyping

610-194

610-856

610-319

611-551

59

9B/10A

1-401,+121aa,402-449

6-7-8-9-9B-10-10A-11

1.33%

1.97%

0.90%

0.54%

60

Del8/9S/9A

1-281,317-372,+16aa

6-7-9S-9A-10-11

ND

ND

ND

ND

61

Del8/9B

1-281,317-401,+121aa,402-640

6-7-9-9B-10-11

0.89%

0.12%

ND

ND
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Table 3. Primers for constructing sequencing libraries, emulsion PCR and sequencing by NGSM
Primers For Library
Construction

Sequence

Oligo AcuI-7mer-2BC-RT-1

5'-AGTTCATCTCAAGCTGAAGTCCA(CT)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-2

5'-AGTTCATCTCAAGCTGAAGTCCA(AG)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-3

5'-AGTTCATCTCAAGCTGAAGTCCA(AA)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-4

5'-AGTTCATCTCAAGCTGAAGTCCA(CC)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-5

5'-AGTTCATCTCAAGCTGAAGTCCA(GC)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-6

5'-AGTTCATCTCAAGCTGAAGTCCA(TT)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-7

5'-AGTTCATCTCAAGCTGAAGTCCA(CA)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Oligo AcuI-7mer-2BC-RT-8

5'-AGTTCATCTCAAGCTGAAGTCCA(TA)NNNNNNNTGCACTTGGTCGTGCTCT-3'

Rev-Oligo AcuI

5'-TCATCTCAAGCTGAAGTCCA-3'

SN-3-For

5'-GGAAGGTCGAACAGGAAGGTTATCTG-3'

AcuI-Inside Adaptor-1

5'-CAGGATAGAGCATGATCTGAAGT-3'

AcuI-Inside Adaptor-2

5'-Phos-CTTCAGATCATGCTCTATCCTGCATT-3'

Circularization U-For

5'-ACGTATCGTGCAUCAGGATAGAGCATGATCTGAA-3'

Circularization U-Rev

5'-ATGCACGATACGUAGTTCATCTCAAGCTGCCGTCCA-3'

FDV-adaptor-1

5'-GCCTCCGCTTTCCTCTCTATGCTTTATACCAATATCCATACTCCAACT-3'

FDV-adaptor-2

5'-Phos-GTTGGAGTATGGATATTGGTATAAAGCATAGAGAGGAAAGCGGAGGCTTAC-3'

RDV-adaptor-1

5'-ACTGCCCCGGGTTCCTCATTCATTTCCTATCTCATGACTACTGAAGT-3'

RDV-adaptor-2

5'-Phos-CTTCAGTAGTCATGAGATAGGAAATGAATGAGGAACCCGGGGCAGTCATT-3'

FDV-BC-PCR

5'-GCCTCCGCTTTCCTCCTATG-3'

RDV-BC-PCR

5'-ACTGCCCCGGGTTCCTCATTC-3'

AcuI-Inside Adaptor

3'-TGAAGTCTAGTACGAGATAGGAC-5'
5'-Phos-CTTCAGATCATGCTCTATCCTGCATT-3'

FDV-Adaptor

3'-TCAACCTCATACCTATAACCATATTTCGTATCTCTCCTTTCGCCTCCG-5'
5'-Phos-GTTGGAGTATGGATATTGGTATAAAGCATAGAGAGGAAAGCGGAGGCTTAG-3'

RDV-Adaptor

3'-TGAAGTCATCAGTACTCTATCCTTTACTTACTCCTTGGGCCCCGTCA-5'
5'-Phos-CTTCAGTAGTCATGAGATAGGAAATGAATGAGGAACCCGGGGCAGTCATT-3'
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Primers for Emulsion PCR and
Polonator Sequencing
FDV-DualBiotin

Sequence

RDV-DualBiotin

5'-dual biotin-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAACCACTACGCCTCCGCTTTCCTCTCTATG-3'
5'-dual biotin-TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTATATGTCAACTGCCCCGGGTTCCTCATTC-3'

FDV-BC-PCR

5'-GCCTCCGCTTTCCTCCTATG-3'

RDV-BC-PCR

5'-ACTGCCCCGGGTTCCTCATTC-3'

Sequence primer FDV-Minus

5'-/5Phos/-AAGTTGGAGTATGGATATTGGTAT-3'

Sequence primer RDV-Minus

5'-/5Phos/-ACTTCAGTAGTCATGAGATAGG-3'

Sequence primer FDV-Plus

5'-GTTCATCTCAAGCTGAAGTCCA-3'

Sequence primer RDV-Plus

5'-GCATCAGGATAGAGCATGATCTGAAGT-3'

FDV-FAM

5'-FAM-AAGTTGGAGTATGGATATTGGTAT-3'
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Nonamers

Sequence

-1 sequencing nonamers

5'Cy5-NNNNNNNNT
5'Cy3-NNNNNNNNA
5'TexasRed-NNNNNNNNNC
5'FAM-NNNNNNNNG
5'-/5Phos/-TNNNNNNNN/3Cy5/-3'
5'-/5Phos/-ANNNNNNNN/3Cy3/-3'
5'-/5Phos/-CNNNNNNNN/3TxRed/-3'
5'-/5Phos/-GNNNNNNNN/3FAM/-3'
5'Cy5-NNNNNNNTN
5'Cy3-NNNNNNNAN
5'TexasRed-NNNNNNNNCN
5'FAM-NNNNNNNGN
5'-/5Phos/-NTNNNNNNN/3Cy5/-3'
5'-/5Phos/-NANNNNNNN/3Cy3/-3'
5'-/5Phos/-NCNNNNNNN/3TxRed/-3'
5'-/5Phos/-NGNNNNNNN/3FAM/-3'
5'Cy5-NNNNNNTNN
5'Cy3-NNNNNNANN
5'TexasRed-NNNNNNNCNN
5'FAM-NNNNNNGNN
5'-/5Phos/-NNTNNNNNN/3Cy5/-3'
5'-/5Phos/-NNANNNNNN/3Cy3/-3'
5'-/5Phos/-NNCNNNNNN/3TxRed/-3'
5'-/5Phos/-NNGNNNNNN/3FAM/-3'
5'Cy5-NNNNNTNNN
5'Cy3-NNNNNANNN
5'TexasRed-NNNNNNCNNN
5'FAM-NNNNNGNNN
5'-/5Phos/-NNNTNNNNN/3Cy5/-3'
5'-/5Phos/-NNNANNNNN/3Cy3/-3'
5'-/5Phos/-NNNCNNNNN/3TxRed/-3'
5'-/5Phos/-NNNGNNNNN/3FAM/-3'
5'Cy5-NNNNTNNNN
5'Cy3-NNNNANNNN
5'TexasRed-NNNNNCNNNN
5'FAM-NNNNGNNNN
5'-/5Phos/-NNNNTNNNN/3Cy5/-3'
5'-/5Phos/-NNNNANNNN/3Cy3/-3'
5'-/5Phos/-NNNNCNNNN/3TxRed/-3'
5'-/5Phos/-NNNNGNNNN/3FAM/-3'
5'Cy5-NNNNNTNNN
5'Cy3-NNNNNANNN
5'TexasRed-NNNNNNCNNN
5'FAM-NNNNNGNNN
5'-/5Phos/-NNNTNNNNN/3Cy5/-3'
5'-/5Phos/-NNNANNNNN/3Cy3/-3'
5'-/5Phos/-NNNCNNNNN/3TxRed/-3'
5'-/5Phos/-NNNGNNNNN/3FAM/-3'

+1 sequencing nonamers

-2 sequencing nonamers

+2 sequencing nonamers

-3 sequencing nonamers

+3 sequencing nonamers

-4 sequencing nonamers

+4 sequencing nonamers

-5 sequencing nonamers

+5 sequencing nonamers

-6 sequencing nonamers

+6 sequencing nonamers
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-7 sequencing nonamers

5'Cy5-NNNNNNTNN
5'Cy3-NNNNNNANN
5'TexasRed-NNNNNNNCNN
5'FAM-NNNNNNGNN

All nonamers were purified via high performance liquid chromatography (HPLC)
and degenerated bases were hand-mixed to the 25:25:25:25 ratios.
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Chapter 4: Discussion
Overall, our study demonstrates that c-myb alternative splicing is highly
elevated in leukemia patient samples and the pattern of c-myb alternative
splicing is more complex and distinct in leukemia patients than in normal
samples. Our data also suggests that activation of c-myb alternative splicing
could be a novel mechanism that contributes to leukemogenesis. We proposed
the hypothesis that aberrant alternative splicing of c-myb transcripts in leukemias
leads to the production of truncated variants of c-Myb with transforming or
leukemogenic activities, which could be used as a biomarker in leukemias. Our
data here support the hypothesis by showing that some splice variants with the
protein structures resembling the oncoprotein v-Myb are more highly expressed
in leukemia patients, which implies c-myb alternatively spliced variants could play
an important role in tumor development or progression. Moreover, we performed
survival analysis that identified some splice variants have a tight link to leukemia
outcome demonstrating the c-myb alternative splicing could be a unique
biomarker for classifying leukemia patients into different treatment groups, as
gene expression-profiling does. To be able to identify the clinical value of
following c-myb alternative splicing in leukemia samples, we further developed
new techniques combining with next generation sequencing platforms to profile
c-myb splice variants in leukemia patients at a large scale. This is the first time
that next-generation methods are applied to determine the structures of entire
cDNAs. The novel use of NGSMs accelerates the speed of analyzing c-myb
alternative splicing in a large number of patient samples simultaneously by
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several orders of magnitude, which may become a promising tool facilitating
medical research in analysis of the cause of leukemias, development of new
drugs and diagnostics.
Do c-myb splice variants have unique transcriptional activities that
contribute to oncogenesis?
Several recent studies 36,37,78 have suggested that relatively minor changes
in the transcriptional activation domain of c-Myb can dramatically affect its
transcriptional activity. The alternative splicing of the c-myb gene products is a
mechanism for producing variants of c-Myb with different transcriptional
activation domains. Our laboratory has shown that variant c-Myb proteins
encoded as a result of alternative splicing have quantitative and qualitative
differences in their transcriptional activities 19. However, very little is known about
the biological roles of the variant c-Myb proteins. Since c-myb undergoes
extensive alternative splicing producing vast amount of variant c-Myb proteins, it
is not feasible to study all of these variant proteins. We need to focus on the ones
that are highly related to disease. Our data identifies some c-myb splice variants
that could have an important role in leukemia and reveals the expression level of
these splice variants could affect the survival time of the patients. These data
provide a foundation for characterizing the transcriptional specificities and
biological functions of the aberrantly expressed splice variants in leukemias.
Variant c-Myb proteins share very similar or identical DNA binding domains,
they recognize a degenerate consensus sequence motif (C/T)AAC(G/T)G 26,247,
which is expected to occur approximately three million times in the human
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genome. Thus, while the DNA binding domain is critical for its activity, the protein
binding sites in the C-terminal domains probably play a crucial role in stabilizing
multi-protein complexes and combinatorial and cooperative interactions that
allow each type of c-Myb proteins to associate with specific sets of target gene
promoters, or allow each c-Myb variant to associate with different sets of cofactors, resulting in different transcriptional activities. The C-terminal region of cMyb also contains the sequences responsible for triggering its rapid
ubiquitinylated and proteolytic turnover 112 113, so truncated variants like 9S/10
might be much more stable than the full length protein and could accumulate to
higher levels than expected, even thought they are encoded by a relative small
fraction of transcripts. Chromatin-ImmunoPrecipitation (ChIP) assays are one of
the means to study the binding with target genes and follow the transcriptional
specificities of variant Myb proteins 186. ChIP assays could determine the specific
locations (promoters) that variant c-Myb proteins are associated with, indicating
the target genes of these proteins. The uses of specific siRNA for splice variants,
which could selectively knockdown variant Myb proteins, followed by
transcriptome sequencing or microarray analysis could further assist with the
identification of the genes that are regulated by variant Myb proteins. It is
essential to develop antibodies that specifically recognize these variant proteins
to study the difference in the target genes of c-Myb protein and its variants
proteins. With genome wide ChIP assays and variant Myb protein knockdown
experiments, a set of clinically relevant Myb target genes would be identified. By
comparing to the target genes of oncoprotein v-Myb in transformed or leukemia
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cells and a comparison of the expression levels of the target genes in normal
cells versus in leukemia samples will offer an insight into the role of aberrantly
expressed variant c-Myb proteins in leukemogenesis.
Do Myb partners define their activities?
Several lines of evidences show that C-terminal domains of Myb proteins
affect intra- and intermolecular interactions with their protein co-factors and are
subject to numerous post-translational modifications, which can regulate Myb
proteins transcriptional activities (see review 172). Our recent studies show that
alternatively spliced c-myb transcripts are associated with polyribosomes, which
indicates that they are translated to produce different forms of c-Myb proteins.
Variant c-Myb proteins have different C-terminal domains, in which some variants
with C-terminal deletion resembling v-Myb are identified by our research to
correlate with human leukemias. These variant proteins are likely to interact with
different co-factors and form different protein complex to regulate different gene
sets.
The C-terminal domain of c-Myb protein is comprised of several subdomains, such as the transactivation domain and negative regulatory domain,
each of which contributes interdependently to c-Myb transcriptional activity (see
review 219). To identify proteins that interact with each domain, a generic tandemaffinity protein purification (TAP) method could be performed to isolate Myb
protein complexes in different types of cells and use proteomics to identify the
proteins that different variant Myb proteins bind to. Classical biochemical
purification methods rely heavily on the biophysical properties of a given protein.
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Variant Myb proteins are unique and the protein purification protocol for each
protein needs to be designed individually, therefore, there is a critical need for
developing widely applicable and efficient purification procedures for isolating
protein complexes formed by variant Myb proteins.
Tandem affinity purification is a two-step affinity purification protocol for
isolation of TAP-tagged proteins together with associated proteins 248. It has
proven to be highly effective in the identification of protein complexes in yeast
and some mammalian systems 249 248 250. The TAP tag is comprised of two
affinity tags, protein A and calmodulin-binding peptide (CBP), separated by a
TEV protease cleavage site, which is fused to either the N- or C-terminus of the
target protein. Extracts prepared from cells expressing the TAP-tagged protein
are subjected to two successive purification steps. The first purification step
involves binding of the protein A tag to an IgG column and eluting the bound
material by cleaving with TEV protease. This elution method significantly reduces
the contaminating proteins bound nonspecifically to the column. The elutes that
contain protein complexes are further purified by binding with calmodulin-coated
beads to remove TEV protease and contaminants. Highly purified protein
complexes are eluted by adjusting the concentration of calcium ions with
chelating reagents. The retrieved protein complexes are then subjected to
proteomics to identify the proteins in the complexes.
To apply this generic purification approach to characterize the protein
partners of variant Myb proteins, we could construct TAP-tagged variant Myb
proteins, ectopically express them in cells and perform TAP purification. Many
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proteins have been identified to interact with c-Myb and interfere with its activity,
some of which are suggested to contribute to the oncogenic capacity of activated
forms of Myb 251. Therefore, if the interacting proteins characterized for different
isoforms of c-Myb were identified as cell cycle regulators, kinases that might
modify Myb proteins, and/or the proteins that are involved in chromatin
remodeling, we will further study whether these different partners will regulate or
affect the activity of variant c-Myb proteins.
Could c-myb alternative splicing affect stem cell fate?
c-Myb protein is clearly involved in the regulation of stem cell proliferation
and differentiation in many cell types, including hematopoietic, epithelial and
neural cells 179 56,57. Recent developments in the stem cell field have shown that
the combined ectopic expression of the transcription factors, KLF4, MYC, SOX2
and OCT4 in primary fibroblasts can induce a stem cell phenotype and the
expression of characteristic stem cell specific genes such as NANOG, resulting
in the production of induced pluripotent stem (iPS) cells 183,252,253. Interestingly,
the MYC gene is regulated by c-Myb in some cell types, suggesting that c-Myb
could play a role in stem cell formation by regulating MYC 53,254,255. Moreover,
bioinformatics approaches have identified c-Myb as a likely regulator of
pluripotency and “stemness” in iPS cells 184.
Evidence of the influence of alternative splicing in stem cells is rapidly
growing. Recent studies indicate the levels of some splice variants of stem cellenriched genes (stemness genes) correlate with particular stages of
differentiation. For example, the POU5F1 gene is an example of a central
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stemness gene that is regulated by alternative splicing. This gene encodes
transcription factor OCT4 that is highly expressed in stem cells and appears to
be essential for reprogramming differentiated cells to an induced pluripotent state
256

. Finer discrimination among the POU5F1 gene products revealed differentially

regulated splice variants 257. The levels and the patterns of these variants are
different in embryonic stem cells compared with more differentiated cells 257 258
and they have distinct roles in self-renewal of stem cells 259. Our laboratory has
shown that alternative splicing of c-myb transcripts is highly regulated during the
differentiation of primary human hematopoietic progenitor cells 19. Furthermore,
our data demonstrates that the alternative splicing occurs more frequently in
leukemia and the profile of c-myb alternative splicing in each patient is unique. All
of the above suggest that by shifting the pattern of c-myb alternative splicing,
stem cells could produce a different repertoire of c-Myb proteins and express a
different subset of Myb target genes than more differentiated cells. Aberrant
alternative splicing could produce oncogenic forms of c-Myb that affect the
“stemness” of the cells, making the normal hematopoiesis process go awry,
resulting in leukemia.
We have different viral vectors that express different c-Myb proteins,
including 9S/10, 9B and c-Myb, which can be used to infect different types of
cells. We can utilize this viral system combining with other transcription factors
that are required for inducing pluripotent stem cells to generate iPS cells. These
iPS cells will be cultured in a standardized in-vitro culture system, and their
abilities to differentiate along multiple hematopoietic lineages could be assessed.
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Alternatively, we can use CD34+/CD133+ hematopoietic progenitor cells as an
experimental model for similar purpose. CD34+ hematopoietic progenitor cells
have the ability to differentiate along multiple lineages. After infecting the CD34+
cells with variant Myb proteins, these cells will be cultured in semi-solid
methylcellulose cultures containing appropriate cytokines and growth factors to
permit proliferation and differentiation along multiple pathways. By measuring the
numbers and ratios of the formed colonies and analyzing the differentiation
status of the cells, we could detect the differences in the activities of variant cMyb proteins on affecting normal hematopoiesis. These experiments could
characterize the activities of variant c-Myb proteins in hematopoietic stem cell
differentiation and proliferation. These experiments could also enhance our
knowledge of whether c-myb alternative splicing could be an important
component to determine stem cell fate and if deregulation of this process could
contribute to leukemogenesis.
Implication for the future
It is clear that alternative splicing provides a mechanism for producing
specific variants of c-Myb with unique functions, which greatly increases the
complexity of c-Myb activities in hematopoiesis and oncogenesis. Our studies
investigating c-myb alternative splicing in leukemia patient samples established
an association between alternatively spliced c-myb variants and clinical
parameters in pediatric pre-B-ALL. The total expression level of the c-myb gene
has never been indicated by microarray analysis as a component for classifying
high-risk leukemia patients. Our results from the novel single molecule analysis
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methods reveal aberrant c-myb alternative splicing as a novel biomarker in
leukemia. Further studies testing the hypothesis that alternative splicing is a
novel mechanism to unmask c-Myb oncogenicity will promote deep
understanding of the normal and oncogenic functions of c-Myb. Future
experiments will determine whether aberrantly expressed Myb variants could
regulate hematopoiesis differently, whether these variant Myb proteins regulate
target genes that are transforming relevant and whether the interacting protein
complexes define their activities. Results from these experiments will expand our
knowledge on how c-Myb becomes oncogenic and have a considerable effect on
the novel molecularly targeted oncotherapeutics.
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APPENDICES
Appendix I: Characterization of variant Myb proteins in NALM-6 cells
Identification of variant Myb proteins target genes is essential for the
complete characterization of Myb protein activity. Myb proteins exert their activity
through regulating their target genes. For example, c-Myb binds to the genes that
are linked to cell proliferation and metastasis, including CXCR4, a gene encoding
the receptor for the chemokine SDF-1, and the CCNA1, CCNB1 and CCNE1
genes, which encode the important cell cycle regulators Cyclin A1, Cyclin B1 and
Cyclin E1, respectively. These target genes indicate the potential function of cMyb in cell proliferation and cell survival. Therefore, identification of the genes
that are directly bound by variant Myb proteins could assist exploring the
underlying molecular mechanism how they contribute to leukemias. By far the
best method to follow the activity and specificity of variant Myb proteins is ChIP
assay 186. With this experiment, the chromatin-embedded gene promoters that
are bound by transcription factor Myb proteins can be identified and compared to
one another among variant forms of c-Myb. However, ChIP assay relies heavily
on the biophysical properties of the interested protein, for each variant Myb
protein, a specific antibody has to be developed and each protein is unique so
that developing a general protocol for individual antibodies specific to each
variant is not feasible. Therefore, we utilized a lentiviral system to ectopically
express Flag-tagged Myb proteins in the cells and only used one Flag-antibody
for all of the interested variant Myb proteins to perform ChIP assay 220,260.
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Materials and Methods
Myb lentiviral Production
N-terminal FLAG-tagged human c-Myb, 9S/10, and 9B transcripts were
cloned into the unique PacI site of the pHR IRES GFP lentiviral vector
downstream of an EF1 alpha promoter. Plasmids were transfected into 293 FT
cells (Invitrogen. Carlsbad CA) by calcium phosphate transfection along with the
lentiviral packaging plasmid delta 8.9 and the pMD.G plasmid expressing the
vesicular stomatitis virus glycoprotein. Supernatant was collected at 24 hr
intervals for 48 hr. Ultrafiltration using an Ambion Ultracell 100 kDa NMWL filter
unit (Millipore, Billelrica MA) was used to concentrate viral supernatants.
Making Stable Cell Lines
NALM-6 cells were transduced individually with different lentiviruses that
express different versions of Myb proteins, at MOI 1:100 in the presence of 8
µg/ml of polybrene (Sigma, St. Louis, MO) in two constitutive days. After 7 day
post-transduction, the cells were sorted to enrich for GFP+ transduced cells.
These GFP positive cells were then expanded by culturing in IMDM (Iscove's
Modified Dulbecco's Medium) (GIBCO, Carlsbad, CA) supplemented with
10%(v/v) FBS, 1 mM L-glutamine, and 50 µM ß-mercaptoethanol.
Immunoprecipitation and Western Blot
Cell pellets (2 x 107) were lysed with 1 ml RIPA buffer [1% (v/v) Nonidet P40 (Sigma, St. Louis, MO), 0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl pH 7.5]
with protease inhibitor (1 µM each chymostatin, leupeptin, antipain, pepstatin-A;
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1 mM each phenylmethylsulfonyl fluoride and benzamidine) for 30 min at 4 °C.
After lysing, samples were spun at 13,000 rpm for 10 min at 4 °C to remove cell
debris. About 10% of the supernatant were removed as input for the following
western blot, and the rest was subjected to immunoprecipitation (IP). IP was
performed with anti-FLAG M2 beads (Sigma, St. Louis, MO) (40 µl) or nonspecific IgG beads for 2 hr. Samples were mixed by rotation at 4 °C for 1 hr. After
binding, the beads were washed with 800 µl of RIPA buffer 3 times to remove all
non-specific protein bindings. Then the proteins were eluted from the beads with
5 x SDS protein loading buffer. Samples were boiled for 10 min, beads were
removed by centrifugation and samples were subjected to Western blot analysis
with anti-c-Myb.
Chromatin Immunoprecipitation
Standard methods were used except chromatin was sheared in a 200 µl
volume of 50 mM Tris pH 8.0 (Sigma, St. Louis, MO) by adding 36 units of
Micrococcal nuclease (USB, Cleveland, Ohio) for 10 min at 37 °C 220,260. Adding
EDTA to 10 mM stopped the reaction and cells were lysed in 1% v/v SDS. Equal
aliquots were subjected to immunoprecipitation with anti-FLAG beads or anti-Myb
monoclonal 1-1 antibodies (Millipore, Burlington, MA) or control non-specific IgG
beads for 24 hr. Anti-Myb monoclonal 1-1 antibodies were used here to
recognize the endogenous c-Myb protein. Primers used for QPCR reactions
using SYBR green (Biorad, Hercules, CA) are listed in Table 1.
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Microarray analysis
RNA was extracted with the RNeasy Mini kit (Qiagen, Valencia, CA) for
each cell line (stably expressed GFP, FLAG-c-Myb, FLAG-9S/10, and FLAG-9B).
RNA quality was judged using the Lab-on-a-Chip Bioanalyzer 2100 (Agilent, Palo
Alto, CA), and total about 2 µg RNA for each cell line was subjected to
microarray analysis. Hybridization probes were prepared and hybridized to
U133A 2.0 GeneChip exactly as described by the manufacturer (Affymetrix,
Santa Clara, CA), using the Superscript Choice System (Invitrogen, Carlsbad,
CA) and the RNA transcript labeling kit (ENZO, Farmingdale, NY) for cRNA
preparation. Microarray analysis was performed using the Affymetirx GeneArray
Scanner G2500A, and the samples were scaled to a median fluorescence of 500
units using Microarray Suite 5.0 software (Affymetrix, Santa Clara, CA). Replicate
samples were generated and analyzed on different days. The data was
normalized to the average of the control samples and up- or down-regulated
genes were identified using GeneSpring GX (Agilent Technologies, Santa Clara,
CA).
Results
FLAG-tagged Myb cell lines
The development of Chromatin-IP assays for the detection of Myb proteins
target genes provided a means to follow the activity and specificity of variant Myb
proteins. However, performing ChIP assay on every variant Myb protein requires
developing specific antibody and different antibody works under different
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condition. In order to circumvent these possible problems, we used lentiviral
vectors to generate stably transduced derivative of NALM-6 cells expressing
FLAG epitope-tagged version of variant Myb proteins (GFP, 9S/10, 9B and cMyb). For these cells, only one antibody (anti-Flag) is needed for all of the ChIP
assays. Since our previous data on the significance of variant Myb proteins in
leukemia were generated from pre-B ALL patients, we chose the pediatric pre-BALL cell line NALM-6. We first measured the expression level of the ectopically
expressed Myb proteins in various stable cell lines. As shown in Figure 1A,
FLAG-9B was expressed at levels comparable to the level of FLAG-c-Myb and
FLAG-9S protein was expressed at a slightly higher level in these cells.
Endogenous c-Myb proteins were also expressed in these cells, and the levels of
the ectopically expressed variant Myb proteins were very close to the level of
endogenous c-Myb protein. This may avoid the possible artifacts caused by high
level of overexpression of these proteins, such as, non-specifically binding and
regulating some genes. To further confirm that one single antibody anti-FLAG
can be used for all of these FLAG-tagged variant Myb proteins in ChIP assay,
immunoprecipitation experiments were carried out on these stable cell lines. The
results showed that the anti-FLAG antibody could efficiently immunoprecipitated
the epitope-tagged variant Myb proteins from these cells (Figure 1B).
Chromatin-IP on the stable cell lines
The results described above suggest that anti-FLAG antibody would be
suitable for performing ChIP assay on all of the variant Myb proteins 220,260. In
order to be able to tell whether ChIP assay works in these stable cell lines, it is
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necessary to know some of the target genes that might be regulated by variant
Myb proteins. For c-Myb protein, many target genes have been identified in the
past, but little is known about the target genes regulated by variant Myb proteins.
Furthermore, many studies suggest that the Myb proteins are subject to contextspecific regulatory mechanisms, and in different cell types the Myb proteins form
different transcription complex with different cellular components and activate
specific sets of genes (see review 172). While c-Myb play an important role in Bcell development 38,39,213,261, little is known about the target genes regulated by cMyb during B-cell differentiation and leukemogenesis. Our laboratory has
identified genome-wide target genes regulated by c-Myb in MCF-7 cells by using
ChIP-chip. Some target genes (MAT2A, CCNB1) are shown regulated by c-Myb
in some types of hematopoietic cells, such as Jurkat, CD34+ cells. Therefore, by
performing ChIP assay, we assessed the association of c-Myb, 9S/10 and 9B
proteins with the promoter of MAT2A, CCNB1, and RAG2 (a target gene
regulated by c-Myb protein in B-cell) 262,263 genes in variant Myb proteins
expressed NALM-6 cell lines. Briefly, NALM-6 cells with ectopically expressed
GFP, FLAG-c-Myb, FLAG-9S/10 and FLAG-9B were fixed with formaldehyde and
the chromatin complexes were immunoprecipitated using control non-immune
IgG, anti-flag beads or a c-Myb specific antibody (1-1) that recognizes a domain
(after 440 aa in c-Myb protein) in c-terminus. This c-Myb specific antibody (1-1)
could be used to pull down endogenous c-Myb protein formed chromatin
complex, while the anti-FlAG antibody could pull down ectopically expressed
variant Myb proteins formed chromatin complexes. The immunoprecipitated
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chromatin complexes were then assayed for the enrichment of the MAT2A,
CCNB1, RAG2 promoters, or control promoters, using quantitative real-time PCR
(QPCR) assays (see details in Table 1).
Our results showed that anti-Myb antibody detected endogenous c-Myb at
the MAT2A and RAG2 promoter (Figure 2) in all of the NALM stable cell lines,
but no c-Myb could be detected at the CCNB1 promoter (data not shown) and
control promoter (GAPDH), suggesting that c-Myb associated with the MAT2A
and RAG2 promoter in NALM-6 cells. When using anti-FLAG beads, we first
tested the ability of the anti-FLAG beads to enrich for the MAT2A and RAG2
promoters in NALM GFP cells with only endogenous c-Myb expression and
NALM-6 FLAG-c-Myb cells with both endogenous and exogenous c-Myb
expression. As shown in Figure 2A, no gene promoter was enriched for antiFLAG beads in NALM-6 GFP cells, indicating there is no non-specific DNA
binding to the anti-FLAG beads. While in FLAG-c-Myb cells, the anti-FLAG beads
showed the similar enrichment on the MAT2A and RAG2 promoters (Figure 2B)
compared to the anti-Myb antibodies, implying that the FLAG-tagged c-Myb
protein has the same activity as the endogenous c-Myb protein on regulating
genes.
In NALM-6 FLAG-9S/10 cells, the anti-c-Myb antibodies efficiently enriched
for the MAT2A and RAG2 promoters, but the anti-FLAG beads did not enrich for
either of the two gene promoters (Figure 2C). This result suggested that 9S/10
has different activity on the MAT2A and RAG2 genes from the activity of c-Myb.
We further tested whether 9S/10 variant protein has different activity on the other
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gene promoter (CCNB1) that was not enriched by c-Myb in NALM-6 cells and
there was no detected enrichment on the CCNB1 promoter (data now shown). In
NALM-6 FLAG-9B cells, the anti-FLAG beads enriched efficiently on the MAT2A
promoter and the RAG2 promoter (Figure 2D) but not on the CCNB1 promoter.
Comparing to endogenous c-Myb protein, FLAG-9B showed very similar
activities on regulating these genes in NALM-6 cells. Based on all of these
results, we conclude that c-Myb, 9S/10 and 9B variant proteins associate with
different target gene promoters in NALM-6 cells and that ChIP assay on the cells
stably expressing FLAG-tagged variant Myb proteins could be a powerful tool to
detect the activity and specificity of Myb proteins.
Gene-expression profiles in NALM-6 cells with variant Myb proteins
expression
Our laboratory has used microarray method to compare the transcription
specificities of Myb proteins (A-Myb, B-Myb, c-Myb and v-Myb) in different cell
types, and identified sets of putative target genes of Myb proteins 36,37,78, though
a lot of them still need to be further verified. Here, we applied the same idea on
the various NALM-6 cells with the stable expression of different variant Myb
proteins, and utilized a microarray approach to compare the specificities of cMyb, 9S/10 and 9B proteins. Briefly, NALM-6 cells expressing variant Myb
proteins and control GFP were seeded at 5 x 105 the night before. After 16 h,
RNA was isolated and changes in gene expression were determined using
Affymetrix microarrays. The entire experiment was conducted twice, and the data
was analyzed to identify the genes that were reproducibly up or down-regulated
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at least twofold as a result of expressing one of the variant Myb proteins.
However, unexpectedly, there were very few genes (total 21 genes) affected by
the expression of variant Myb proteins and the changes in gene expression for
these genes were not significant (see details in Table 2). To partially validate the
microarray results, we performed real-time PCR analysis to independently
assess the changes in gene expression for several representative genes, such
as MLL2 gene that was only induced by the expression of FLAG-c-Myb, PLAC8
gene that was only induced by the expression of 9B variant, and GNG11 gene
that was more significantly repressed by the expression of 9S/10 variant. The
results of the real-time PCR analysis (data not shown) were very similar as the
microarray results. All of the above indicate that variant Myb proteins had nondistinct and almost similar effects on gene expression in these NALM-6 stable
cell lines.
Discussion
These data demonstrated that by developing cells expressing FLAG-tagged
variant Myb proteins, ChIP assays on different versions of Myb proteins could be
greatly simplified by using only one anti-FLAG antibody, and it would be a useful
tool to identify the target genes of variant Myb proteins. However, we were not
able to identify the transcriptional specificities of each variant Myb protein in
NALM-6 cells by microarray approach. It is possible that normally we compare
the transcriptional specificities of Myb proteins by using recombinant adenovirus
system, which can ectopically express proteins at very high level (much higher
than the level of endogenous proteins). While we were using lentiviral system to
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express variant Myb proteins in these NALM-6 cells, the expression levels of
these variant proteins were very close to the level of endogenous c-Myb protein.
Also, it is very hard to introduce exogenous genes into NALM-6 cells. We have
tried used other ways such as adenovirus or electroporation to introduce these cMyb transcript variants into NALM-6 cells, and they all failed to do so. When
using lentiviral system, the cells that were positively transduced (GFP+) were
only 3-10% of the total population after 7 days, and these cells were sorted out
for making stable cell lines. In the whole process of making stable cell lines of
NALM-6 cells, these cells went through a long term of massive selection and the
initial changes in gene expression led by different activities of these variant Myb
proteins probably could have been set off.
To circumvent these possible problems, we could choose different cell
models, such as Jurkat cells. This cell line is much easier for introducing
exogenous genes and the transcriptional activities of c-Myb protein in this cell
line has been well-characterized by ChIP assay 260. Or instead of growing the
positively transduced NALM-6 cells into stable cell lines for a long term, we could
just sort the positive cells after being transduced for 4 days, and directly perform
ChIP assay and microarray on these sorted cells and do a short term experiment.
Using these new model systems, the progress in discovering the transcriptional
specificities of variant Myb proteins and identifying the different sets of target
genes of these variant Myb proteins will be made at tremendous strides.
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Figure Legends
Figure 1. The expression of variant Myb proteins in stable cell lines
(A) Western blot of lentiviral transduced NALM-6 cells. Cell lysates were
directly subject to Western Blot analysis. Each cell line expresses FLAG-tagged
c-Myb, 9S/10 and 9B, respectively. Western Blot was analyzed with anti-c-Myb
antibody. (B) Immunoprecipitation on lentiviral transduced NALM-6 cells. Lysates
from cells were subjected to IP with anti-FLAG beads or control IgG beads and
Western Blot was performed with anti-c-Myb antibody.

Figure 2. FLAG-tagged variant Myb proteins bind to different gene
promoters.
ChIP assay using anti-FLAG beads and anti-c-Myb antibody 1-1 and
chromatin from GFP control (A), FLAG-c-Myb (B), FLAG-9S/10 (C), and FLAG9B (D) expressing NALM-6 cells. QPCR was performed with primers specific to
the MAT2A and RAG2 promoters, and primers designed to recognize no-specific
binding site within the GAPDH promoter. Black bar in each plot represents the
ChIP results from anti-c-Myb 1-1 antibody, and the white bar represents the ChIP
results from anti-FLAG beads. Error bars represent standard deviation from
triplicate QPCR reactions. Each sample is normalized to IgG control.
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Tables
Table 1: Promoter Primers for SYBR Green
Gene Promoters
MAT2A promoter
For
MAT2A promoter
Rev
RAG2 promoter For
RAG2 promoter Rev
CCNB1 promoter
For
CCNB1 promoter
Rev
GAPDH promoter
For
GAPDH promoter
Rev

Sequence
ACCCACCAAACGGGACTCCATACTC
TCTCTTGACGGCGTGGAATGG
GTGAATTGTGTTGCCATTGTTGC
TGTGTGCCTACAGATGTTC
TTGTGCCCCACCTTAAT
CATGTTGATCTTCGCCTTATT
GTGCAGGAGTTCATGACCAAC
CACCTGGGCTAGAGTAC
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Table 2: The gene expression changes induced by variant Myb proteins

Symbol

Unigene

GNG11
RAP1A
CD99
RBP1

HS.83381
Hs.190334
Hs.654354
Hs.529571

GZMA

Hs.90708

KCNJ2
PIP3-E
PLAC8
SORBS1

Hs.1547
Hs.146100
Hs.546392
Hs.696027

SGCB

Hs.438953

MLL2

Hs.120228
Hs.
655939
Hs.675711
Hs.679013

SPP1
LEF1
CALD1

Hs.313
Hs.555947
Hs.490203

AGPAT2
SMOC2
DDIT4L

Hs.320151
Hs.487200
Hs.480378

GPSM1
NPY

Hs.239370
Hs.1832

CASP1

Hs.2490
Hs.
424156

IRX1

Description
guanine nucleotide binding protein (G
protein), gamma 11
RAP1A, member of RAS oncogene family
CD99 molecule
retinol binding protein 1, cellular
granzyme A(granzyme 1, cytotoxic Tlymphocyte-associated serine esterase 3)
postassium inwardly-rectifying channel,
subfamily J, member 2)
phosphoinositide-binding protein PIP3-E
placenta-specific 8
sorbin and SH3 domain containing 1
sarcoglycan, beta (43kDa dystrophinassociated glycoprotein)
myeloid/lymphoid or mixed-lineage
leukemia 2

secreted phosphoprotein 1(osteopontin,
bone sialoprotein I, early T-lymphocyte
activation 1)
lymphoid enhancer-binding factor 1
caldesmon 1
1-acylglycerol-3-phosphate-Oacyltransferase 2(lysophosphatidic acid
acyltransferase,beta)
SPARC related modular calcium binding 2
DNA-damage-inducible transcript 4-like
G-protein signaling modulator 1 (AGS3-like,
c.elegans)
neuropeptide Y
caspase 1, apoptosis-related cysteine
peptidase(interleukin 1, beta, convertase)
iroquois homeobox 1

FLAG9B

FLAG9S

FLAGMyb

0.65
0.28
2.63
0.93

0.27
0.09
1.72
1.25

0.61
0.05
1
0.41

0.79

0.69

3.38

0.48
0.47
2.11
0.96

0.58
0.68
1.38
0.76

1.43
1
0.94
2.17

0.79

0.98

0.38

1.31

1.13

3.47

0.37
1.99
0.44

0.4
1.54
0.52

0.44
1.57
0.67

0.53
0.48
0.28

0.61
0.77
0.41

0.66
0.52
0.5

0.75
0.76

0.92
0.83

0.45
0.49

0.81

0.67

0.43

0.71

0.83

0.45

Table 2 Legends. The gene expression data of 21 genes that were most significantly up or downregulated in response to stably ectopically expressing FLAG-c-Myb, FLAG-9S or FLAG-9B in
NALM-6 cells. Repressed genes are shown in green, and activated genes are in red over a range
of 0.2-5 fold activation. Each gene is identified by its Affymetrix probe set identification number
and by its common name, when available.
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Appendix II: Develop cell lines ectopically expressing TAPtagged variant Myb proteins to study protein-protein interaction
Our recent studies show that alternately spliced c-myb transcripts are
associated with polyribosomes, which indicates that they are translated to
produce different forms of c-Myb proteins 19. Variant proteins with different
structures, especially with unique C-terminal regions, are likely to bind different
co-factors that may confer different biological activities on them.
To identify the different proteins interacting with Myb proteins we used a
new technique tandem affinity purification to isolate Myb protein-complex and
use proteomics to identify the proteins that different versions of c-Myb bind to.
Tandem affinity purification is a generic two-step affinity purification protocol for
the isolation of TAP-tagged proteins together with associated proteins 264. It
requires fusion of the TAP tag, either N- or C-terminally, to the target protein of
interest. All of the steps in TAP purification are illustrated in Figure 3.
For our purpose, we generated a series of vectors expressing TAP-tagged
variant Myb proteins, in which the TAP tag was fused to the N-termini of Myb
proteins. By using a luciferase assay to test the functional ability of TAP-tagged
c-Myb protein, we confirmed that the TAP tag did not change c-Myb protein
functions. Further, we established two cell lines (Jurkat and MCF-7 cells) that can
stably express TAP-tagged c-Myb and performed TAP purification on these cells.
The proteins recovered from the TAP purification was subject to western blotting
to check whether c-Myb formed protein complex could be efficiently purified.
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Our preliminary data indicates that TAP-tag does not affect the normal
function of Myb proteins, TAP-tagged Myb variant proteins could be stably
expressed in different cell lines and TAP purification could be efficiently applied
to the study on comparing the difference in the protein complexes formed with
variant Myb proteins.
Materials and Methods
Generation of NTAP-MYB
TAP-tag sequence was amplified from pZome-1-N vector (CellZome,
Germany) and then cloned in pcDNA3 vector (Invitrogen, Carlsbad CA) to
generate pcDNA3-NTAP vector. The human c-Myb transcript sequence and its
variants 9S/10 and 9B were then cloned into pcDNA3-NTAP vector, respectively.
The lentiviral vectors with TAP-tagged Myb were constructed by cloning NTAPMyb into pLenti6/V5-GW/LacZ vector (Invitrogen, Carlsbad CA), which would
replace the entire sequence from attB1 to V5 epitope in the original vector.
Myb Lentiviral Production
N-terminal TAP-tagged human c-Myb, 9S/10, and 9B transcripts were
cloned into the unique BamHI and XhoI site of the pLenti6/V5-GW/LacZ lentiviral
vector downstream of a CMV promoter. Plasmids were transfected into 293 FT
cells (Invitrogen. Carlsbad CA) by calcium phosphate transfection along with the
lentiviral packaging plasmid delta 8.9 and the pMD.G plasmid expressing the
vesicular stomatitis virus glycoprotein. Supernatant was collected at 24 hr

182

intervals for 48 hr. Ultrafiltration using an Ambion Ultracell 100 kDa NMWL filter
unit (Millipore, Billelrica MA) was used to concentrate viral supernatants.
Cell Culture
MCF-7 cells (ATCC Manassas, VA) and 293 cells (ATCC CRL-1573) were
cultured at 37°/5% CO2 in DMEM (Dulbecco’s Modified Eagle Medium)
(Invitrogen, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine serum
(Invitrogen, Carlsbad, CA). Human Jurkat T-cells (ATCC TIB152 Manassas, VA)
were cultured at 37°/5% CO2 in RPMI + Glutamax medium (Invitrogen, Carlsbad,
CA) supplemented with 10% (v/v) fetal bovine serum (Invitrogen, Carlsbad, CA).
Transfection assay
For reporter gene activation assays, triplicate samples of 293 cells in 24well dishes were transfected with 350 ng of the c-Myb-responsive EW5 reporter
gene, along with 50 ng of the pcDNA3 c-Myb expression plasmid (or pcDNA3NTAP-c-Myb expression plasmid or pcDNA3 plasmid) and 10 ng of a renilla
luciferase plasmid as a control for transfection efficiency. This transfection assay
were used Polyfect as instructed by manufacturer (QIAGEN, Valencia, CA).
Luciferase levels were analyzed 2 days later with a dual luciferase kit (Promega,
Madison, WI).
Making Stable Cell Lines
Cells were transduced individually with different lentiviruses that express
different versions of Myb proteins, at MOI 1: 100 in the presence of 8 µg/ml of
polybrene (Sigma, St. Louis, MO) in two constitutive days. After 7 day post183

transduction, the cells were sorted to by adding 8 -10 µg/ml blasticidin to drugselect for positively transduced cells. These blastcidin-resistent positive cells
were then expanded by culturing in their respective media as described in “cell
culture” with 8 - 10 µg/ml blasticidin.
TAP Purification and Western Blot
TAP purification was performed as described 265,266. In brief, approximately
2x107 cells were harvested. Cells were flash frozen and lysed with 5 ml lysis
buffer (10% glycerol, 50 mM Hepes-KOH pH 8.0, 100 mM KCl, 2 mM EDTA,
0.1% NP-40, 2 mM DTT, 1X Sigma Protein inhibitor, 10 mM NaF, 0.25 mM
NaOVO3, 5 nM okadaic acid, 5 nM calyculin A and 50 mM betaglycerolhosphate). After lyzing, the debris was spun down for 10 min at maximum
speed at 4 °C. The clear supernatant was recovered and 100 µl was taken for
input control. Then 30 µl IgG beads (Amersham, Piscataway, NJ) (60 µl of slurry)
was added to the extract and rotated at 4 °C for 2 hr (after binding, the
supernatant was aliquoted a portion for western blot analysis). The beads were
then washed 3 times with 1ml lysis buffer and 3 times with TEV buffer (10 mM
Hepes-KOH pH8.0, 150 mM NaCl, 0.1% NP-40, 0.5 mM EDTA and 1mM DTT).
Beads were resuspended in 120 µl of TEV buffer, 40 units of AcTEV protease
(Invitrogen, Carlsbad, CA) and rotated for 4 hr at 4 °C. After digesting, the
supernatant was transferred into the same amount of Calmodulin beads (30 µl)
(here also aliquot a small portion) and the IgG beads were washed 2 times with 1
volume of Calmodulin binding buffer (10 mM beta-mercaptoethanol, 10 mM
Hepes-KOH pH8.0, 150 mM NaCl, 1 mM MgOAC, 1 mM imidazole, 0.1% NP-40,
184

and 2 mM CaCl2). These washing buffers were also transferred to Calmodulin
beads (Amersham, Piscataway, NJ). 1/250 volume of 1 M CaCl2 was also added
into the beads. The calmodulin beads were rotated for 90 min at 4 °C (after
binding, the supernatant here was also aliquoted for western blot analysis). The
beads were washed 3 times with 1 ml Calmodulin binding buffer. The bound
protein complex was then eluted from the calmodulin beads by calmodulin elution
buffer (50 mM Amm.bicarb pH 8.0, 75 mM NaCl, 1 mM MgOAC2, 1 mM
imidazole, 50 mM EDTA and 2 mM CaCl2). All of the protein portions that
aliquoted from each step and the final eluted protein were subject to western blot.
Results
TAP-tag does not affect the transcriptional activities of c-Myb protein
Compare to other available tag protein, such as HIS, FLAG, or GST, TAP
tag is a relatively bigger, about 21 KDa, protein tag. To make sure that fusing
such big tag to N-terminal of variant Myb proteins would not affect their normal
functions, we compared the activities of c-Myb protein and TAP-tagged c-Myb
protein by using a well-established co-transfection assay incorporating a Myb
responsive reporter gene. Myb-negative 293 cells were transfected with plasmids
expressing normal and TAP-tagged c-Myb proteins, along with a Myb-reponsive
reporter plasmid containing five high-affinity Myb binding sites from the Mybregulated mim-1 gene promoter upstream of a minimal promoter 26,27,36,267 and a
luciferase reporter gene. As shown in Figure 4, the expression of c-Myb resulted
in an approximately 14 folds increase in reporter gene activity compared to the
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vector (pCDNA3) control. The TAP-tagged c-Myb protein resulted in a12-fold
activation in luciferase, which is similar to that of the normal c-Myb protein. The
results suggest that TAP tag does not affect the normal activities of variant Myb
proteins.
Purification of c-Myb Complexes
Tandem affinity purification of protein complexes has become an important
tool in the field of proteomic research. Through performing TAP purification,
novel protein-protein interactions could be identified. To apply the TAP method to
theidentification of different protein-partners of variant Myb proteins, we
constructed TAP-c-Myb vectors and prepared lentiviruses, to infect human breast
cancer MCF-7 cells and T lymphocyte Jurkat cells. Through blasticidin selection,
the positive-infected cells were further cultured to make stable cell lines
expressing TAP-c-Myb proteins. We compared the expression level of the TAP
tagged c-Myb protein with the level of endogenous c-Myb protein in these stable
cell lines. As shown in Figure 5A, endogenous c-Myb was not detectable in MCF7 cells while the TAP-c-Myb proteins (100KDa) in both MCF-7 cells and Jurkat
cells were expressed at the levels comparable with the expression level of
endogenous c-Myb protein in Jurkat cells. To further test whether a tandem
affinity tag purification method works in our system, we first chose to purify the cMyb protein complex from MCF-7 cells expressing TAP-c-Myb. In brief, total
2x107 cells were seeded in 150-mm culture dishes at 5x 105 cells/ml the night
before and were harvested 14 hr later. The cells were harvested by flash
freezing. Protein extracts were prepared from these cells and incubated with IgG186

Sepharose 6 Fast Flow beads. The IgG beads were recovered by brief
centrifugation, and subsequently incubated with TEV protease 4 hr at 4 °C. A
portion of the elutes obtained after TEV cleavage were analyzed by western blot.
As shown in Figure 5B, compared to original cell lysates, after cleaving, the cMyb protein with only Calmodulin binding domain was efficiently released. The
rest elutes were further incubated with Calmodulin beads for 90 min at 4 °C. A
portion of the unbound supernatant was removed for western blot analysis. After
washing the beads, proteins bound to calmodulin beads were eluted by
calmodulin elution buffer and subject to western blot. We found that most of the
elutes after TEV cleavage were efficiently bound to Calmodulin beads, a few was
left in the unbound supernatant. After second purification with Calmodulin beads,
the 75-KDa c-Myb proteins were successfully eluted from the beads. Our results
suggest that the two-step tandem purification procedure could efficiently purify
TAP- Myb protein complexes from the cells expressing TAP tagged variant Myb
proteins.
Implications
In many transcription systems the co-activators have turned out to be
considerably more complex than initially envisioned. To fully understand the
mechanism of action of any given transcription factor, knowledge of its interacting
partners is essential. Therefore, it is important to develop an efficient purification
method for isolating protein complexes. Affinity purification appears to be the
most efficient and gentle separation technique for the retrieval of protein
complexes, such as well-characterized small affinity tags FLAG and GST. TAP
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purification procedure consists of two successive affinity purification steps, which
can produce an extremely pure preparation of the protein of interest with
associated proteins in yeast and mammalian systems 264 265,268-270. Here, we
explored the possible application of the TAP purification approach in identifying
the protein partners of variant Myb proteins. The expression of the TAP-tagged
exogenous c-Myb protein in the cell lines were similar to endogenous protein
levels, which is important for the identification of protein partners present in
physiologically relevant Myb protein complexes. The efficiency of the TAP
purification was demonstrated by our western blot results that significant amount
of c-Myb was recovered even from small cell numbers. For future work, we could
perform TAP purification on more starting numbers of cells to obtain enough
proteins, which could be enough for separating on SDS-PAGE gel and
visualizing by silver staining. Visible bands will be excised and subjected to
proteomics. From these preliminary results, it is clear that the TAP purification
could assist the future research on identifying the different protein-partners of
variant Myb proteins and defining the possible mechanisms that differentiate
variant Myb proteins specificities.
Figure Legends
Figure 3. Schematic of the tandem affinity purification of NTAP-c-Myb
protein complex.
TAP tag comprised Protein A, a TEV protease cutting sequence, and
calmodulin binding domain (CBD). NTAP-c-Myb formed protein complex were
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first pull down by proteinA-IgG beads binding. After binding to the IgG beads, the
complex was released by cleaving with AcTEV protease. Then the second affinity
purification was performed by CBD binding to calmodulin beads. The final protein
complex was eluted by elution buffer, and the protein partners of c-Myb were
subject to proteomic analysis.

Figure 4. Activation of a c-Myb-responsive reporter gene by TAP-c-Myb and
normal c-Myb proteins.
Cells were co-transfected with plasmids expressing the indicated Myb
proteins and a Myb responsive reporter plasmid, and extracts were prepared and
assayed for Myb-dependent luciferase activity after 2 days. Results are plotted
as the average normalized luciferase activities from triplicate measurements in a
representative experiment performed twice. Error bars represent standard
deviation.

Figure 5. Tandem affinity purification of TAP-c-Myb protein.
(A) TAP-tagged c-Myb expressed in lentiviral transduced MCF-7 cells and
Jurkat cells. Total cell lysates were subjected to western blot analysis. The blot
was performed with anti-c-Myb antibody 1-1. (B) Tandem affinity purification on
lentiviral transduced MCF-7 cells. A portion of the proteins from each step was
analyzed by Western Blot. The blot was detected by blotting with anti-c-Myb
antibody 1-1. Lane 1,3,5, and 7 are from MCF-7 LacZ control cell lines; Lane
189

2,4,6, and 8 are from MCF-7 TAP-c-Myb expressing cells. Lane 1, and 2 are total
cell lysate prior to purification. Lane 3, and 4 are protein elutes after cleaving with
TEV protease. Lane 5, and 6 are supernatants after proteins binding to
calmoduline beads. Lane 7, and 8 are proteins eluted from calmodulin beads.
Numbers at left are molecular masses (KDa).
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